DOWNLOAD THE FREE 12th ECE APP

Download the FREE 12th European Congress on Epileptology App now to access congress information at the touch of a button

**Key App features:**
- Scientific Programme
- Session Details
- Abstracts
- General Information
- Exhibition Information
- and many more...

**Search: 12th ECE Prague 2016**

Download the App for iPhone, iPad, Android Phone/Tablet, Kindle Fire or Windows Phone. There is FREE wifi available during the congress for all registered delegates

The Congress App is supported by:

www.epilepsyprague2016.org
WELCOME MESSAGES

WELCOME MESSAGE FROM THE CO-CHAIRS OF THE INTERNATIONAL SCIENTIFIC AND ORGANISING COMMITTEE

Dear Colleagues,

On behalf of Czech Chapter and the Commission on European affairs (CEA) of the International League Against Epilepsy (ILAE) as well as the International Scientific and Organising Committee (ISOC), it is our pleasure to welcome you to Prague for the 12th European Congress on Epileptology (ECE). In keeping up with the tradition and the reputation that the European Congress on Epileptology has for being an innovative and highly educational meeting, the 12th ECE will utilise all of the best features from recent ECEs and combine these with local Czech elements.

The ISOC has created a scientific program which we are sure will be of great interest to all, encompassing recent scientific developments and exchange of ideas and information between basic scientists, researchers and clinicians working in the field of epilepsy throughout the region.

From the many session proposals submitted by our colleagues in the region, the ISOC has chosen four main themes and selected a Chairs’ Symposium, teaching courses, ECE forums and workshops. The programme will cover many aspects of modern epileptology, bridging molecular and social levels of the disease along with basic science and everyday clinical practice.

The long and great Czech tradition in medical sciences, including Jan Marcus Marci, Jan Evangelista Purkinje and Johann Gregor Mendel, will meet with recent scientific discoveries in the magical city of Prague. This will be a unique opportunity not only to uncover the past and see the future, but also to pursue professional passions and an unrivalled opportunity to meet with colleagues, old and new.

We trust that you will enjoy the congress, as well as your stay in the beautiful city of Prague.

With kind regards,

Meir Bialer
Co-chair
12th ECE ISOC

Milan Brázdil
Co-chair
12th ECE ISOC
MESSAGE FROM THE PRESIDENT OF THE ILAE

Dear Colleagues,

On behalf of the International League Against Epilepsy (ILAE), it gives me great pleasure to welcome you all to the 12th European Congress on Epileptology in the beautiful and historic city of Prague.

The International Scientific and Organising Committee has done a wonderful job in assembling a wide range of exciting scientific sessions which highlight the latest developments in understanding the mechanisms of epilepsy and state-of-the-art approaches to improve diagnosis and management. The congress will also offer a great opportunity to meet colleagues and friends from all over the world, exchange ideas, and establish fruitful collaborations.

The ILAE was established in 1909 and now has over 100 Chapters throughout the world. The ILAE Commission on European Affairs continues to promote epilepsy care, education and research across Europe, and dedicates a remarkable amount of time and effort to ensure excellence in the scientific quality of the European Congress on Epileptology.

The city of Prague is designated as a UNESCO World Heritage City and has been called “the city of a hundred spires”. It is both an ancient and modern city, renowned for its architectural and cultural richness. Throughout the centuries, Prague’s strategic position at the heart of central Europe has enabled the city to play an important role in European history. On the occasion of the 12th ECE, the city will once again become a strategic meeting point for people from many countries, with the common goal of improving the care of persons with epilepsy in Europe and beyond.

I look forward to meeting you over the coming days and trust that you will have a productive and enjoyable experience at the 12th European Congress on Epileptology and in Prague.

With best wishes,

Emilio Perucca
ILAE President

CONGRESS INFORMATION

FACILITIES TIMETABLE OVERVIEW

<table>
<thead>
<tr>
<th></th>
<th>Sunday</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>08:00-19:00</td>
<td>07:00-17:30</td>
<td>07:00-18:30</td>
<td>07:00-18:30</td>
<td>07:00-18:30</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>-</td>
<td>11:00-11:30</td>
<td>11:00-11:30</td>
<td>11:00-11:30</td>
<td>10:30-11:00</td>
</tr>
<tr>
<td>Posters</td>
<td>-</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
<td>-</td>
</tr>
<tr>
<td>Exhibition</td>
<td>-</td>
<td>09:00-16:30</td>
<td>09:00-16:30</td>
<td>09:00-16:30</td>
<td>-</td>
</tr>
<tr>
<td>Cloakroom</td>
<td>08:15-20:45</td>
<td>07:15-18:15</td>
<td>07:15-19:45</td>
<td>07:15-20:00</td>
<td>07:15-13:45</td>
</tr>
<tr>
<td>Speakers’ Room</td>
<td>09:00-19:00</td>
<td>07:00-17:00</td>
<td>07:00-18:30</td>
<td>07:00-18:30</td>
<td>07:00-13:00</td>
</tr>
</tbody>
</table>

ABSTRACTS USB STICK

The abstract USB sticks are available at the BIAL exhibition booth. Vouchers are available at the congress bag counter.

CERTIFICATES OF ATTENDANCE

Certificates of attendance may be collected from the registration area from Tuesday 13th September onwards during registration opening hours.

CLOAKROOM

The cloakroom is located in the Forum Hall Foyer on the first floor of the congress centre beside the registration area. The cloakroom is free of charge for congress participants. Opening times can be found in the Facilities Timetable Overview.

CME ACCREDITATION

The 12th European Congress on Epileptology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 12th European Congress on Epileptology is designated for a maximum of (or ‘for up to’) 23 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS/EACCME for CMECME credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
CONGRESS APP

A free congress app "12th ECE, Prague 2016" is available for Apple, Windows and Android devices. Search on the app store for "12ECE".
The app provides access to all scientific sessions information such as date, times and content as well as enabling delegates to create their own personalised schedule.
The congress app is supported by UCBBIOPHARMA SPRL.

COFFEE BREAKS

Coffee breaks will be served Monday to Wednesday mornings in the Exhibition Area, in the Congress Hall Foyer on the second floor of the congress centre. On Thursday, coffee breaks will be served in the Forum Hall Foyer on the second floor.

CONGRESS BAGS

Congress bags may be collected from the Registration Area.

CONGRESS SECRETARIAT

Members of the congress secretariat may be contacted at any time at the registration area. For queries arising after the congress, please contact:
12th ECE Prague 2016: Tel: +353 1 2056720 | Fax: +353 1 2056156 | Email: prague@epilepsycongress.org

EXHIBITION AREA

The exhibition area is situated in the Congress Hall Foyer on the second floor of the congress centre. Exhibition opening times are listed in the Facilities Timetable Overview.

INTERNET CENTRE

The internet centre is located on the second floor, adjacent to the exhibition and poster areas.
The internet centre is supported by BIAL and Eisai.

LANGUAGE

The official language of the congress is English; please note that translation facilities are not provided.

LIABILITY AND INSURANCE

The International League Against Epilepsy (ILAE) and its agents do not accept any liability whatsoever for death, personal injury, accidents, theft, loss or damage to persons, property or belongings of participants or accompanying persons, either before, during or following the congress, tours or their stay in Prague. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.

PUBLIC TRANSPORT PASSES

Free public transport passes are provided for all delegates and are available for collection at the congress bag counter.

REGISTRATION

The registration area is located in the Forum Hall Foyer on the first floor of the congress centre. Please note that name badges must be worn at all times.

SPEAKERS’ ROOM

The Speakers’ Room is located in Meeting Room 2.1, on the second floor of the congress centre. Opening times are listed on the Facilities Timetable Overview. Facilities to review and amend presentations are available to all speakers and technical assistance will also be provided in this room.
Please note that all speakers should submit their final PowerPoint presentation(s) to the Speakers’ Room no less than 3 hours in advance of their session. Speakers at early morning sessions are required to submit their material no later than 17:00 on the evening before their session is scheduled.

VENUE

Prague Congress Centre (Kongresové centrum Praha)
5. května 65, 140 21 Prague 4, Czech Republic
Phone: +420 261 171 111 | Website: http://www.kcp.cz/en/homepage

WELCOME CEREMONY AND RECEPTION

All delegates are invited to attend the Welcome Ceremony which takes place from 18:30 to 19:30 on Sunday 11th September in the Congress Hall. The ceremony will open with welcomes from the ISOC Co-chairs and the ILAE President. This will be followed by the Awards Ceremony, in which the CEA awardees will be celebrated with short presentations. The ceremony will have a distinctly Czech flavour as Dr. Günter Kämmer will give a talk on Epileptology and Prague, which will be followed by a performance by the local Black Light Theatre 5mer.

The Ceremony will be immediately followed by a Welcome Reception, which all delegates are invited to join.

WHEELCHAIR ACCESS

The 12th ECE venue is wheelchair accessible and assistance will be provided onsite to any wheelchair user.

WIFI

Free wifi is available in the venue for the duration of the congress to registered delegates.

Network name: Bial_Eisai@12ECE
Password: 12ece2016

The WIFI is supported by BIAL and Eisai.
PRAGUE TRANSPORT INFORMATION

Situated in the heart of Europe, Prague represents a major transport junction and an ideal strategic location for international meetings. The city has an efficient and safe public transport system which makes it very easy for visitors to get around.

BUSES
Buses (autobusy) cover the outskirts of Prague and areas where trams or the metro do not run. Bus 119 connects the Ruzyňe airport with the Dejvická metro station and bus 100 connects the airport with the Zličín station. They are both a convenient and cheap way to get to and from the Prague airport.

TAXIS
There are a number of reputable Prague taxi companies that you can rely on for good service and fair rates:

- AAA Radiotaxi - www.aaa-taxi.cz
- City Taxi - www.citytaxi.cz
- Profi Taxi - www.profitaxi.cz
- Halotaxi - www.halotaxi.cz
- Sedop - www.sedop.cz

If you need to catch a taxi on the street, make sure it is a real, registered taxi. The yellow roof lamp must be permanently installed and must say TAXI in black letters on both sides. The driver’s name, licence number and rates should be printed on both front doors.

METRO (SUBWAY)
The Prague subway is fast, efficient, clean and easy to use. Its three lines consist of about 60 km of tracks, running mostly underground, and 57 stations. Trains arrive in 1-3 minute intervals during the peak hours of the morning and afternoon commute and in 4-10 minute intervals in the off-peak hours. All stations are equipped with escalators and about two thirds of all metro stations allow access for the disabled.

The Prague Congress Centre is adjacent to the Vyšehrad station on Metro Line C (Red Line), providing convenient access by public transport from the city centre and all major rail and bus stations.

Useful dictionary:

eskáloator - escalator
linka (A, B, C)- line (A, B, C)
metro - subway
přestup - transfer
stanice metra - subway station

trasa - route
vstup - entrance
výstup - exit
Placený prostor, označte sižiždenku – Paid area, validate your ticket
TRAMS
With 500 km of tracks, trams (tramvaje) cover a large area of Prague and are used by some 300 million people a year. Daytime trams run from 04:30 until midnight in 8-10 minute intervals (8-15 minutes on weekends). Night trams (numbers 51-58) run from 00:30 until 04:30 in 40 minute intervals.
SCIENTIFIC PROGRAMME INFORMATION

SESSIONS
The sessions form the main part of the congress. The main topics were chosen by the International Scientific & Organising Committee (ISOC) and the sessions were selected from the numerous proposals submitted by ILAE members and other experts. These sessions were selected to represent the best in European and global epileptology.

Our programme covers all aspects of epileptology, but four main themes have been selected. Each day has different themes representing Basic Science, Paediatric Epileptology, Pharmacotherapy and Epilepsy Surgery.

The titles of the four main sessions address the following topics:
- Trials and tribulations in the development of medical therapies
- Neurogenesis in epilepsy
- Challenges in the management of epilepsy in children - systems and technologies as solutions
- The changing landscape of epilepsy surgery; assessment and treatment

SPECIAL SYMPOSIA
Special symposia include the Chairs’ Symposium, which this year is dedicated to “Pharmacoresistant epilepsy from bench to seizure control”. The symposium will address the issue of phenotyping of refractory adult and paediatric patients, preclinical models for pharmacoresistant epilepsies as well as new antiepileptic drugs (AEDs) and other future therapies beyond AEDs for the treatment of resistant epilepsies.

Two other special symposia entitled “Learning about focal ictogenesis from patients (and animal models)” and “The Michael Debate: Remission and epilepsy” will also form part of the scientific programme.

The programme will also feature the following joint symposia between the ILAE-Commission on European Affairs (CEA) and two other European societies:
- CEA – EAN (European Academy of Neurology) Symposium
- CEA – EMA (European Medicines Agency) Symposium

TEACHING SESSIONS
Teaching sessions will feature seven attractive, separated three-day, two-day and one-day morning series: 3 morning teaching sessions will be dedicated to VIREPA courses.

The “How to do” series will also take place over three consecutive morning sessions. It will cover all aspects of clinical epileptology.

The “Seizure Clubs” series, with didactic video presentations of ictal semiology, will take place over two morning sessions.

There will be four other teaching sessions running over just one morning: “Autoimmune epilepsies; The risk/benefit stratification for epilepsy surgery”; “Pre-surgical evaluation”; “First seizures and early onset epilepsy”.

ECE TEACHING DAY
Thursday 15th September will feature three main courses.

A half-day course on “Seizures in emergency situations” will run from 08:00 to 12:30. This course will provide the audience with updated information on the two most relevant aspects of epileptology in the ICU: status epilepticus and the use, interpretation and impact of EEG in an intensive care unit environment.

An educational teaching course on “Pharmacological aspects of AEDs” will run for two hours.

A third teaching course primarily aimed at EEG technicians will run from 08:00 to 16:00. It will cover logistic and safety issues at the epilepsy monitoring unit. New systems for EEG reporting and practical tips for artefact recognition and management will be discussed. Experience with home video-EEG monitoring as a novel tool in epilepsy diagnostics will be presented.

ECE FORUMS
The ECE Forums were an innovation in the scientific programme of the 10th ECE in London, and following on from their success during the London (2012) and Stockholm (2014) ECEs, the innovative and popular ECE Forums will again form part of the programme for the Prague ECE.

They are designed to be sessions in which selected topics can be explored and discussed in an informal workshop or clubroom style. The topics have been selected from proposals made by ILAE members worldwide and generally focus on cutting-edge or controversial aspects of epilepsy work, not least including discussions on new or planned projects of general interest.

The sessions are intended to be creative and interactive, and are open free-of-charge to all participants of the congress.

AWARDS
We would like to congratulate the following awardees:
- Pavel Mareš - European Epileptology Award 2016
- Federico Vigevano - European Epileptology Award 2016
- Nana Tatishvili - European Epilepsy Education Award 2016
- Julia Jacobs – CEA Young Investigator Award 2016
- Nicola Specchio – CEA Young Investigator Award 2016
- Ioana Mindruta – Epileptic Disorders Prize 2016

All awards will be presented at the Welcome Ceremony on Sunday 11th September from 18:30-19:30.

The Symposium of Excellence in Epileptology, on Wednesday 14th September, will include lectures presented by the recipients of the 2016 European Epileptology Award, the CEA Young Investigator Award and the Epileptic Disorders Prize.

POSTER PRESENTATIONS AND PLATFORMS
112 of the best submitted abstracts have been selected by the International Scientific and Organising Committee for oral presentation and will be presented in Platform Sessions from Monday to Wednesday. There will be a special dedicated Platform Session for late breaking abstracts on Sunday 11th September.

Special attention has also been given to poster presentations during the congress. Posters will be on display from Monday to Wednesday and guided poster tours will be held at lunchtime, giving the opportunity to all authors to present their work and for delegates to ask questions.

HIGHLIGHTS SESSION
This concluding session is intended to give delegates an overview of the most important advancements that have been presented during the congress. Each main topic chair has been asked to summarise what they consider to be the highlights from presentations within their theme.
SCIENTIFIC PROGRAMME AT A GLANCE

Sunday
September 11

07.30-08.00
Welcome Ceremony
10.30-10.30
Welcome Reception
10.30-10.30

08.00-08.30
ECE Forums (1)
08.30-10.00
Course: Seizures in emergency situations
10.00-11.30
Course: EEG technicians
11.30-13.30
Course: Pharmacotherapy
13.30-15.00
Course: Excellence in Epileptology
15.30-16.30
Course: Exemplary Courses (2)
16.30-18.00
ECE Forums (2)
18.00-19.30
Congress Highlights Session
19.30-20.30
Welcome Reception
20.30-20.30

Monday
September 12

07.30-09.00
Course: Seizures in emergency situations
09.00-10.30
Course: EEG technicians
10.30-12.30
Course: Pharmacotherapy
12.30-13.30
Course: Excellence in Epileptology
13.30-15.00
Course: Exemplary Courses (2)
15.30-16.30
ECE Forums (2)
16.30-18.00
ECE Forums (3)
18.00-19.30
Congress Highlights Session
19.30-20.30
Welcome Reception
20.30-20.30

Tuesday
September 13

07.30-09.00
Course: Seizures in emergency situations
09.00-10.30
Course: EEG technicians
10.30-12.30
Course: Pharmacotherapy
12.30-13.30
Course: Excellence in Epileptology
13.30-15.00
Course: Exemplary Courses (2)
15.30-16.30
ECE Forums (4)
16.30-18.00
ECE Forums (5)
18.00-19.30
Congress Highlights Session
19.30-20.30
Welcome Reception
20.30-20.30

Scientific Programme

www.epilepsyprague2016.org
### Sunday, September 11, 2016

#### Congress Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:30</td>
<td>The Burden and Care of Epilepsy in Europe</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Challenges of drug development for neonatal seizures</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Late breaking Abstracts</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>The Michael Debate: Remission and Epilepsy</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Break</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Welcome Ceremony</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Course Session</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>ECE Forums</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Other</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Sessions</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Courses</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Other</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Sessions</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>Courses</td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Other</td>
</tr>
<tr>
<td>18:30-19:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>19:00-19:30</td>
<td>Sessions</td>
</tr>
<tr>
<td>19:30-20:00</td>
<td>Courses</td>
</tr>
<tr>
<td>20:00-20:30</td>
<td>Other</td>
</tr>
<tr>
<td>20:30-21:00</td>
<td>Satellite Symposium</td>
</tr>
</tbody>
</table>

#### South Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:30</td>
<td>Seizure detection in the EMU</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>MicroRNA as meta-controllers of gene expression in epilepsy</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Neurobiology Symposium</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Neuroinflammation: a treatment target for early life epileptic encephalopathies?</td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Courses</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Other</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Sessions</td>
</tr>
<tr>
<td>13:30-14:00</td>
<td>Courses</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Other</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Sessions</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Courses</td>
</tr>
<tr>
<td>16:00-16:30</td>
<td>Other</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>17:00-17:30</td>
<td>Courses</td>
</tr>
<tr>
<td>17:30-18:00</td>
<td>Other</td>
</tr>
<tr>
<td>18:00-18:30</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>18:30-19:00</td>
<td>Courses</td>
</tr>
<tr>
<td>19:00-19:30</td>
<td>Other</td>
</tr>
<tr>
<td>19:30-20:00</td>
<td>Satellite Symposium</td>
</tr>
<tr>
<td>20:00-20:30</td>
<td>Courses</td>
</tr>
<tr>
<td>20:30-21:00</td>
<td>Other</td>
</tr>
</tbody>
</table>
**PARALLEL SESSION**

**Congress Hall**

14:30 – 16:00

**The burden and care of epilepsy in Europe**

*Co-chair: Jakob Christensen, Denmark*
*Co-chair: Ettore Beghi, Italy*

**The prevalence of epilepsy: does it vary across Europe?**
Christine Linehan, Ireland

**Assessing the cost of epilepsy: methodological aspects**
Poul Jernum, Denmark

**Epilepsy, stigma and quality of life: what is the situation in Europe?**
Ettore Beghi, Italy

**ESBACE: an EU-funded study of the burden and care of epilepsy in Europe**
Jakob Christensen, Denmark

**PARALLEL SESSION**

**Forum Hall**

14:30 – 16:00

**Challenges of drug development for neonatal seizures**

*Co-chair: Michele Simonato, Italy*
*Co-chair: Cecilie Johannessen Landmark, Norway*

**Finding the right animal model**
Stéphane Auvin, France

**Translational aspects – developing innovative drugs**
Aristea Galanopoulou, USA

**Pitfalls of AED trials in neonatal seizures**
Ronit Pressler, United Kingdom

**Developing innovative methods**
Catherine Chiron, France

**PARALLEL SESSION**

**South Hall**

14:30 – 16:00

**Seizure detection in the EMU (Epilepsy Monitoring Unit)**

*Co-chair: Margitta Seeck, Switzerland*
*Co-chair: Rainer Surges, Germany*

**Automatic seizure detection system for epilepsy monitoring units**
Christoph Baumgartner, Austria

**The detection of active epilepsy in the scalp EEG**
Francesca Pittau, Switzerland

**Seizure prediction and treatment using intracranial EEG**
Paul Boon, Belgium

**Multi-model seizure detection, which modality tells us most?**
Sándor Beniczky, Denmark
PARALLEL SESSION
Meeting Hall I

14:30 – 16:00

MicroRNA as meta-controllers of gene expression in epilepsy: targets, diagnostics and opportunities for treatment

Co-chair: Eleonora Aronica, Netherlands
Co-chair: David Henshall, Ireland

microRNA and inflammation: new therapeutic opportunities in epilepsy associated pathologies
Annamaria Vezzani, Italy

microRNA as mechanism-linked biomarkers of epileptogenesis
David Henshall, Ireland

Methodical approaches to PCR based quantification of miRNA in epilepsy
Petra Bencúrová, Czech Republic

microRNAs control neuronal morphology in health and disease
Vamshidhar Vangoor, Netherlands

NEUROBIOLOGY SYMPOSIUM
Panorama Hall

14:30 – 16:00

Learning about focal ictogenesis from patients (and animal models)

Co-chair: Marco de Curtis, Italy
Co-chair: Premysl Jirouška, Czech Republic

Unit activity in human focal seizures
Wilson Truccolo, USA

Synchronization in human focal seizures
Kaspar Schindler, Switzerland

Onset, progression and termination of a focal seizure
Marco de Curtis, Italy

Interictal and ictal HFOs
Julia Jacobs, Germany

PLATFORM SESSION
Congress Hall

16:00 – 17:00

Late Breaking Abstracts

Co-chair: Petr Marusic, Czech Republic
Co-chair: Reetta Kälviäinen, Finland
SCIENTIFIC PROGRAMME

SUNDAY 11TH SEPTEMBER 2016

SPECIAL SYMPOSIUM
Forum Hall

16:30 – 18:00

The Michael Debate: Remission and epilepsy
Co-chair: Peter Wolf, Denmark
Co-chair: Vladimir Donáth, Slovakia

Basic mechanism of remission in epilepsy
Uwe Heinemann, Germany

Remission in benign childhood epilepsies
Helen Cross, United Kingdom

Remission in juvenile myoclonic epilepsy
Betül Baykan, Turkey

PARALLEL SESSION
South Hall

16:30 – 18:00

Neuroinflammation: a treatment target for early life epileptic encephalopathies?
Co-chair: Aristeia Galanopoulou, USA
Co-chair: Annamaria Vezzani, Italy

Perinatal inflammation: does it contribute to neurodevelopmental deficits?
Stefanie Dedeurwaerdere, Belgium

Early life inflammation: putative role in the pathogenesis of early life epileptic encephalopathies
Aristea Galanopoulou, USA

In vivo biomarkers of neuroinflammation: can they track disease progression?
Teresa Ravizza, Italy

From bench and bedside: can we envision novel pathway specific strategies for targeting neuroinflammation in early life epileptic encephalopathies?
Stéphane Auvin, France
ECF FORUM
Panorama Hall

16:30 – 18:00  Contribution of epileptic sources to scalp EEG and MEG signals
Chair: Louis Maillard, France

Observability and detectability of epileptic sources in EEG and MEG
Christoph Michel, Switzerland

Simultaneous intracerebral and scalp EEG correlates of temporal sources
Laurent Koessler, France

Simultaneous subdural- and scalp EEG correlates of frontal lobe epileptic sources
Georgia Ramuntani, Germany

SATELLITE SYMPOSIUM
Meeting Hall I

16:30 – 18:00  Please see page 102 for full details on the satellite symposium
### MONDAY 12TH SEPTEMBER 2016

<table>
<thead>
<tr>
<th>Congress Hall</th>
<th>Forum Hall</th>
<th>South Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00-08:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30-09:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-11:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Lunch and Posters</td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00-18.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-19.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00-19.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.30-20.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00-20.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.30-21.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **VIREPA EEG basic and advanced courses**
- **How to do**
- **Seizure Club I**
- **Pharmacoresistant epilepsy from bench to seizure control**
- **Basic science 1 From clinical trials to clinical practice: What kind of evidence do we need?**
- **Epidemiology**
- **Pre-surgical evaluation**
- **FROM CLINICAL TRIALS TO CLINICAL PRACTICE: WHAT KIND OF EVIDENCE DO WE NEED?**
- **MECHANISMS OF EPILEPTOGENICITY IN HUMAN BRAIN LESIONS**
- **EPILEPSY AND INTELLECTUAL DISABILITY**
- **EPILEPSY IN CHILDHOOD**
- **EPIDEMIOLOGY**
- **INTELLIGENCE AND EPILEPSY**
- **Basic science 1**
SCIENTIFIC PROGRAMME  MONDAY 12TH SEPTEMBER 2016

TEACHING SESSION
Congress Hall

07:30 – 09:00  VIREPA EEG: basic and advanced courses
Co-chair Sándor Beniczky, Denmark
Co-chair Walter Van Emde Boas, Netherlands

VIREPA basic EEG course: the use and abuse of clinical EEG
Walter Van Emde Boas, Netherlands

VIREPA advanced EEG course: source localization in the clinical practice
Sándor Beniczky, Denmark

TEACHING SESSION
Forum Hall

07:30 – 09:00  How to do
Co-chair Christian Elger, Germany
Co-chair Dieter Schmidt, Germany

How to diagnose an event as either epileptic or non epileptic
Christian Elger, Germany

How to decide when and how to start drug therapy
Dieter Schmidt, Germany

SCIENTIFIC PROGRAMME  MONDAY 12TH SEPTEMBER 2016

TEACHING SESSION
South Hall

07:30 – 09:00  Seizure Club I
Co-chair Philippe Kehane, France
Co-chair Hans Holthausen, Germany

Case presentations and discussion
Milan Brázdil, Czech Republic
Margitta Seeck, Switzerland
Philippe Kehane, France
Hans Holthausen, Germany

SATELLITE SYMPOSIUM
Meeting Hall I

07:30 – 09:00  Please see page 102 for full details on the satellite symposium

TEACHING SESSION
Panorama Hall

07:30 – 09:00  Pre-surgical evaluation
Co-chair Ivan Rektor, Czech Republic
Co-chair Felix Rosenow, Germany

Concept of presurgical evaluation, indications, neuropsychology
Kristina Malmgren, Sweden

Non-invasive investigation (video-EEG monitoring, imaging methods)
Petr Marusic, Czech Republic

Invasive video-EEG monitoring, ictal manifestations
Ivan Rektor, Czech Republic
09:00 – 11:00  Pharmaco-resistant epilepsy from bench to seizure control

Co-chair: Milan Brázdíl, Czech Republic
Co-chair: Meir Bialer, Israel

Phenotyping of refractory adult patients with epilepsy: where does it help?
Simon Shorvon, United Kingdom

Phenotyping of refractory paediatric patients with epilepsy: where does it help?
Sameer Zuberi, United Kingdom

Preclinical models for pharmaco-resistant epilepsies
Hana Kubová, Czech Republic

New antiepileptic drugs with potential for therapy-resistant epilepsy
Michael Rogawski, USA

Are there future therapies in pharmaco-resistant epilepsies beyond antiepileptic drugs?
Kristl Vonck, Belgium

11:30 – 13:00  Antiepileptic drugs 1

Co-chair: Svein Johannessen, Norway
Co-chair: Nicola Specchio, Italy

Prescribing trends for sodium valproate in Ireland
Sinead Murphy, Ireland

Marked reduction in secondarily generalized seizures in patients treated with perampanel for 3 and 4 years
Emilio Perucca, Italy

Efficacy and tolerability of lacosamide monotherapy in patients with newly diagnosed epilepsy: a prospective randomized double-blind non-inferiority trial versus controlled-release carbamazepine
Michel Baulac, France

Possible clinically relevant interactions between antiepileptic drugs and other prescription medications in elderly patients with newly diagnosed epilepsy
Tapani Keränen, Finland

Discontinuation of the first antiepileptic drug in patients with epilepsy in the general population: rate and predictors
Ettore Beghi, Italy

Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit
Alexandra Rohracher, Austria
SCIENTIFIC PROGRAMME

MONDAY 12TH SEPTEMBER 2016

PLATFORM SESSION
Forum Hall

11:30 – 13:00

Clinical neurophysiology

Co-chair: Uwe Heinemann, Germany
Co-chair: Francesca Pittau, Switzerland

Source localization of interictal activity in suspected extra-temporal drug-resistant focal epilepsy: a prospective high-density EEG and stereo-EEG study
Steve Gibbs, Canada

What different intracranial EEG seizure patterns can tell us about ictogenic mechanisms
Vadym Gnatovsky, Italy

Frequency-dependent changes of neural networks from pre-ictal to ictal stages in childhood absence epilepsy
Xiaoshan Wang, China

Seizure onset patterns in focal cortical dysplasia and neurodevelopmental tumours: relationship with surgical prognosis and neuropathological subtypes
Stanislas Lagarde, France

A novel model-based method for real-time detection of electrographic seizures
Armen Sargsyan, Australia

Epilog: a framework for automatic detection of epileptic spikes and subsequent EEG source imaging to localize the epileptogenic zone with high sensitivity and specificity
Pieter van Mierlo, Belgium

Epilepsy in childhood

Co-chair: Vladimir Komárek, Czech Republic
Co-chair: Floor Jansen, Netherlands

Clinico-neurophysiological and genetic features of ESES/CSWS in Denmark
Daniella Terney, Denmark

Cognitive problems among children exposed to antiepileptic drugs. Preliminary data
Lars Skou Elkjær, Denmark

Emotional functioning, fatigue, sleep quality and stress in parents of children with early onset epilepsy: a population-based study
Chloe Jones, United Kingdom

Parent reported child development, quality of life and family stress data from a Scottish population based cohort of children with newly diagnosed epilepsy
Jack Waldman, United Kingdom

Perception of epilepsy by epileptic children, their parents and doctors
Nebal Waill Saad, Iraq

Three-month outcomes of an RCT psychosocial group intervention for young people with epilepsy (PIE)
Liam Dorris, United Kingdom
Scientific Programme

12th European Congress on Epileptology

MONDAY 12TH SEPTEMBER 2016

Scientific Programme

Platform Session
Meeting Hall I

11:30 – 13:00

Basic science 1

Co-chair Julia Jacobs, Germany
Co-chair Pavel Mareš, Czech Republic

Correlation of epileptiform activity and c-fos mRNA expression in an acute in vitro model of epilepsy
Sophie Schlabitz, Germany

Dual and opposing roles of miR-124 in epileptogenesis are mediated through NRSF and inflammatory pathways
Gary Brennan, Ireland

Accessory β subunits are protective towards gating modifications induced by Dravet syndrome NaV1.1 sodium channel truncated mutants
Massimo Mantegazza, France

Hippocampal cellular prion protein expression in the pilocarpine model of temporal lobe epilepsy
Kelin Cristine Martin, Brazil

QTc prolongation in an experimental epilepsy model
Sofia Markoula, United Kingdom

Distribution of neuronal tissue damage in epilepsy surgery specimens
Laura Rossini, Italy

Special Symposium
Panorama Hall

11:30 – 13:00

From clinical trials to clinical practice: what kind of evidence do we need?
Co-chair Jacqueline French, USA
Co-chair Manuel Haas, United Kingdom

Development of anti-epileptic drugs for young children
Alexis Arzimanoglou, France

Shortening placebo exposure in anti-epileptic drug trials
Emilia Bagiella, USA

Treatments for acute seizures and status epilepticus
Eugen Trinka, Austria
14:30 – 16:00  The current role of valproic acid in epilepsy therapy

Co-chair: Svein Johannessen, Norway
Co-chair: Matthew Walker, United Kingdom

The story of valproate and how it changed the course of history of epilepsy treatment
Simon Shorvon, United Kingdom

How valproic acid structure and clinical experience affected the design of its 2nd generation antiepileptic drugs?
Meir Bialer, Israel

Is valproic acid such a terrible teratogen? From the basic science point of view
Richard Finnell, USA

Clinical teratogenicity and impact of EMA’s warning on the use of valproic acid in women
Torbjörn Tomson, Sweden

14:30 – 16:00  Purkinje’s Symposium – The cerebellum and epilepsy

Co-chair: Philippe Kahane, France
Co-chair: Kristina Malmgren, Sweden

Cerebellar connections and interactions with the cerebral cortex
Richard Apps, United Kingdom

Epilepsy and cerebellar atrophy
Milan Brázdil, Czech Republic

Cerebellar epilepsy – is it a myth?
Hans Holthausen, Germany

Cerebellar neurostimulation in the treatment of epilepsy
Gregory Krauss, USA
PARALLEL SESSION
Meeting Hall I

14:30 – 16:00

Epilepsy and intellectual disability

Co-chair: Christian Brandt, Germany
Co-chair: Christoph Helmstaedter, Germany

Epidemiology of epilepsy and intellectual disability in Europe
Christine Linehan, Ireland

Efficacy of antiepileptic drug treatment in persons with epilepsy and intellectual disability
Michael Kerr, United Kingdom

Assessment of drug side effects in persons with intellectual disability
Christian Brandt, Germany

Epilepsy surgery in patients with epilepsy and intellectual disability
Vicente Villanueva, Spain

PARALLEL SESSION
Panorama Hall

14:30 – 16:00

Mechanisms of epileptogenicity in human brain lesions

Co-chair: Albert Becker, Germany
Co-chair: Dimitri Kullmann, United Kingdom

Mechanisms underlying seizure generation around human glioma
Gilles Huberfeld, France

LIM-domain-binding proteins: role for epilepsy development in glioneuronal tumors
Albert Becker, Germany

Selective silencing of parvalbumin interneurons in the subiculum induces recurrent spontaneous seizures
Günther Sperk, Austria

Impaired intrinsic plasticity in hippocampal epileptogenesis
Yoel Yaari, Israel
12th European Congress on Epileptology

SCIENTIFIC PROGRAMME

MONDAY 12TH SEPTEMBER 2016

PLATFORM SESSION
Meeting Hall V

14:30 – 16:00

Epidemiology

Co-chair: Ettore Beghi, Italy
Co-chair: Günter Krämer, Switzerland

A multi-cohort approach to establishing major depressive disorder as both an independent risk factor and modifier of the expression of epilepsy
Colin Josephson, Canada

Selective serotonin reuptake inhibitors and risk of posttraumatic epilepsy – a population based cohort study
Jakob Christensen, Denmark

The risk of seizure recurrence and clinical predictors in patients with defined epileptic syndromes: a prospective study
Elisa Bruno, Italy

Prevalence of autoimmune temporal lobe epilepsy
Martin Elsak, Czech Republic

The incidence of SUDEP: a nationwide population-based study
Olafur Sveinsson, Sweden

Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
Melissa Maguire, United Kingdom

SATellite SYMposium
Forum Hall

16:30 – 18:00
Please see page 102 for full details on the satellite symposium

www.epilepsyprague2016.org
## TUESDAY 13TH SEPTEMBER 2016

### Forum Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>VIREPA: Neuroimaging and medical treatment of epilepsy</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>How to do</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Trials and Tribulations in the Development of Medical Therapies</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>The changing landscape of epilepsy surgery: assessment and treatment</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Break</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Antiepileptic Drugs 2</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Neuroimaging</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Lunch and Posters</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>VIREPA: Neuroimaging and medical treatment of epilepsy</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>How to do</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Trials and Tribulations in the Development of Medical Therapies</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>The changing landscape of epilepsy surgery: assessment and treatment</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Novel therapies for status epilepticus (SE)</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>MARCUS MARCI’S SYMPOSIUM</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>What is a seizure? New perspectives</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>SATELLITE SYMPOSISSION</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Novel predictive biomarkers of epileptogenesis and therapy response</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>18.00-18.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>18.30-19.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>19.00-19.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>19.30-20.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>20.00-20.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>20.30-21.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
</tbody>
</table>

### South Hall

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>VIREPA: Neuroimaging and medical treatment of epilepsy</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>How to do</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Trials and Tribulations in the Development of Medical Therapies</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>The changing landscape of epilepsy surgery: assessment and treatment</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td>Break</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Antiepileptic Drugs 2</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Neuroimaging</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Lunch and Posters</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>VIREPA: Neuroimaging and medical treatment of epilepsy</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>How to do</td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Trials and Tribulations in the Development of Medical Therapies</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>The changing landscape of epilepsy surgery: assessment and treatment</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Novel therapies for status epilepticus (SE)</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>MARCUS MARCI’S SYMPOSIUM</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>What is a seizure? New perspectives</td>
</tr>
<tr>
<td>15.00-15.30</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>16.00-16.30</td>
<td>SATELLITE SYMPOSISSION</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Novel predictive biomarkers of epileptogenesis and therapy response</td>
</tr>
<tr>
<td>17.00-17.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>17.30-18.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>18.00-18.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>18.30-19.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>19.00-19.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>19.30-20.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
<tr>
<td>20.00-20.30</td>
<td>Treatment Adherence in Epilepsy: An undervalued subject</td>
</tr>
<tr>
<td>20.30-21.00</td>
<td>Alterations of consciousness in epilepsy</td>
</tr>
</tbody>
</table>
TUESDAY 13TH SEPTEMBER 2016

Scientific Programme

TEACHING SESSION
Forum Hall

07:30 – 09:00

VIREPA courses on neuroimaging and medical treatment of epilepsy

Co-chair: Janet Mifsud, Malta
Co-chair: Petr Marusic, Czech Republic

VIREPA neuroimaging course
Petr Marusic, Czech Republic

VIREPA course on medical treatment of epilepsy
Janet Mifsud, Malta

TEACHING SESSION
South Hall

07:30 – 09:00

How to do

Co-chair: Christian Elger, Germany
Co-chair: Dieter Schmidt, Germany

How to select the special AED
Dieter Schmidt, Germany

How to deal with pharmacoresistance
Christian Elger, Germany

SATELLITE SYMPOSIUM
Panorama Hall

07:30 – 09:00

Seizure Club II

Chair: Christoph Baumgartner, Austria

Case presentations and discussion
Christoph Baumgartner, Austria
Walter Van Emde Boas, Netherlands
Ivan Rektor, Czech Republic
Felix Rosenow, Germany

07:30 – 09:00

Please see page 102 for full details on the satellite symposium

TEACHING SESSION
Meeting Hall V

07:30 – 09:00

The risk/benefit stratification for epilepsy surgery

Co-chair: Pavel Krsel, Czech Republic
Co-chair: Andreas Schulze-Bonhage, Germany

Efficacy and prognostic factors of surgical procedures
Serge Vuillemez, Switzerland

Medical and psychosocial risks of surgical procedures
Kristina Malmgren, Sweden

Risk stratification: risk/benefit ratio and hierarchy of procedures
Michael Sperling, USA
SCIENTIFIC PROGRAMME  
TUESDAY 13TH SEPTEMBER 2016

MAIN SESSION  
Forum Hall

09:00 – 11:00  
Trials and tribulations in the development of medical therapies
Co-chair Christian Elger, Germany  
Co-chair Jacqueline French, USA

Seizure counting and its consequences for clinical trials in epilepsies
Christian Elger, Germany

Relationships between efficacy and placebo rates
Sylvian Rheims, France

Open vs. blinded trials in epilepsy
Tony Marson, United Kingdom

Monotherapy trials in epilepsy: are they necessary and how should they be designed?
Jacqueline French, USA

SCIENTIFIC PROGRAMME  
TUESDAY 13TH SEPTEMBER 2016

MAIN SESSION  
South Hall

09:00 – 11:00  
The changing landscape of epilepsy surgery: assessment and treatment
Co-chair Margitta Seeck, Switzerland  
Co-chair Petr Marusic, Czech Republic

The true outcome of surgical therapy in the 21st Century in Europe
Margitta Seeck, Switzerland

Why don’t patients get epilepsy surgery?
Eva Kumlien, Sweden

Antiepileptic drug withdrawal after epilepsy surgery
Kees Braun, Netherlands

The future of epilepsy surgery techniques
Karl Schaller, Switzerland
Scientific Programme

12th European Congress on Epileptology

Scientific Programme

**TUESDAY 13TH SEPTEMBER 2016**

**PLATFORM SESSION**
Forum Hall

11:30 – 13:00

**Antiepileptic drugs 2**

Co-chair: Norman Delanty, Ireland
Co-chair: Cecilie Johannessen Landmark, Norway

Pharmacokinetic and pharmacodynamic analysis after various routes of administration of sec-butylpropylacetamide (SPD), a new CNS drug possessing a unique activity against status epilepticus
David Bibi, Israel

Pharmacokinetic variability of valproate in women of childbearing age and during pregnancy
Cecilie Johannessen Landmark, Norway

The role of anti-epileptic drugs as a cause of behavioral problems in children with tuberous sclerosis complex: a retrospective cohort study
Hanna Hulshof, Netherlands

EARLY-ESLI study: efficacy, tolerability and conversion to monotherapy with eslicarbazepine acetate after first monotherapy failure
Vicente Villanueva, Spain

Retrospective study about effectiveness and tolerability of perampanel in drug resistant myoclonic epilepsies
Francisco Gil, Spain

Safety aspects of antiepileptic drugs used in epilepsy and other indications in Norway
Arton Bafliu, Norway

**PLATFORM SESSION**
South Hall

11:30 – 13:00

**Neuroimaging**

Co-chair: Kees Braun, Netherlands
Co-chair: Hajo Hamer, Germany

Two for the price of one. The combination of EEG-fMRI and ESI contributes to the localization of epileptogenic region and is highly predictive of seizure outcome
Maria Centeno, United Kingdom

Resting state functional connectivity alterations by independent component analysis correspond with intra-operative EEG in prospective large pediatric intractable epilepsy study
Varina Boerwinkle-Wolf, USA

7 Tesla MRI in the pre-surgical evaluation of patients with refractory focal epilepsy
Tim Veersma, Netherlands

Simultaneous EEG and functional MRI at ultra-high field (7T) in epilepsy: Feasibility and first results
Francesca Pittau, Switzerland

Connectivity in ictal SPECT perfusion: a cortico-cortical evoked potential study
Simon Tousseyn, Belgium

Magnetoecephalography-guided frontal lobe epilepsy surgery using neuronavigation and intraoperative MR imaging
Björn Sommer, Germany
**Scientific Programme**

**TUESDAY 13TH SEPTEMBER 2016**

**Platform Session**
Meeting Hall I

11:30 – 13:00

**Epileptic encephalopathies**

*Co-chair: Vladimir Komdrek, Czech Republic*
*Co-chair: Patrick Van Bogaert, Belgium*

**Targeted resequencing in epileptic encephalopathies: diagnostic implications and genotype-phenotype correlations**
Pasquale Striano, Italy

**The molecular and phenotypic spectrum of IQSEC2 related epilepsy**
Ayelet Zerem, Israel

**Late breaking abstract**
TBC

**Epileptic phenotype in children with early onset mitochondrial diseases**
Sara Matricardi, Italy

**Epileptic encephalopathy with electrical status epilepticus in sleep: correlation of EEG network characteristics and IQ**
Bart Van den Munckhof, Netherlands

**Electro-clinical features of a new channelopathy due to loss of function or gain of function mutations in KCNA2**
Guido Rubboli, Denmark

**Scientific Programme**

**TUESDAY 13TH SEPTEMBER 2016**

**Platform Session**
Panorama Hall

11:30 – 13:00

**Status epilepticus**

*Co-chair: Mar Carreño, Spain*
*Co-chair: Simon Shorvon, United Kingdom*

**Etiology and clinical characteristics of convulsive status epilepticus as initial epileptic event: a cohort of 236 children**
Ruzica Kravljanc, Serbia

**Falling status epilepticus mortality rates in England & Wales: 2001-2013?**
Aidan Neligan, United Kingdom

**Treatment delays of prolonged and recurrent epileptic seizures**
Joni Sairanen, Finland

**GPED voltage maps as distinctive biomarkers between non-convulsive status epilepticus and anoxic brain injury**
Dimitris Sakellariou, Greece

**Refractory status epilepticus: potential prognostic markers and clinical outcomes**
Montserrat Gonzalez-Cuevas, Spain

**Population-based evaluation of treatment costs of super-refractory status epilepticus (SRSE) in Germany**
Adam Strzelczyk, Germany
**Scientific Programme**

**Tuesday 13th September 2016**

**Platform Session**
Meeting Hall V

11:30 – 13:00  
**Basic science 2**

*Co-chair: Stefanie DeDeurwaerdere, Belgium*  
*Co-chair: Michael Rogawski, USA*

L-alpha-glycerophosphorylcholine (α-GPC) enhances hippocampal neurogenesis and cognitive function in pilocarpine seizure-induced neuronal death and cognitive impairment  
Joo Young Lee, Korea, Republic of

Attenuation of the changes in the expression of BDNF and c-fos in adult mice brain undergoing kindling: implications for antiepileptogenic properties of novel antiepileptic compound isoxylitones [E/Z]  
Shabana U. Simjee, Pakistan

Effect of newly designed mTOR inhibitors on target activation and seizure threshold in healthy versus epileptic mice  
Claudia Brandt, Lower Saxony, Germany

Systemic delivery of antagonim-134 produces anti-epileptogenic effects  
Cristina Ruedell Reschke, Dublin, Ireland

Protective effects of fingolimod on epileptogenesis and neuropsychiatric comorbidities in WAG/Rij rats, a genetic animal model of absence epilepsy and depressive-like behavior  
Emilio Russo, Italy

**Three-stage anticonvulsant screening program for chronic epilepsy**  
Kevin J. Staley, MA, USA

**Parallel Session**
Forum Hall

14:30 – 16:00  
**Novel therapies for status epilepticus (SE)**

*Co-chair: Reetta Kälviäinen, Finland*  
*Co-chair: Eugen Trinka, Austria*

New approaches to treatment of acute seizures and the early stage of status epilepticus  
Simon Shorvon, United Kingdom

The potential of valproic acid derivatives valnoctamide and SPD in treatment of benzodiazepine-resistant status epilepticus (stage of established status epilepticus)  
Meir Bialer, Israel

Allopregnanolone (SAGE 547) potential in the treatment of refractory and super refractory status epilepticus  
Michael Rogawski, USA

Challenges for novel therapies in the acute epilepsy setting – industry perspective  
Konrad Werhahn, Germany
PARALLEL SESSION
South Hall

14:30 – 16:00

Marcus Marcic’s Symposium – What is a seizure? New perspectives
Co-chair: John Jefferys, United Kingdom
Co-chair: Viktor Jirsa, France

Are seizures really random events?
Premysl Jiruska, Czech Republic

Common principles of seizures: from cells to human brain
Viktor Jirsa, France

Neuronal behavior during seizure: insights from human patients
Catherine Schovon, USA

Genetic therapy to control seizures in humans – sci-fi or reality?
Robert Wykes, United Kingdom

PARALLEL SESSION
Meeting Hall I

14:30 – 16:00

Alterations of consciousness in epilepsy: A developmental trajectory?
Co-chair: Andrea Cavanna United Kingdom
Co-chair: Adam Zeman, United Kingdom

Common mechanism of loss of consciousness in seizures
Hal Blumenfeld, USA

Ictal consciousness in children with temporal lobe epilepsy: clinical, neurophysiological and neuroimaging correlates
Stefano Seri, United Kingdom

Intracranial recording and ictal consciousness in temporal lobe epilepsy
Fabrice Bartolomei, France

Clinical assessment of ictal consciousness in epilepsy across the lifespan
Andrea Cavanna, United Kingdom
**PARALLEL SESSION**
Panorama Hall

14:30 – 16:00
**A TP1A3 related epilepsies: novel phenomena, therapeutic insights and underlying pathophysiology**

*Co-chair: Alexis Arzimanoglou, France*
*Co-chair: Catherine Chiron, France*

**Epilepsies in alternating hemiplegia of childhood and other ATP1A3 related diseases by Eleni Panagiotakaki (France) and Hendrik Rosewich (Germany)**
Eleni Panagiotakaki, France

**Acute and long term management of seizures and related disorders in alternating hemiplegia of childhood**
Federico Vigevano, Italy

**Underlying pathophysiology of ATP1A3 related epilepsies: animal models and the promise of novel therapies**
Mohamad Mikati, USA

---

**PARALLEL SESSION**
Meeting Hall V

14:30 – 16:00
**The mysteries of insular epilepsy**

*Co-chair: Milan Brázdil, Czech Republic*
*Co-chair: Mark Richardson, United Kingdom*

**Anatomo-functional organisation of the insular cortex: the many faces of a small island**
François Mauguïère, France

**Electroclinical manifestations of insular seizures: the great mimicker**
Philippe Kahane, France

**Insular seizures and SUDEP**
Rainer Surges, Germany

**Surgery of insular epilepsy: yes, you can!**
Pavel Krsek, Czech Republic

---

**SATELLITE SYMPOSIUM**
Forum Hall

16:30 – 18:00
**Please see page 102 for full details on the satellite symposium**
SCIENTIFIC PROGRAMME  
TUESDAY 13TH SEPTEMBER 2016

18:00 – 19:30

**ECF FORUM**

Forum Hall

**Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench - and back**

*Co-chair: Stéphane Auvin, France*
*Co-chair: Lieven Lagae, Belgium*

**PET imaging as a biomarker of epileptogenesis**

Stefanie Dedeurwaerdere, Belgium

**A novel serum neuroinflammatory biomarker of epileptogenesis that predicts response to therapy: preclinical and clinical evidence**

Lauren Walker, United Kingdom

**Astrocytic myo-inositol on MRS together with cognitive deficits predict epilepsy development in experimental epilepsy models**

Teresa Ravizza, Italy

**EEG tracking of epileptogenesis and therapeutic response in TSC patients**

Lieven Lagae, Belgium

---

18:00 – 19:30

**ECF FORUM**

South Hall

**Treatment adherence in epilepsy: an undervalued subject**

*Co-chair: Antonio Martins da Silva, Portugal*
*Co-chair: Emilio Perucca, Italy*

**Minimization of AED effects that could influence adherence to treatment**

Emilio Perucca, Italy

**Adherence to medication in epilepsy and consequences of non-adherence**

Torbjorn Tomson, Sweden

**Adherence to treatment among patients with epilepsy: the patients’ perspectives**

Robert Horne, United Kingdom

---

18:00 – 19:30

**Horizons for Dravet Syndrome: update**

*Co-chair: Tiziana Granata, Italy*
*Co-chair: Bernardo Dalla Bernardina, Italy*

**Roundtable Discussion**

Renzo Guerrini, Italy
Rima Nabbout, France
Massimo Mantegazza, France
Helen Cross, United Kingdom
Ana Mingorance-Le Meur, Spain
Catherine Chiron, France
<table>
<thead>
<tr>
<th>Time</th>
<th>Platform Session</th>
<th>Location</th>
<th>Session Title</th>
<th>Co-chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:00 – 19:30</td>
<td>Genetics</td>
<td>Panorama Hall</td>
<td>Whole exome sequencing in the epilepsies: the developing diagnostic exome signature of epilepsy genes over a five-year period</td>
<td>Katherine Helbig, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genetics of sleep-related hypermotor epilepsy (SHE): whole exome sequencing (WES) analysis in a large Italian cohort</td>
<td>Laura Licchetta, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A prospective whole Scottish population study of genetic and immune causes of epilepsy and complex febrile seizures in children under 3 years of age: The Genetic and Autoimmune Childhood Epilepsy (GACE) Study</td>
<td>Joseph Symonds, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Search for de novo variants in microRNA genes that cause epileptic encephalopathies</td>
<td>Jolien Roovers, Belgium</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Detection of rare mutations with therapeutic relevance in infants with genetic epilepsy: the great benefit of NGS diagnostics</td>
<td>Oliver Puk, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Epileptic phenotype in patients with AP4M1 mutations</td>
<td>Marie Therese Abi Warde, France</td>
</tr>
<tr>
<td>18:00 – 19:30</td>
<td>Epilepsy and cognition</td>
<td>Meeting Hall V</td>
<td>Daytime naps, night time sleep and everyday memory in adults with epilepsy</td>
<td>Zoe C. Thayer, Australia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nocturnal supervision at an epilepsy residential setting</td>
<td>Marije van der Lende, Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The long-term cognitive outcomes after anterior temporal lobectomy</td>
<td>Anna Rita Giovagnoli, Italy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A cognitive-behavioral intervention (HOBSCOTCH) improves quality of life and attention in epilepsy: A pilot study</td>
<td>Barbara Jobst, USA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cognitive behavioural therapy vs standardised medical care for adults with Dissociative non-Epileptic Seizures (CODES): progress in a randomised controlled trial</td>
<td>Laura Goldstein, United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>An RCT of self-management education in epilepsy: characteristics of participants at baseline</td>
<td>Leone Ridsdale, United Kingdom</td>
</tr>
</tbody>
</table>
### WEDNESDAY 14TH SEPTEMBER 2016

#### Forum Hall | South Hall
--- | ---
07.30-08.00 | Paediatric and sleep courses | How to do
08.00-08.30 | Challenges in the management of epilepsy in children – systems and technology as solutions | Neurogenesis in epilepsy
08.30-09.00 | Break | 
09.00-10.00 | Antiepileptic Drugs 3 | Surgical treatment
10.00-10.30 | The life cycle of antiepileptic drugs | Seizures and stroke: from bad to worse and what could be done about it?
10.30-11.00 | Break | 
11.00-11.30 | Epilepsy management in countries with limited resources | When epilepsy sets in - your (family/personal) life
11.30-12.00 | MENDEL’S SYMPOSIUM | 
12.00-12.30 | Lunch and Posters | 
12.30-13.00 | Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery | 
13.00-13.30 | Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more? | 
13.30-14.00 | The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools | 
14.00-14.30 | Prognosis and outcome | 
14.30-15.00 | What is SHE (Sleep-related Hypermotor Epilepsy). Epileptologists meet sleep experts | 
15.00-15.30 | Symposium of Excellence in Epileptology | 
15.30-16.00 | Basic Science 3 | Classification of the Epilepsies
16.00-16.30 | CEA-EAN Symposium | Inhibition synchronization ahead of seizures – protective or harmful?
16.30-17.00 | Epilepsy Syndromes | 
17.00-17.30 | MENDEL’S SYMPOSIUM | Molecular genetic testing in Epilepsies, anno 2016: an essential diagnostic tool
17.30-18.00 | Break | 
18.00-18.30 | What is SHE (Sleep-related Hypermotor Epilepsy). Epileptologists meet sleep experts | 
18.30-19.00 | Prognosis and outcome | 
19.00-19.30 | Sys | 
19.30-20.00 | Vari | 
20.00-20.30 | V | 
20.30-21.00 | V | 

#### Meeting Hall I | Panorama Hall | Meeting Hall V
--- | --- | ---
First seizure and early onset epilepsy: the need to review our current practise | SATELLITE SYMPOSIUM | Autoimmune Epilepsies
Epilepsy Syndromes | Basic Science 3 | Classification of the Epilepsies
Lunch and Posters | | 
CEA-EAN Symposium | Inhibition synchronization ahead of seizures – protective or harmful? | 
Break | Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery | 
Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more? | 
The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools | 
What is SHE (Sleep-related Hypermotor Epilepsy). Epileptologists meet sleep experts | 
Prognosis and outcome | 
Vari | 

---

**Scientific Programme**

www.epilepsyprague2016.org
SCIENTIFIC PROGRAMME

WEDNESDAY 14TH SEPTEMBER 2016

TEACHING SESSION
Forum Hall

07:30 – 09:00

VIREPA EEG: paediatric and sleep courses
Co-chair: Monika Eisermann, France
Co-chair: Al de Weerd, Netherlands

VIREPA paediatric EEG course: from polygraphic video-EEG recording to seizure type and syndrome diagnosis
Monika Eisermann, France

Virepa EEG course on sleep: epilepsy and sleep
Al de Weerd, Netherlands

TEACHING SESSION
South Hall

07:30 – 09:00

How to do
Co-chair: Christian Elger, Germany
Co-chair: Dieter Schmidt, Germany

How to decide for epilepsy surgery
Christian Elger, Germany

How and when to end therapy
Dieter Schmidt, Germany

SCIENTIFIC PROGRAMME

WEDNESDAY 14TH SEPTEMBER 2016

TEACHING SESSION
Meeting Hall I

07:30 – 09:00

First seizures and early onset epilepsy: the need to review our current practices
Co-chair: Dana Craiu, Romania
Co-chair: Stefano Seri, United Kingdom

Expert epileptology work-up after a first unprovoked seizure
Margitta Seeck, Switzerland

MRI after the first seizure
Roland Wiest, Switzerland

When is it safe to return driving after a first seizure?
Tony Marson, United Kingdom

Comorbidities are crucial for the prognosis of early onset epilepsy
Christoph Baumgartner, Austria

SATELLITE SYMPOSIUM
Panorama Hall

07:30 – 09:00

Please see page 102 for full details on the satellite symposium
TEACHING SESSION
Meeting Hall V

07:30 – 09:00 Autoimmune epilepsies

Co-chair: Petr Marusic, Czech Republic
Co-chair: Christian Bien, Germany

Clinical phenotypes
David Krysl, Czech Republic

Indications for testing autoantibodies in patients with epilepsy
Christian Bien, Germany

Immunotherapies – when to start, which drugs and when to stop
Sarosh Irani, United Kingdom

MAIN SESSION
Forum Hall

09:00 – 11:00 Challenges in the management of epilepsy in children – systems and technology as solutions

Co-chair: Sameer Zuberi, United Kingdom
Co-chair: Peter Uldall, Denmark

Clinical networks – breaking barriers between primary, secondary & tertiary care
Sameer Zuberi, United Kingdom

The internet, apps & social media – education, interaction & management
Kate Riney, Australia

Guidelines, pathways & checklists – raising standards or preventing personalized care?
Dana Craiu, Romania

Alarms & monitors – distractions or life savers?
Lieven Lagae, Belgium
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**MAIN SESSION**
South Hall

**09:00 – 11:00**

**Neurogenesis in epilepsy**
**Co-chair: Hana Kubová, Czech Republic**
**Co-chair: Helen Scharfman, USA**

*Adult neurogenesis: from genes to brain function*
Sebastian Jessberger, Switzerland

*Neurogenesis in epileptic brain: possible target for therapy?*
Helen Scharfman, USA

*Neurogenesis in epileptic brain: does it contribute to epileptic comorbidities?*
Gerd Kempermann, Germany

*Does neurogenesis happen in the human brain?*
Embla Steiner, Sweden

---

**PLATFORM SESSION**
Forum Hall

**11:30 – 13:00**

**Antiepileptic drugs 3**
**Co-chair: Michael Rogawski, USA**
**Co-chair: Vicente Villanueva, Spain**

*A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy*
Francesco Brigo, Italy

*Myoclonic and absence seizures in patients with idiopathic generalized epilepsy (IGE): exploratory outcomes in a phase III PGTC study with adjunctive perampanel*
Terence O’Brien, Australia

*Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures*
Eugen Trinka, Austria

*A review of the drug–drug interactions of the new antiepileptic drug brivaracetam*
Brian D. Moseley, USA

*Intracerebroventricular ceréponsase alfa (BMN 190) in children with CLN2 disease: results from a phase 1/2, open-label, dose-escalation study*
Nicola Specchio, Italy

*Cognition improves via immunotherapy in patients with onconeural but not GAD65 autoantibody-associated limbic encephalitis*
Niels Hansen, Germany
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**PLATFORM SESSION**
South Hall

11:30 – 13:00

**Surgical treatment**

*Co-chair: Kristina Malmgren, Sweden
Co-chair: Sylvain Rheims, France*

Can histologically normal epileptogenic zone share common electrophysiological phenotypes with focal cortical dysplasia? SEEG-based study in MRI-negative epileptic patients
Julia Scholly, France

Increased subcortical oligodendroglia-like cells in pharmaco-resistant focal epilepsy in children correlate with extensive epileptogenic zone
Satoru Sakuma, Canada

**Stereotactic radiofrequency thermocoagulation for hypothalamic hamartoma**
Hiroshi Shirozu, Japan

Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy: a longitudinal data analysis
Won Gu Lee, Korea, Republic of

**Increased seizure frequency after epilepsy surgery: a population-based, observational study**
Johan Bjellvi, Sweden

Memory performance after stereotactic radiofrequency amygdalohippocampectomy – five years follow up
Lenka Kramská, Czech Republic

**EPILEPSY SYMPOSIUM**
Meeting Hall I

11:30 – 13:00

**Epilepsy syndromes**

*Co-chair: Michael Kerr, United Kingdom
Co-chair: Vasilios Kimiskidis, Greece*

**Expert consensus for the diagnosis of Dravet syndrome**
Elaine Wirrell, USA

**West syndrome: electroclinical and etiological aspects about 93 patients followed in Senegal**
Fidelie Scholastique Ngoungoue Halima, Senegal

**Investigation of clinical and EEG features in patients with genetic generalized epilepsy presenting with eyelid myoclonia**
Güneş Altıokkaz Uzun, Turkey

**Clinical and electroencephalographic characterization of myoclonic epilepsy with photosensitivity in juvenile pure-bred dogs**
Franziska Wieland, Germany

**Limbic encephalitis in late-onset partial epilepsies: a prospective, population-based study**
Felix von Podewils, Germany

**Epilepsy and its treatment in Nicolaides-Baraitser syndrome**
Gerhard Kluger, Germany


**Scientific Programme**

**Wednesday 14th September 2016**

**Platform Session**
Panorama Hall

**11:30 – 13:00**

**Basic science 3**

*Co-chair: Marco de Curtis, Italy*
*Co-chair: Annamaria Vezzani, Italy*

- Disulfide HMGB1 is generated by oxidative stress in the rat hippocampus during epileptogenesis and represents a novel mechanism of disease onset and progression
  Annamaria Vezzani, Italy

- Neuronal auto-antibodies in mesial temporal lobe epilepsy with hippocampal sclerosis: epiphenomenon or marker for an autoimmune subtype?
  Ebru Nur Vanli-Yavuz, Turkey

- Biomarkers of blood-brain barrier damage and their association with disease activity in patients with chronic epilepsy
  Elżbieta Bronisz, Poland

- Macro and microglial activation in the eye following epileptic seizures
  Matilda Ahl, Sweden

- Beta and gamma suppression of background EEG predicts brain injury and subsequent epilepsy in a rat model of perinatal hypoxia-ischemia
  F.E. Dudek, USA

- Non-invasive detection of fast ripples in low-noise EEG recordings
  Ece Boran, Switzerland

**Parallel Session**
Meeting Hall V

**11:30 – 13:00**

- Classification of the epilepsies
  *Co-chair: Sameer Zuberi, United Kingdom*
  *Co-chair: Emilio Perucca, Italy*

- The framework for the new classification of the epilepsies
  Ingrid Scheffer, Australia

- Summary of online feedback
  Sameer Zuberi, United Kingdom

- Panel discussion
  Emilio Perucca, Italy
  Ingrid Scheffer, Australia
  Sameer Zuberi, United Kingdom

**Parallel Session**
Forum Hall

**14:30 – 16:00**

- The life cycle of antiepileptic drugs
  *Co-chair: Torbjörn Tomson, Sweden*
  *Co-chair: Heinz Beck, Germany*

- Pitfalls of preclinical studies: a tale of networks and power
  Heinz Beck, Germany

- Pitfalls of clinical studies
  Jacqueline French, USA

- Pitfalls during and after approval of antiepileptic drugs
  Hajo Hamer, Germany
**Scientific Programme**

**Wednesday 14th September 2016**

**Parallel Session**
South Hall

14:30 – 16:00

**Seizures and stroke: from bad to worse and what could be done about it?**
Chair: Ivan Rektor, Czech Republic

A devastating outcome of the devastating disease: implications for patients and burden for the society
Alla Guekht, Russian Federation

**Seizures after stroke. Can we predict?**
Miri Neufeld, Israel

**Stroke after seizures**
Eugen Trinka, Austria

**Seizures after stroke. Can we prevent?**
Felix Rosenow, Germany

---

**Scientific Programme**

**Wednesday 14th September 2016**

**Parallel Session**
Panorama Hall

14:30 – 16:00

**Neurostimulation in epilepsy – a joint CEA–EAN Symposium**
Co-chair: Christoph Baumgartner, Austria
Co-chair: Kristl Vonck, Belgium

**Neurostimulation in neurology**
Paul Boon, Belgium

Basic biophysical principles of neurostimulation
Wyse Wadman, Netherlands

**Non invasive neurostimulation**
Christoph Baumgartner, Austria

**Neurostimulation in epilepsy – what have we achieved and where should we go?**
Andreas Schulze-Bonhage, Germany

---

**Inhibition synchronization ahead of seizures – protective or harmful?**
Co-chair: Marco de Curtis, Italy
Co-chair: Roberto Spreadsico, Italy

**Ictal onset and inhibitory networks: inhibition precipitates seizures**
Massimo Avoli, Canada

**The concept of seizure penumbra: inhibition protects against seizures**
Andrew Trevelyan, United Kingdom

**Optogenetic challenge of inhibitory networks and icotogenesis**
Merab Kokaia, Sweden

**GABAergic neurons in human epileptic networks**
Roberto Spreadsico, Italy
**SCIENTIFIC PROGRAMME**

**WEDNESDAY 14TH SEPTEMBER 2016**

**SPECIAL SYMPOSIUM**
Meeting Hall V

14:30 – 16:30  
**Symposium of Excellence in Epileptology**

*Co-chairs: Meir Bialer, Israel  
Co-chair: Martin Brodie, United Kingdom*

**Why is immature brain prone to seizures?**  
Pavel Mareš, Czech Republic

**The spectrum of benign infantile seizures**  
Federico Vigevano, Italy

**Fast oscillations and fast imaging – new ways of understanding epileptic networks**  
Julia Jacobs, Germany

**Epileptic encephalopathies: clues for future diagnosis and management**  
Nicola Specchio, Italy

**Anatomo-electro-clinical reasoning in epilepsy surgery**  
The 2016 Epileptic Disorders–ILAE Educational Award  
Ioana Mindruta, Romania

**SATELLITE SYMPOSIUM**
Forum Hall

16:30 – 18:00  
*Please see page 102 for full details on the satellite symposium*

**PARALLEL SESSION**
South Hall

16:30 – 18:00  
**Mendel’s Symposium – Molecular genetic testing in epilepsies, anno 2016: an essential diagnostic tool**

*Co-chairs: Peter De Jonghe, Belgium  
Co-chair: Vladimir Kondrek, Czech Republic*

**Molecular diagnosis in genetic epilepsies: complexity, needs, tools and opportunities**  
Sarah Wackhuyzen, Belgium

**Next generation sequencing with gene panels: a revolution in molecular diagnostics**  
Johannes Lemke, Germany

**Whole Exome Sequencing (WES) in diagnostics; the new kid on the block**  
Heather Mefford, USA

**Copy number variants: now easy to detect but still difficult to interpret**  
Ingo Helbig, Germany
16:30 – 18:00 Memory in temporal lobe epilepsy – from basic memory research to clinical application in epilepsy surgery

Co-chair: Ylva Østby, Norway
Co-chair: Miri Neufeld, Israel

In search of memory networks in TLE – new evidence and opportunities using fMRI
Mary Pat McAndrews, Canada

Localization/lateralization diagnostics and its value for monitoring of the course and the surgical treatment of TLE
Christoph Helmstaedter, Germany

Memory and the brain in temporal lobe epilepsy – integrating basic science and clinical perspectives in epilepsy surgery
Ylva Østby, Norway

16:30 – 18:00 Genetic (idiopathic) focal epilepsies with sleep activation – “benign” no more?

Co-chair: Edouard Hirsch, France
Co-chair: Helen Cross, United Kingdom

Rolandic epilepsy to epilepsy with CSWS via Landau-Kleffner syndrome: one syndrome or many?
Eliane Roulet-Perez, Switzerland

Insights into neuropsychological impairments from functional neuroimaging
Patrick Van Bogaert, Belgium

Can molecular genetics reveal mechanisms and novel targets for therapy?
Pierre Szepetowski, France

The evidence base for pharmacological therapy & treatment paradigms
Floor Jansen, Netherlands
**WEDNESDAY 14TH SEPTEMBER 2016**

**PARALLEL SESSION**
Meeting Hall V

16:30 – 18:00  
**The neurobiology of Focal Cortical Dysplasias (FCD) – new genes, mechanisms and diagnostic tools**

Co-chair: Ingmar Blümcke, Germany
Co-chair: Betül Baykan, Turkey

The genetics of FCD
Jamel Chelly, France

Epigenetic biomarkers in FCD
Katja Kobow, Germany

New diagnostic tools in FCD (clinical)
Roberto Spreafico, Italy

New challenges in FCD: molecular mechanisms of epileptogenesis
Eleonora Aronica, Netherlands

**EGE FORUM**
Forum Hall

18:15 – 19:45  
**Epilepsy management in countries with limited resources – current state and future perspectives**

Co-chair: Silvio Basic, Croatia
Co-chair: Alla Guekht, Russian Federation

Pharmacoresistant epilepsy – diagnostic and therapeutic challenge in countries with limited resources
Joanna Jędrzejczak, Poland

How to build up and run a video-EEG monitoring unit
Eugen Trinka, Austria

Establishing invasive EEG monitoring (SEEG) in countries with limited resources – our eight year experience
Silvio Basic, Croatia

Advanced techniques in epilepsy surgery with limited resources – neurosurgical point of view
Darko Chudy, Croatia

Panel Discussion (all speakers and chairs): Treating epilepsy in countries with limited resources
18:15 – 19:45 When epilepsy sets in – your (personal/family) life

Chair: David Gosar, Slovenia

Video, short questionnaire, panel discussion, roundtable, open discussion
Stéphane Auvin, France
David Gosar, Slovenia
Petra Musek, Slovenia
Vesna Krkoč, Slovenia
Daša Kočjančič, Slovenia
Ljubica Vrba, Slovenia
Latica Friedrich, Croatia
Gal Grande, Slovenia
Reetta Kälviäinen, Finland

18:15 – 19:45 What is SHE (Sleep-related Hypermotor Epilepsy)? Epileptologists meet sleep experts

Co-chair Paolo Tinuper, Italy
Co-chair Andreas Schulze-Bonhage, Germany

The history of SHE, a new syndrome aged 35 years
Francesca Bisulli, Italy

Looking around (outside of) the frontal lobes
Philippe Kahan, France

Etiology of SHE: genetic, lesional and the blurring boundary
Ingrid Scheffer, Australia

Discussion with the experts in sleep medicine at the European Sleep Research Society Congress in Bologna
Coordinator: Lino Nobili, Italy
**Scientific Programme**

**12th European Congress on Epileptology**

**Scientific Programme**

**Wednesday 14th September 2016**

**Platform Session**

**Panorama Hall**

18:15 – 19:45

**Prognosis and outcome**

*Co-chair: Renzo Guerrini, Italy  
Co-chair: Eva Kumlien, Sweden*

- Outcomes of West syndrome treatment at the long-term follow-up  
  Rimma Gamirova, Russian Federation
- Long-term prognosis of adolescent-onset idiopathic generalised epilepsies  
  Bernd J Vorderwülbecke, Germany
- Epilepsy with auditory features (EAF): long-term outcome in a large cohort  
  Veronica Menghi, Italy
- Post-stroke epilepsy and stroke recurrence in long-term follow-up after ischemic stroke  
  Petra Redfors, Sweden
- Poststroke epilepsy in Sweden: a population-based registry study  
  Johan Zelano, Sweden
- VNS in patients with drug resistant epilepsy: younger age at implantation may result in better efficacy  
  Zvonka Rener-Primec, Slovenia

**Platform Session**

**Meeting Hall V**

18:15 – 19:45

**Varia**

*Co-chair: David Krysl, Czech Republic  
Co-chair: Stefano Meletti, Italy*

- Ictal dystonic posturing with tremor and ipsilateral tonic leg extension after the figure of four sign – new lateralizing and localizing semio logic signs  
  Gudrun Kalss, Austria
- Motor phenomena in vasovagal syncope: clinical aspects and comparison with convulsive seizures  
  Sharon Shmueli, Netherlands
- Preliminary results of a systematic review on diagnostic accuracy and clinical value of long term video-EEG monitoring in non-invasive presurgical evaluation of patients with epilepsy  
  Tela Kobulashvili, Austria
- Polysomnographic based study of sleep in juvenile myoclonic epilepsy patients  
  Sonia Elbhrawy, Egypt
- Late breaking abstract  
  TBC
- Holistic application of new technology to the management of epilepsy: The epilepsy networks project  
  Rupert Page, United Kingdom
Thursday, September 15, 2016

**Forum Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-08.00</td>
<td>Déjà vu phenomenon – physiologic or pathologic?</td>
</tr>
<tr>
<td>08.00-08.30</td>
<td>Increasing Participation in Clinical Research in Epilepsy</td>
</tr>
<tr>
<td>08.30-09.00</td>
<td>Large scale brain networks in epilepsy</td>
</tr>
<tr>
<td>09.00-09.30</td>
<td>Understanding epilepsy through glia</td>
</tr>
<tr>
<td>09.30-10.00</td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Break</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Taking a fresh look at excitation / inhibition (im)balance and its role in seizure generation</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Social cognition in epilepsy patients</td>
</tr>
<tr>
<td>12.00-12.30</td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td>Congress Highlights Session</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td></td>
</tr>
<tr>
<td>13.30-14.00</td>
<td></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td></td>
</tr>
<tr>
<td>14.30-15.00</td>
<td></td>
</tr>
<tr>
<td>15.00-15.30</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td></td>
</tr>
<tr>
<td>16.00-16.30</td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td></td>
</tr>
<tr>
<td>17.00-17.30</td>
<td></td>
</tr>
<tr>
<td>17.30-18.00</td>
<td></td>
</tr>
</tbody>
</table>

---

**South Hall**

- Increasing Participation in Clinical Research in Epilepsy
- Understanding epilepsy through glia
- Large scale brain networks in epilepsy
- Break
- Social cognition in epilepsy patients
- Congress Highlights Session

---

**Meeting Hall I**

- Young investigators forum - Neurovascular alterations in epilepsy
- Epileptic encephalopathies: old and new treatment strategies
- Seizure in Emergency Situations course: Epileptology in the ICU
- Psychiatric disorders in epileptic encephalopathies

**Panorama Hall**

- EEG Technicians course
- Break
- Pharmacological aspects of antiepileptic drugs (AEDs)

**Meeting Hall V**

- Congress Highlights Session
**SCIENTIFIC PROGRAMME**

**THURSDAY 15TH SEPTEMBER 2016**

**ECE FORUM**
Forum Hall

07:30 – 09:00  **Déjà vu phenomenon – physiologic or pathologic?**

*Co-chair: Antonio Gambardella, Italy*
*Co-chair: Milan Brázdil, Czech Republic*

**Presentations and Panel Discussion**
Milan Brázdil, Czech Republic
Adam Zeman, United Kingdom
Angelo Labate, Italy

**ECE FORUM**
South Hall

07:30 – 09:00  **Increasing participation in clinical research in epilepsy**

*Co-chair: Peter Bergin, New Zealand*
*Co-chair: Merab Kokaia, Sweden*

**Interactive Workshop**
Peter Bergin, New Zealand
Ettore Beghi, Italy
Jeremy Jost, France
Tony Marson, United Kingdom

---

**ECF FORUM**
Meeting Hall I

07:30 – 09:00  **Young investigators forum – Neurovascular alterations in epilepsy**

*Co-chair: Erwin van Vliet, Netherlands*
*Co-chair: Nicola Marchi, USA*

**Perivascular inflammation and anti-inflammatory treatment**
Teresa Ravizza, Italy

**Vascular alterations after traumatic brain injury**
Xavier Ekolle Ndode Ekane, Finland

**Role of pericytes in cerebrovascular remodeling and epilepsy**
Nicola Marchi, USA

**mTOR inhibition to restore blood-brain barrier leakage in epilepsy**
Erwin van Vliet, Netherlands

**Losartan prevents acquired epilepsy via TGF-β signaling suppression**
Guy Bar-Klein, Israel
TEACHING COURSE  
Panorama Hall

08:00 – 10:00  EEG Technician Course

Co-chair: Jana Zarušová, Czech Republic  
Co-chair: Christian Skaarup, Denmark

Activation methods during EEG – benefits, risks  
Irena Doležalová, Czech Republic  
Petr Zlonicky, Czech Republic

Safety in epilepsy monitoring unit and role of technicians  
Gudrun Kalis, Austria

Artifacts – tips and tricks to avoid them  
Christian Skaarup, Denmark

Ambulatory electroencephalography and home video-EEG monitoring  
Franz Brunnhuber, United Kingdom

TEACHING COURSE  
Meeting Hall V

08:00 – 12:30  Epileptology in the ICU

Co-chair: Eugen Trinka, Austria  
Co-chair: Andrea Rossetti, Switzerland

Definition, classification, and incidence of status epilepticus  
Eugen Trinka, Austria

EEG features and differential diagnosis of status epilepticus  
Vincent Navarro, France

Treatment of status epilepticus  
Felix Rosenow, Germany

Clinical neurophysiology for the prognosis of postanoxic coma  
Andrea Rossetti, Switzerland

The ACNS EEG nomenclature: usefulness and limits  
Nicolas Gaspard, Belgium
09:00 – 10:30  
**Large scale brain networks in epilepsy**

Co-chair Maxime Guye, France  
Co-chair Serge Vulliemoz, Switzerland

- Contribution of network structure and dynamics to EEG-based diagnosis of epilepsy  
  Mark Richardson, United Kingdom

- The role of the relation between cognition and large scale networks in focal epilepsies  
  Ivan Rektor, Czech Republic

- Can we define specific properties of epileptogenic networks by studying large-scale networks during interictal state?  
  Maxime Guye, France

09:00 – 10:30  
**Understanding epilepsy through glia**

Co-chair Christian Steinhäusser, Germany  
Co-chair Pavel Mareš, Czech Republic

- A new mouse model of mesial temporal lobe epilepsy to identify the role of activated microglia and dysfunctional astrocytes in early epileptogenesis  
  Peter Bedner, Germany

- Optogenetic analysis of astrocyte gliotransmission in the healthy and epileptic hippocampus of the mouse  
  Etienne Audinat, France

- Abnormal astrocytic Ca2+ signalling in the sclerotic hippocampus of awake mice: two-photon imaging using the unilateral intracortical kainate model of mesial temporal lobe epilepsy  
  Kjell Heuser, Norway

- The relationship between seizure activity per se and neuroinflammation: specific glial molecule expression in the intrahippocampal kainate model and in human dysplasias  
  Marco de Curtis, Italy  
  Rita Garbelli, Italy

- Experimental considerations for in vivo Ca2+ imaging in animal models of epilepsy  
  Frank Kirchhoff, Germany

- The pros and cons of a brain slice model to investigate the role of astrocytes in acute focal seizures  
  Giorgio Carmignoto, Italy
**Scientific Programme**

**Thursday 15th September 2016**

**ECE Forum**
Meeting Hall I

**09:00 – 10:30**  

**Epileptic encephalopathies: old and new treatment strategies**  
*Co-chair: Federico Vigeano, Italy  
Co-chair: Petia Dimova, Bulgaria*

**Epileptic encephalopathy versus encephalopathy with epilepsy**  
Nicola Specchio, Italy

**From diagnosis to standard therapeutic approach**  
Federico Vigeano, Italy

**Alternative treatments in epileptic encephalopathies**  
Stéphane Auvin, France

**Epilepsy surgery and neuromodulation**  
Petia Dimova, Bulgaria

---

**Teaching Course**
Panorama Hall

**10:30 – 12:30**  

**Pharmacological aspects of antiepileptic drugs (AEDs)**  
*Co-chair: Svein Johannessen, Norway  
Co-chair: Hana Kubová, Czech Republic*

**What is the best mechanism of action for optimal response and tolerability?**  
Hana Kubová, Czech Republic

**Can we hope for newer and better antiepileptic drugs?**  
Meir Biaser, Israel

**Is pharmacokinetic variability of clinical importance?**  
Cecilie Johannessen Landmark, Norway

**Can pharmacokinetic variability be controlled for patients’ benefit?**  
Svein Johannessen, Norway
12th European Congress on Epileptology

SCIENTIFIC PROGRAMME

THURSDAY 15TH SEPTEMBER 2016

ECF FORUM
Forum Hall

11:00 – 12:30
Taking a fresh look at excitation / inhibition (im)balance and its role in seizure generation. A pro and contra debate

Co-chair: Rüdiger Köhling, Germany
Co-chair: Massimo Avoli, Canada

Pro inhibition: Inhibitory activity and seizure initiation
Marco de Curtis, Italy

Pro excitation: And what about excitation? Is there still a role for the excitation-inhibition imbalance, or do we have to rephrase it?
Gilles Huberfeld, France

Pro inhibition? Optogenetic modulation of chloride using optogenetics: an approach to tackle seizures?
Andrew Trevelyan, United Kingdom

Pro excitation? Taking a new look at an old acquaintance: role of potassium in seizure generation
Massimo Avoli, Canada

ECF FORUM
South Hall

11:00 – 12:30
Social cognition in epilepsy patients

Co-chair: Hrvoje Hecimovic, Croatia
Co-chair: Petr Marusic, Czech Republic

Presentations & Panel Discussion
Bettina Steiger, Switzerland
Stefano Meletti, Italy
Jana Ámherova, Czech Republic
Hrvoje Hecimovic, Croatia

ECF FORUM
Meeting Hall I

11:00 – 12:30
“Epilepsy is more than seizures”: psychiatric disorders in epileptic encephalopathies, an underdiagnosed condition

Co-chair: Rima Nabbout, France
Co-chair: Nicola Specchio, Italy

Series presentation (DS/PCDH19/TSC) and general panel discussion
Lisa Ouss, France
Nicola Specchio, Italy
Elisabeth Thiele, USA

HIGHLIGHTS SESSION
Forum Hall

12:30 – 13:30
Highlights Session

Co-chair: Meir Bialer, Israel
Co-chair: Milan Brázdił, Czech Republic

Pharmacology highlights
Christian Elger, Germany

Basic science highlights
Hana Kubová, Czech Republic

Surgery highlights
Margitta Seeck, Switzerland

Paediatric highlights
Sameer Zuberi, United Kingdom
SATELLITE SYMPOSIA

SUNDAY 11TH SEPTEMBER

Satellite Symposium
Meeting Hall I

16:30 – 18:00 LivaNova: SUDEP and mortality – expect the unexpected

Chair: Philippe Ryvlin, Switzerland

Introduction – expect the unexpected
Philippe Ryvlin, Switzerland

SUDEP – epidemiology & pathophysiology
Torbjörn Tomson, Sweden

Roadmap to prevention – Seizure Detection & Biomarkers
Orrin Devinsky, USA

VNS therapy & SUDEP
Philippe Ryvlin, Switzerland

MONDAY 12TH SEPTEMBER

Satellite Symposium
Meeting Hall I

07:30 – 09:00 Zogenix Incorporated: understanding the biology and treating early-onset epileptic encephalopathies (EEs): how will evolving science shape future treatments?

Co-chair: Joseph Sullivan, USA
Co-chair: Lieven Lagae, Belgium

Basic science and preclinical models of EEs – improving the construct, face, and predictive validity of current models in the search for new treatment options
Ben Whalley, United Kingdom

The evolving and critically important role of genetics in EEs
Rima Nabbout, France

Early-onset EE management – might treatment change as the science evolves?
Tilman Polster, Germany

Satellite Symposium
Forum Hall

16:30 – 18:00 Elekta: Magnetoencephalography: a useful tool in the clinical practice

Chair: Paul Boon, Belgium

Value of MEG in clinical neurology
Evelien Carrette, Belgium

MEG and high-density EEG: is it useful or diagnostic overkill?
Hermann Stefan, Germany

Source montages: scanning the MEG for spikes in source space
Sándor Beniczky, Denmark
TUESDAY 13TH SEPTEMBER

Satellite Symposium
Panorama Hall

07:30 – 09:00  EISAI Europe: Reflections on the AMPA receptor as a target in epilepsy

Chair: Matthew Walker, United Kingdom

AMPA receptors in seizure pathophysiology
Matthew Walker, United Kingdom

Spotlight on AMPA receptors in focal seizures associated with brain tumours
Antonietta Coppola, United Kingdom

Focus on the patient: applying knowledge to clinical decision-making
Mar Carreño, Spain

Discussion with Q&A

Satellite Symposium
Forum Hall

16:30 – 18:00  Eisai and Bial – Portela & C S.A.: Optimising Epilepsy Monotherapy: unmasking the smoke & mirrors

Chair: Martin Holtkamp, Germany

The US conversion to monotherapy trials
Jacqueline French, USA

The EU non-inferiority monotherapy trials
Eugen Trinka, Austria

Discussion with the active participation from the audience, moderated by the chairman
Martin Holtkamp, Germany

WEDNESDAY 14TH SEPTEMBER

Satellite Symposium
Panorama Hall

07:30 – 09:00  EISAI Europe: Debating the impact of AEDs on behavioural change and cognitive impairment in epilepsy

Chair: Mar Carreño, Spain

DEBATE 1: Should behavioural and psychiatric side effects limit our use of AEDs?
Martin Brodie, United Kingdom
Matthew Walker, United Kingdom

DEBATE 2: Are cognitive impairments in patients with epilepsy caused primarily by AEDs?
Lieven Lagae, Belgium
Christoph Helmstaedter, Germany

Discussion and Q&A. Moderated by the chair, with participation from all speakers
Mar Carreño, Spain
WEDNESDAY 14TH SEPTEMBER

Satellite Symposium
Forum Hall

16:30 – 18:00
EISAI Europe: Lessons from the clinic: What have we learned from real-world use?

Chair: Milan Brázdil, Czech Republic

Clinical experience from large cohorts
Eugen Trinka, Austria

Real-world evidence in special sub-populations
Bertrand de Toffol, France

Putting real-world data into practice: case studies in idiopathic generalised epilepsies
José Serratos, Spain

My perspective: The patient voice
Patient speaker

Conclusions and Q&A
POSTERS INFORMATION

Posters are exhibited in the Forum Hall Foyer, situated on the second floor of the congress centre directly above the Registration Area. Posters are on display from 10:00 to 17:00, Monday to Wednesday, with different posters presented each day. Poster presenters are required to set up their posters between 09:00 and 10:00 each morning. Posters must be removed each evening between 17:00 and 18:00.

The poster abstracts are available on the 12th ECE website www.epilepsyprague2016.org in the interactive session planner. Full abstracts, including the authors’ list and affiliations, will be published in an Epilepsia online supplement post congress.

Delegates can search for abstracts by keywords and access the full papers on the Congress App which can be downloaded from the App Store on your device.

POSTER TOURS

The International Scientific and Organising Committee has chosen to organise guided poster tours (led by experts in the field) giving researchers the opportunity to present their work during the congress. Presenters will be available at their posters on their assigned day. Each presenter shall be given three minutes to outline their findings and answer questions.

Guided poster tours will start at 13:00, Monday – Wednesday, from the first poster listed in each tour.

Please note that abstracts number 001 to 106 have been selected for platform presentation.

MONDAY 12TH SEPTEMBER

13:00 – 14:30 BASIC SCIENCE 1

P107 Comparison of tyrosine hydroxylase immunoreactivity in substantia nigra pars compacta between gaers and wistar rats
Ozlem Akman, Turkey

P108 The myelin mutant taiep rat as a model of absence epilepsy
Jose Eguibar, Mexico

P109 Effect of external perturbations on seizure dynamics – in vitro results and computational modelling
Jaroslav Hlinka, Czech Republic

P110 A new rat model of infantile spasms based on methylazoxymethanol (MAM)-induced cortical dysplasia
Eun-Hee Kim, Korea, Republic of

P111 Aliskiren, a direct renin inhibitor, protects against pentylenetetrazole-induced seizures in mice
Krzysztof Łukawski, Poland

P112 Effect of GABA-B drugs on seizures and motor performance in immature rats
Pavel Mareš, Czech Republic

P113 Somatostatin immunoreactive interneurons survival in the intrahippocampal kainite model. A model characterization
Esbjörn Melin, Sweden

P114 A new rat model of sustained cortical spike-and-wave seizures
Cristian Sevcencu, Denmark

P115 Acute electrophysiological changes induced by cortical photochemical ischemia in adult rat
Jan Svoboda, Czech Republic

P116 Computational assessment of hippocampal sclerosis in mesial temporal lobe epilepsy
Anna Maria Toeglhofer, Austria

P117 Neurochemical changes in the endothelin-1 model of focal cerebral ischemia in immature rats
Kateřina Vondráková, Czech Republic
MONDAY 12TH SEPTEMBER

13:00 – 14:30 BASIC SCIENCE 2

P118 Training in novelty exploration tasks prevents cognitive decline in a rat model of temporal lobe epilepsy
Ángela Amaro-Leal, Portugal

P119 Aberrant neuronal activity and behavior is underlined by the loss of constitutive androstane receptor
Badreddine Boussadia, France

P120 The peculiarities of epileptiform activity formation in rats during subconvulsive doses picrotoxin and pentylenetetrazole repetitive injections
Oksana Viktorovna Denysenko, Ukraine

P121 Antiepileptic potential of K+-channels in acute and chronic models of epilepsy
Rüdiger Köhling, Germany

P122 Do seizures effect cerebral uptake mechanisms for essential compounds? Preliminary results from rat lithium pilocarpine model
Aniv Mann, Israel

P123 Analysis of HFOs during microseizures in humans with epilepsy
Eva Martínez-Lizana, Spain

P124 Differential epileptiform activity results in disparate responses in interneurons
R Ryley Parrish, United Kingdom

P125 The progression of EEG abnormalities during epileptogenesis after lateral fluid percussion injury
Ayllin Reid, Canada

P126 Chronic deficiency in the brain energy supply is a triggering mechanism in the early stage of epileptogenesis
Evgenia Samokhina, Russian Federation

P127 Uncomplete recovery from Mg2+ suppression of nonsynaptic epileptiform activity on an invertebrate model system
Marija Stanojević, Serbia

P128 A novel focal seizure pattern associated with blockade of synaptic transmission
Laura Uva, Italy

MONDAY 12TH SEPTEMBER

13:00 – 14:30 CLINICAL EPILEPSY 1

P170 Prevalence and clinical characteristic of childhood-onset frontal lobe epilepsy in Algiers
Walid Abdellaoui, Algeria

P171 Diagnostic text database on Android OS tablet personal computer which contains the typological classification of motor, sensory, autonomic, cognitive, psychic paroxysmal symptoms and their related seizures/syndromes with algorithm based on symbolic logical duality and intersection of common syndrome
Vladimir Andreev, Russian Federation

P172 Evaluation of 11 cases with epileptic nystagmus
Ibrahim Aydogdu, Turkey

P173 Complex and non-stereotyped visual hallucinations as symptoms of acute symptomatic crises
Paolo Benna, Italy

P174 Use of the DISCOVER form (a structured diagnostic interview) to ensure correct classification in a study of disease impact
Jacqueline French, USA

P175 Prone sleeping and SUDEP risk: the dynamics of body positions in non-fatal convulsive seizures
Sharon Shmuely, Netherlands

P176 Classification and therapeutic outcome in 96 cases with Sturge-Weber syndrome
Hiroharu Suzuki, Japan

P177 Using random forest for diagnosis and lateralization of temporal lobe epilepsy from EEG-based directed functional connectivity
Pieter van Mierlo, Belgium

P178 Non-convulsive status epilepticus in children and young adults at a residential epilepsy centre
Daniel Yusef, United Kingdom
MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL EPILEPSY 2

P179  Superficial hemosiderosis of the central nervous system: a rare cause of epilepsy
Filip Derke, Croatia

P180  Antiepileptic drug treatment in elderly patients with epilepsy
Revital Gandelman-Marton, Israel

P181  Sleep changes and epilepsy in Alzheimer’s: causes or complications?
András Horváth, Hungary

P182  Clinical features and prognosis of epilepsy in the elderly in western China
Cheng Huang, China

P183  Lacosamide as conversion to monotherapy in older adults with epilepsy: a retrospective study
Francesca Izzi, Italy

P184  Acute symptomatic seizures and epilepsy in stroke patients; etiological subtypes and clinical characteristics
Petr Jansky, Czech Republic

P185  Status epilepticus in the elderly patients: a national data study in Thailand
Somsak Tiamkao, Thailand

MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL NEUROPHYSIOLOGY 1

P222  Blink reflex studies in genetic generalized epilepsy patients with eyelid myoclonia
Gunes Altıokka Uzun, Turkey

P223  Added value of the inferior temporal electrode chain in the identification of EEG abnormalities
Sándor Beniczky, Denmark

P224  Afternoon NAP versus all-night sleep EEG for the diagnosis of ESES
Elena Gardella, Denmark

P225  Changes in cardiovascular autonomic function in patients with newly diagnosed epilepsy
Rajesh Kumar Goit, Nepal

P226  Single calcified neurocysticercosis lesion as a true Pediatric epilepsy subtype in endemic regions: a prevalence and clinico-electroencephalographic-anatomical correlation study
Rachana Dubey, India

P227  Caffeine maintains arousal level and prevents change of electroencephalogram spectra powers
Howon Lee, Korea, Republic of

P228  Chloral hydrate is more effective than melatonin in inducing sleep for sleep-deprived children undergoing paediatric EEG
Hian-Tat Ong, Singapore

P229  A pilot study of ambulatory home video telemetry (AHVT) in adults at St Thomas’ Hospital, London
Joanne M Pauline, United Kingdom

P230  Automated classification of epileptic spikes in iEEG recorded during fMRI acquisition for improved BOLD modelling
Niraj Sharma, United Kingdom
MONDAY 12TH SEPTEMBER

13:00 – 14:30  CLINICAL NEUROPHYSIOLOGY 2

P231  Coherent analysis of interconnections in the drug-resistant multifocal epilepsy pathologic system
      Michael Alexandrov, Russian Federation

P232  Contribution of video-electroencephalography in the study of non-epileptic psychogenic seizures
      Fatoumata Ba, Senegal

P233  Framework for introducing high-frequency oscillation analysis into clinical decision making process
      Jan Cimbalnik, Czech Republic

P234  Convenient and portable subcutaneous EEG monitor for ultra-long term out-patient use
      Jonas Duun-Henriksen, Denmark

P235  Detection of epileptic seizures using phase–amplitude coupling in intracranial electroencephalography
      Kohtaroh Edakawa, Japan

P236  Electroencephalogram findings in patients with uremic encephalopathy
      Dragica Milikic, Montenegro

P237  Electro-clinical features of Video-EEG recorded seizures in 51 patients with TSC related epilepsy
      Alessia Mingarelli, Italy

P238  Differentiating epileptic from non-epileptic high frequency iEEG signals using wavelet entropy
      Anne H Mooij, Canada

P239  Epilepsy and sleep apnea: comorbidity or related disorder?
      Natela Okujava, Georgia

P240  Frequency domain connectivity patterns in EEG focal and generalized interictal epileptogenic discharges and its relation to 3-D spike source analysis
      Alberto Pinzon, USA

P241  Electroclinical features of epilepsy associated with SYNGAP1 mutation
      Vasiliki Tsirka, United Kingdom

P262  Periventricular nodular heterotopia and epileptic seizures
      Eleni Alexiou, Greece

P263  Stereo-EEG recording, radiofrequency thermocoagulation and neuropathologic correlations in a patient with MRI negative type IIb focal cortical dysplasia
      Rita Garbelli, Italy

P264  Early seizures in patient with acute stroke in Kosovo
      Valbona Govori, Albania

P265  Electroencephalographic markers of preictal disorders
      Marina Korsakova, Russian Federation

P266  Electroencephalographic change of non-affected side of hemimegalencephaly and developmental progress after hemispherotomy
      Eiji Nakagawa, Japan

P267  The role of cerebral imaging in diagnosing a rare case of electro-clinically silent tuberous sclerosis
      Smaranda Antonia Nita, Romania

P268  Anti-epileptic treatment of five adult institutionalized patients with subcortical band heterotopia due to DCX mutations: a 20-year follow-up
      Helenius Jurgen Schelhaas, Netherlands

P269  Focal cortical dysplasia associated to brain tumor (FCD Type IIIb according the ILAE). Clinic, pathological and immunohistochemistry approaches. Running head: focal cortical dysplasia associated to brain tumor
      Martha Lilia Tena Suck, Mexico

P270  Focal cortical dysplasia associated with cavernoma (FDC Type IIIc according the ILAE). Clinical, histopathology and immunohistochemistry correlation
      Salvador Vergara Lopez, Mexico
**MONDAY 12TH SEPTEMBER**

**EPILEPSY IN CHILDHOOD 2**

13:00 – 14:30

**P296**
A new homozygous mutation on NPC2 gene: as a cause of refractory epilepsy in a child  
Kürşad Aydın, Turkey

**P297**
Antiphospholipid antibodies in children with epilepsy  
Cornelia Calci, Moldova, Republic of

**P298**
Genetic syndromes in children with epileptic encephalopathia  
Maria Fomina, Russian Federation

**P299**
Serum trace element levels in children with epilepsy; an observational study  
Sheffali Gulati, India

**P300**
Hippocampal neurogenesis after seizures: a role in development of chronic epilepsy  
Ayushi Jain, India

**P301**
Evaluation of cognitive and behavioral functions in children of epileptic mothers  
Nirmeen Kishk, Egypt

**P302**
Etiology of convulsive and nonconvulsive seizures in patients with severe TBI  
Olga Kochetkova, Russian Federation

**P303**
A refractory epilepsy case with ictal asystole  
Leman Tekin Orgun, Turkey

**P304**
A rare form of seizure: epileptic nystagmus  
Leman Tekin Orgun, Turkey

**MONDAY 12TH SEPTEMBER**

**EPILEPSY IN CHILDHOOD 3**

13:00 – 14:30

**P305**
Children and adolescents with neurofibromatosis type 1 without epilepsy: how useful are EEG and MRI?  
Bora Cekic, Serbia

**P306**
BDNF in children with epilepsy  
Svetlana Hadjiu, Moldova, Republic of

**P307**
Behavioral disturbances in children with epilepsy  
Svetlana Hadjiu, Moldova, Republic of

**P308**
Correction of cognitive deficiency in children having cerebral palsy with symptomatic epilepsy  
Tatiana Kazennykh, Russian Federation

**P309**
Characteristics of Polish paediatric patients with early and late post-stroke seizures  
Ilona Kopyta, Poland

**P310**
Crohn’s disease associated with focal epilepsy and neuroimaging findings of hippocampal sclerosis and cerebral hemiatrophy  
Kelin Cristine Martin, Brazil

**P311**
Comparison of Polish paediatric patients with and without diagnosed post-stroke epilepsy  
Beata Sarecka-Hujar, Poland

**P312**
Case report with autoimun epilepsy  
Aferdita Tako Kumaraku, Albania

**P313**
Initial treatment of epileptic disintegrative disorders in children  
Dmitry Zaytsev, Russian Federation
P358 Epilepsy, cutis verticis gyrata, dysphagia, severe intellectual disability, and other features: a new epilepsy syndrome?
Simona Balestrini, United Kingdom

P314 Epilepsy in young Tsc1+-/ mice exhibits age-dependent expression mimicking that of human tuberous sclerosis complex
Svetlana Gataullina, France

P315 Electroencephalogram requests in paediatrics: are paediatricians following NICE (National Institute of Clinical Excellence) guidance?
Eleanor Glenday, United Kingdom

P316 Etiology and clinical characteristics of seizures in the first year of life treated in tertiary center: a cohort of 127 infants
Miljana Grkinic Jovanovic, Serbia

P317 Epidemiology of epilepsy in pediatric population in Zabaikalsky Krai
Natalia Marueva, Russian Federation

P318 Encephalitis associated with GABAA-R autoantibodies in a child: long-term outcome and therapeutic challenges
Giorgia Olivieri, Italy

P319 ESES – “The stranger with many faces”: our clinical experience
Eugenia Roza, Romania

P320 Epilepsy after stroke in children
Inna Shchederkina, Russian Federation

P321 Epilepsy with myoclonic atonic seizures in a seven-years old child with ischemic cerebral stroke – a consequence or a parallel condition?
Gabriela Tavchioska, Macedonia, the Former Yugoslav Republic of

P365 Clinical and neurophysiological features of patients with PCDH19-related epilepsy
Katrin Bamdeg, Denmark

P366 A novel FARS2 mutation in familial cases of early onset epileptic encephalopathy
Jae So Cho, Korea, Republic of

P367 De novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy
Iris De Lange, Netherlands

P368 Congenital central hypoventilation syndrome. Clinical case
Valentina Ivanovna Guzeva, Russian Federation

P369 Clinical heterogeneity and its potential therapeutic implications in children with SCN2A-related disorders
Katrine M Johannesen, Denmark

P370 A family with epilepsy and intellectual disability due to an ARHGEF9 mutation
Karl Martin Klein, Germany

P371 Diagnostic targeted next generation sequencing in patients with epilepsy
Patrick Rump, Netherlands

P372 Diagnostic epilepsy gene panel testing – first results from the Czech Republic
Katalin Štěrbová, Czech Republic

P373 830 monogenic diseases with epilepsy or seizures – a contemporary gamut of epilepsy genetics
Birutė Tumiene, Lithuania
MONDAY 12TH SEPTEMBER

13:00 – 14:30 NEUROIMAGING 1

P401 Bilateral thalamic volume loss in patients with pharmacoresistant temporal lobe epilepsy with and without hippocampal sclerosis Stanislav A Groppa, Moldova, Republic of

P402 Directed functional connectivity during interictal spikes: a simultaneous intracranial and high-density scalp EEG study Ana Coito, Switzerland

P403 Diffusion tensor imaging and MRI tractography of the brain in patient with epilepsy and depression Tatiana Kapustina, Russian Federation

P404 Altered basal ganglia-cortical connections in frontal lobe epilepsy using resting-state fMRI functional connectivity analysis Tiejun Liu, China

P405 Beamforming improves ripple visibility in scalp EEG Arjen Mol, Netherlands

P406 Brivaracetam enters the human brain faster than Levetiracetam Jonas Hannestad, Belgium

P407 Distinctive patterns of seizure-induced white matter damage in right and left temporal lobe epilepsy Irena Štěpán-Buksakowska, Czech Republic

P408 Altered functional connectivity in temporal lobe epilepsy patients with verbal memory impairment Naoki Tani, Japan

P409 Contributions of regional properties on patient network connectomics Peter Neal Taylor, United Kingdom

P410 Decreased default mode network in drug-resistant generalized tonic-clonic seizures Zhongyuan Wang, China

MONDAY 12TH SEPTEMBER

13:00 – 14:30 NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 1

P442 Epilepsy and depression: Recognizing the double burden in Albania Serla Grabova, Albania

P443 Long term follow-up of neuropsychological outcome in patients with temporal lobe epilepsy Candan Gurses, Turkey

P445 Complexity of ictal-onset ECoG patterns in patients with type II cortical dysplasia Antonina Kozlova, Russian Federation

P446 Comparative description of psychic and emotional state of parents bringing up children with chronic neurologic pathology Alisa Kudlatch, Belarus

P447 Generalized epileptiform activity in sleep disrupts cognitive functions in children with intractable extratemporal epilepsy Vilém Novák, Czech Republic

P450 Developmental delay in Verbal working memory (WM) at the start of primary school in children with epilepsy compared to controls matched for verbal short term memory (STM) Loretta van Iterson, Netherlands

P451 Neuropsychological outcome after temporobasal versus transsylvian approach for selective amygdalohippocampectomy in patients with temporal lobe epilepsy – a randomized prospective clinical trial Viola Vogt, Germany

P452 Emotion recognition in patients with mesial temporal lobe epilepsy Oliwia Zaborowska, Poland

P444 Cognitive problems in children and adolescents with epilepsy: validity of a standardized proxy report measure (KOPKIJ) Christoph Helmstaedter, Germany

P448 Are the neuropsychological profiles of temporal lobe epilepsy patients with neuronal auto-antibodies different? Mine Sezgin, Turkey

P449 A 7 year neuropsychological follow-up of a well functioning girl with Aicardi syndrome Mia Tuft, Norway
### MONDAY 12TH SEPTEMBER

#### OTHERS 1

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P473</td>
<td>Clinical response to oral cannabis extracts in severe refractory epilepsy: preliminary experience in chilean patients</td>
<td>Gisela Kuester, Chile</td>
<td>Chile</td>
</tr>
<tr>
<td>P474</td>
<td>Perception and used of alternative treatment among patients with epilepsy</td>
<td>Sunee Lertsinudom, Thailand</td>
<td>Thailand</td>
</tr>
<tr>
<td>P475</td>
<td>Beta lactams antibiotic ceftriaxone modulates seizures, oxidative stress and connexin 43 (Cx43) expression in hippocampus of pentylentetrazole kindled rats</td>
<td>Khaled Sadek, Egypt</td>
<td>Egypt</td>
</tr>
<tr>
<td>P476</td>
<td>Stress and seizures: development and piloting of a self-help stress management intervention for patients with seizures</td>
<td>Barbora Novakova, United Kingdom</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>P477</td>
<td>Quantitative biomarker of VNS therapy using EEG data</td>
<td>Maryam Ravan, USA</td>
<td>USA</td>
</tr>
<tr>
<td>P478</td>
<td>Role of oxidative stress, neuroprotective heat shock protein 70 and connexin 43 in pentylentetrazole-induced seizures in rats: possible protective effect of ferulic acid</td>
<td>Khaled Sadek, Egypt</td>
<td>Egypt</td>
</tr>
<tr>
<td>P479</td>
<td>The efficacy of an 8 day comprehensive care program for inpatients with epilepsy</td>
<td>Frank Seyer, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>P480</td>
<td>Low glycemic index diet for the treatment of refractory epilepsy in children and young adults: a systematic review of efficacy</td>
<td>Leeha Singh, India</td>
<td>India</td>
</tr>
<tr>
<td>P481</td>
<td>Experience of using intravenous immunoglobulin for treatment of resistant forms of epilepsy in children</td>
<td>Tetiana Stetsenko, Ukraine</td>
<td>Ukraine</td>
</tr>
</tbody>
</table>

#### OTHERS 2

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P482</td>
<td>Zinc treatment in epilepsy due to PIGA mutations</td>
<td>Marie Therese Abi Warde, France</td>
<td>France</td>
</tr>
<tr>
<td>P483</td>
<td>Investigation of the expression of calcium binding proteins in somatosensory cortex of WAG/Rij rats</td>
<td>Sertan Arkan, Turkey</td>
<td>Turkey</td>
</tr>
<tr>
<td>P484</td>
<td>Evaluation of synaptic protein alterations during the acute, sub-acute, and chronic inflammatory response following status epilepticus (SE)</td>
<td>Una Avdic, Sweden</td>
<td>Sweden</td>
</tr>
<tr>
<td>P485</td>
<td>In vivo longitudinal changes in interictal metabolism and cannabinoid type 1 receptor expression during temporal lobe epileptogenesis</td>
<td>Evy Cleeren, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>P486</td>
<td>Expression of miR22 in mesial temporal lobe epilepsy patients– a preliminary study</td>
<td>Bárábara Leal, Portugal</td>
<td>Portugal</td>
</tr>
<tr>
<td>P487</td>
<td>2-deoxy-D-glucose-mediated deceleration of kindling-induced epileptogenesis is reflected by 18-F-FDG brain kinetics</td>
<td>Ina Leiter, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>P488</td>
<td>Activation of transforming growth factor beta (TGFβ) signalling in mesial temporal lobe epilepsy (MTLE) patients</td>
<td>Debasmita Paul, India</td>
<td>India</td>
</tr>
<tr>
<td>P489</td>
<td>The impact of music on the bioelectrical activity of the brain in children with idiopathic epilepsy</td>
<td>Domantė Sakalauskaitė, Lithuania</td>
<td>Lithuania</td>
</tr>
<tr>
<td>P490</td>
<td>The Mozart effect comparing in children and adults with intractable epilepsy</td>
<td>Sheida Shaafi, Iran, Islamic Republic of</td>
<td>Iran</td>
</tr>
<tr>
<td>P491</td>
<td>Expression of MRP/ P-glycoprotein in pharmacoresistant temporal lobe epilepsy in PTZ-kindled mice</td>
<td>Mehwish Tanveer, Pakistan</td>
<td>Pakistan</td>
</tr>
</tbody>
</table>
MONDAY 12th SEPTEMBER

13:00 – 14:30  OTHERS 3

P492  Anticonvulsant and neuroprotective effects of argan oil on pilocarpine model induced status epilepticus in Wistar rats
Youssef Bahbiti, Morocco

P493  Role of the RNA-binding proteins Pumilio 2 and Staufen 2 in epileptogenesis – impacts on neurogenesis and long-term memory
Antonia Demleitner, Germany

P494  The SeLECT score: a novel tool to predict seizures after ischemic stroke
Marian Galovic, United Kingdom

P495  The study of citicoline (cytidine 5′-diphosphocholine) effect on seizure-induced neuronal death
Sung-Hee Hwang, Korea, Republic of

P496  Presurgical diagnosis and differentiated surgical treatment of drug-resistant focal and multifocal temporal lobe epilepsy basing on epileptogenesis conception
Svetlana Kravtsova, Russian Federation

P497  Diagnostic challenges in non-epileptic psychogenic seizures
Gulnihar Kutlu, Turkey

P498  Novel biallelic missense mutations in CTC1 gene identified in a Chinese family with cerebroretinal microangiopathy with calcification and cysts (CRMCC)
Hua Lin, China

P499  Whole exome sequencing reveals novel NOV and DCAF13 mutations in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy
Hua Lin, China

P500  Ischemia and inflammation are involved in the onset of epilepsy in Sturge-Weber syndrome
Madoka Nakajima, Japan

P501  Low levels of secure attachment styles in patients with psychogenic non-epileptic seizures
Antonia Villagran, Norway

124  www.epilepsyprague2016.org

MONDAY 12th SEPTEMBER

13:00 – 14:30  PHARMACOLOGY/AEDS 1

P543  Effect on serum vitamin D levels and bone mineral density in children aged 3 to 14 years with newly diagnosed epilepsy on 6 months of valproate monotherapy – a longitudinal study
Sheffali Gulati, India

P544  A retrospective study of Lacosamide efficacy and tolerability as early and late add-on treatment in adult patients with focal epilepsy
Andrew Lawley, United Kingdom

P545  A randomized, open-label, parallel group, multi-center comparative trial of levetiracetam and topiramate as adjunctive treatment in refractory focal epilepsy
Byung-In Lee, Korea, Republic of

P546  Alteration in grey matter volumes in children of mothers with epilepsy
Ruma Madhu Sreedharan, India

P547  A validated high performance liquid chromatographic method for lamotrigine analysis in plasma samples
Janet Mifsud, Malta

P548  Some words about the effectiveness of perampanel as adjunctive therapy for pharmacoresistant epilepsy in children
Gulisa Musina, Russian Federation

P549  Adverse drug reaction of antiepileptic drugs in epilepsy clinic, Tertiary Hospital, Thailand
Thanida Nuntasaen, Khonkaen, Thailand

P550  Add-on antiepileptic drug treatment in patients with seizures after epilepsy surgery
Michal Ryzí, Czech Republic
MONDAY 12th SEPTEMBER

13:00 – 14:30 \textbf{PHARMACOLOGY/AEDS 2}

\textbf{P566} \hspace{1cm} Antiictogenic and antiepileptogenic properties of perampanel in mature and immature rats  
Stéphane Auvin, France

\textbf{P567} \hspace{1cm} Analysis of antiepileptic drug selection based on the known mechanism of action in difficult-to-treat partial epilepsy  
Gábor Barcs, Hungary

\textbf{P568} \hspace{1cm} Alzheimer’s disease, epilepsy and eslicarbazepine  
Pedro Emilio Bermejo, Spain

\textbf{P569} \hspace{1cm} Antiepileptic drug-induced skin reactions in Polish patients with epilepsy  
Magdalena Bosak, Poland

\textbf{P570} \hspace{1cm} Availability of antiepileptic drugs in primary care hospitals of northeastern, Thailand  
Nanthaphan Chainirun, Thailand

\textbf{P571} \hspace{1cm} Clinical use of PER in real-life clinical setting: a retrospective study in patients with “super-refractory” epilepsies  
Jinane Fattouch, Italy

\textbf{P572} \hspace{1cm} Bone metabolism serum markers in adult patients with epilepsy and effect of Vitamin D administration on the control of seizures  
Mario Tombini, Italy

\textbf{P573} \hspace{1cm} Clinical effects and MRI morphometry changes after using antiepileptic drugs in temporal lobe epilepsy in Uzbekistan  
Azamatjon Umarov, Uzbekistan

---

\textbf{MONDAY 12th SEPTEMBER}

13:00 – 14:30 \textbf{PHARMACOLOGY/AEDS 3}

\textbf{P574} \hspace{1cm} Drug and substance abuse in refractory epilepsy  
Raafat Abdeldayem, Egypt

\textbf{P575} \hspace{1cm} Effectiveness and tolerability of Perampanel in children and adolescents with refractory epilepsies – an Italian multicenter study  
Paola De Liso, Italy

\textbf{P576} \hspace{1cm} Effectiveness of perampanel as adjunctive therapy in patients with refractory focal seizures with GCI assessment  
Giovanni De Maria, Italy

\textbf{P577} \hspace{1cm} Effect of valproic acid on the placental barrier in the pregnant mouse: optical imaging and transporter expression studies  
Sara Eyal, Israel

\textbf{P578} \hspace{1cm} Effectiveness of eslicarbazepine acetate as adjunctive therapy for partial epilepsy in clinical practice: design of a European pooled analysis of real-world data  
Rob McMurray, United Kingdom

\textbf{P579} \hspace{1cm} Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study  
Rodrigo Rocamora, Spain

\textbf{P580} \hspace{1cm} Effect of Perampanel over the quality of sleep and daytime somnolence in focal epilepsy  
Javier Salas-Puig, Spain

\textbf{P581} \hspace{1cm} Effectiveness and tolerability of lacosamide in Thai children & adolescents with intractable epilepsy  
Chaiyos Khongkhathithum, Thailand
MONDAY 12TH SEPTEMBER

13:00 – 14:30  PROGNOSIS/EPIDEMIOLOGY 1

P630  Epidemiology of focal and generalized onset seizures in Algeria
       Walid Abdellaoui, Algeria

P631  A picture of clinical research in epilepsy
       Maria Grazia Celani, Italy

P632  Clinical and etiological profiles of adult patients with symptomatic epilepsy in Bishkek
       Asel Jusupova, Kyrgyzstan

P633  Descriptive analysis of status epilepticus among patients admitted in the medical intensive care unit and neurological intensive care unit from January 2010 to December 2014
       Ronald Ramos, Philippines

P634  Comparison of patients with status epilepticus or epileptic seizure admitted to the emergency room
       Sophie Reinecke, Germany

P635  Comorbidity of epilepsy
       Irina Stefanova, Bulgaria

P636  Epidemiology of seizures in children with neuroinfections
       Anna Surovtseva, Russian Federation

P637  A comparison from Mexico and Canada of waiting times for assessment and epilepsy surgery
       Jose F. Tellez-Zenteno, Canada

MONDAY 12TH SEPTEMBER

13:00 – 14:30  STATUS EPILEPTICUS 1

P655  Emergent vagal nerve stimulator implant during paediatric refractory status epilepticus: report of three cases
       Andrea Landi, Italy

P656  Diagnostic accuracy of Salzburg-criteria for nonconvulsive status epilepticus
       Markus Leitinger, Austria

P657  Correlation of inflammatory cytokines, synaptic proteins and growth factors in the immunopathogenesis of temporal lobe epilepsy
       Vinod Kumar Mehta, India

P658  Electroclinical features and outcomes in new onset refractory status epilepticus with Claustrum damage
       Stefano Meletti, Italy

P659  Endogenous neurosteroids levels are decreased in CSF during status epilepticus
       Giulia Monti, Italy

P660  Did new definition of status epilepticus have impact on its incidence in older patients with acute stroke?
       Petar Nikic, Serbia

P661  Efficacy and tolerability of intravenous lacosamide in treatment of status epilepticus in elderly epileptic patients
       Nicola Paciello, Italy

P662  Comparison of the effectiveness of four antiepileptic drugs in treatment of status epilepticus according to four different efficacy criteria
       Johannes Rösche, Germany

P663  Cryptogenic focal epilepsy presenting as new onset refractory status epilepticus (NORSE): implication of autoimmunity?
       Martha Spilioti, Greece
MONDAY 12TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 1

P683  Occurrence of abnormal rhythmic transients and the response to stimulation in a computational model of epileptiform activity
Gerold Baier, United Kingdom

P684  Prolonged seizure remission after electrode insertion in patients submitted to hippocampal deep brain stimulation (Hip-DBS) for refractory temporal lobe epilepsy
Arthur Cukiert, Brazil

P685  Post-operative contacts’ location in patients submitted to hippocampal deep brain stimulation (Hip-DBS)
Cristine Cukiert, Brazil

P686  Efficacy of vagal nerve stimulation in a cohort of 32 drug-resistant epileptic paediatric patients
Daniele Grioni, Italy

P687  Cortical autonomic and respiratory control structures in patients with epilepsy
Nuria Lacuey Lecumberri, USA

P688  Altered cortical excitability in drug-naïve epilepsy patients
Jung Hwa Lee, Korea, Republic of

P689  High spectral changes induced by SPES- a comparison between physiologic and pathologic network interaction in SEEG
Mihai Dragos Maliia, Romania

P690  Electrical continuous neuromodulation in the internal globus pallidus for treatment of drug-resistant myoclonus (and refractory epilepsy) in patients suffering from the Unverricht-Lundborg disease
Blanca Mercedes Alvarez, France

P691  Effects of vagal nerve stimulation on people with epilepsy and cognitive disabilities
Eva Pipan, Slovenia

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  BASIC SCIENCE 3

P129  Nucleus dentatus role in the suppression of focal cortical epileptic activity
Valeria Chubach, Ukraine

P130  Endogenous kynurenic acid, a tryptophan metabolite, synthesis is decreased in resected brain specimens obtained from patients with mesial temporal lobe epilepsy
Soumil Dey, India

P131  Oxidative stress and mitochondrial dysfunction in immature brain during epileptogenesis
Jaroslava Folbegrová, Czech Republic

P132  Neocortical gamma-oscillations before stimulus presentation predict successful memory encoding in humans – an intracranial EEG-study
Stephanie Gollwitzer, Germany

P133  Methionine nutritional overload facilitates epileptogenesis: possible role of modulation of rat brain Na+/K+-ATPase and E-NTPDase activity
Dragan Hrncic, Serbia

P134  Effective connectivity changes reveal neuronal population activity during seizures in humans
Radek Janca, Czech Republic

P135  Focal 4-aminopyridine-induced seizure-like events initiated by inhibitory network activity induce [K+]0 increase, but are not dependent on KCC2 channels
Laura Librizzi, Italy

P136  Neuronal firing analysis of epileptic interictal activity in humans
Andreas Schulze-Bonhage, Germany

P137  Gene expression analysis of drug transporters & biotransformation enzyme in patients with mesial temporal lobe epilepsy & focal cortical dysplasia: a comparative study
Devina Sharma, India

P138  Epilepsy may cause increased pain sensitivity: preliminary data from absence epileptic WAG/Rij rats nociceptive threshold
Sibel K Velioglu, Turkey

P139  Mechanisms underlying different onset patterns of focal seizures
Yuijiang Wang, United Kingdom
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  BASIC SCIENCE 4

P140  Sirt3 mediates antioxidant defense via regulating MnSOD activity in mouse hippocampus after pilocarpine-induced status epilepticus
In Ja Cho, Korea, Republic of

P141  The rhythm specificity of DMN during temporal lobe epilepsy seizure
Yan Cui, China

P142  Single microvascular pericyte tracking during epileptiform activity in vitro
Frederic de Bock, France

P143  Spontaneously hypertensive rats with cerebral small vessel disease are prone to temporal lobe epilepsy
Giovambattista De Sarro, Italy

P144  The role of oxidative stress in neurodegeneration in the immature brain following status epilepticus
Lubica Demeterova, Czech Republic

P145  The role of adenosine in hippocampal excitability after status epilepticus in immature and adult rats
Petr Fabera, Czech Republic

P146  A low-noise amplifier improves automated fast ripple (FR) detection in intraoperative ECoG
Tommaso Fedele, Switzerland

P147  Asymmetry in temporal lobe cortex organisation
Adam Kalina, Czech Republic

P148  The implication of Cav1 and Ca2+-dependent cation channels in PDS formation
Helmut Kubista, Austria

P149  Allopregnanolone is reduced in patients with PCDH19-related epilepsy
Marina Trivisano, Italy

P150  The correlation study between electrophysiological DMN and cognitive impairment based on experimental TLE rats
Yang Xia, China

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  CLINICAL EPILEPSY 3

P186  Pregnancy and perinatal outcome in Chinese epileptic women: prospective continuous hospital based registration study
Lei Chen, China

P187  Anti-mullerian hormone is higher in women with epilepsy who report seizure-freedom compared to those who report ongoing seizures
Cynthia Harden, USA

P188  Pregnancy outcome in women with epilepsy beyond child age of one year
Gordana Kiteva-Trenchevska, Macedonia, the Former Yugoslav Republic of

P189  Gender features of drug resistance in female epilepsy
Anastasia Chugunova, Russian Federation

P190  Effect of UGT1A4 and UGT2B7 polymorphism on lamotrigine metabolism during pregnancy
Vaiva Petrenaitė, Denmark

P191  The use of lacosamide in elderly patients
Sirpa Rainesalo, Finland

P192  Effects of valproic acid on the expression of folate transporters in the human placenta
Nino Tetro, Israel

P193  Plasma and breast milk levels of lacosamide before, during and post pregnancy
Jana Zarubova, Czech Republic
**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30 CLINICAL EPILEPSY 4**

**P194** The rate of congenital malformations in epileptic pregnant patients: a prospective study  
Hacer Bozdemir, Turkey

**P195** Pregnancy-related knowledge of women with epilepsy – an internet based survey in German speaking countries  
Carolin Dierking, Germany

**P196** Development and validation of modified INCLEN diagnostic instrument for epilepsy in children aged up to 18 years  
Sheffali Gulati, India

**P197** Quality of life in children with epilepsy  
Valentina Ivanovna Guzeva, Russian Federation

**P198** Characteristics and health care of adult tuberous sclerosis complex (TSC) patients in German epilepsy centers  
Hajo Hamer, Germany

**P199** Seizure control and antiepileptic drug use by pregnant women with epilepsy enrolled in China  
Nanya Hao, China

**P200** Women and epilepsy: a review of practices in the public and private setting in Jamaica, 2012 – 2015  
Uma Menon, USA

**P201** Yes you can: a video for women with epilepsy planning a family  
Catie Picton, United Kingdom

**P202** Service availability of phenytoin products for treatment of epilepsy in government hospitals in Thailand  
Thanarat Suansanae, Thailand

**P203** Survey of the awareness and clinical practice of medical association members regarding comprehensive management of epilepsy in the San-in region of Japan  
Shin-Ichi Yoshioka, Japan

**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30 CLINICAL NEUROPHYSIOLOGY 3**

**P242** How useful is repeat continuous EEG monitoring in the intensive care unit?  
Jeffrey M. Chung, USA

**P243** Ictal pattern on scalp EEG indicates resection area in mesial temporal lobe epilepsy  
Izumi Itabashi, Japan

**P244** Paroxismal brain: epilepsy and panic attack  
Vladimir Karlov, Russian Federation

**P245** Impact of video-ambulatory electroencephalography on the medical management of epilepsy  
Francesco Manfredonia, United Kingdom

**P246** Perampanel in add-on: effect on EEG background activity and efficacy on seizure control in patients with brain tumour-related epilepsy. Preliminary data  
Marta Maschio, Italy

**P247** Frequency, pattern and determinants of electrocardiographic markers of sudden cardiac arrest in black African patients with epilepsy in Enugu, South East Nigeria  
Orakwue Molokwu, Nigeria

**P248** Photosensitivity is an early marker of infantile neuronal ceroidlipofuscinosis (NCL-2)  
Nicola Pietrafusa, Italy

**P249** MEG connectivity for the lateralization of language – a proof of concept  
Stefan Rampp, Germany

**P250** Olfactory dysfunction in patients with mesial temporal lobe epilepsy: what is the difference of the problem?  
Bedia Samanci, Turkey

**P251** Lateralization of receptive language function in epilepsy patients: a high resolution scalp-derived event-related potential (ERP) study  
Karin Trimmel, Austria
**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 5**

**P322**  
Etiology in childhood-onset temporal lobe epilepsy  
Walid Abdellaoui, Algeria

**P323**  
Features epilepsy in patients with cerebral palsy  
Ikbol Abdukadirova, Uzbekistan

**P324**  
Features of epilepsy in children with complicated perinatal history  
Elena Morozova, Russian Federation

**P325**  
Febrile infection-related epilepsy syndrome (FIRES) and super-refractory status epilepticus in children  
Sofia Quintas, Portugal

**P326**  
Febrile seizures clinical features in patients with afterwards epilepsy  
Leanid Shalkevich, Belarus

**P327**  
Glucose transporter deficiency type 1 (GLUT1-DS) due to gene SLC2A1 mutations – how often epileptic patients display movement disorders. Experience from one Polish medical centre  
Elzbieta Szczepanik, Poland

**P328**  
Hemispheric lateralization in benign focal epilepsy in childhood with centrotemporal spikes (BECTS) in Uzbekistan  
Ruzieva Dilnoza, Uzbekistan

**P329**  
Frequency of tuberous sclerosis complex diagnosis in pediatric patients the last 15 years in the island of Crete  
Pelagia Vorgia, Greece

**P330**  
Frequency-dependent changes of neural networks from pre-ictal to ictal stages in childhood absence epilepsy  
Xiaoshan Wang, China

---

**TUESDAY 13TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 6**

**P331**  
Incidence of febrile seizures and risk of subsequent epilepsy in children with febrile seizures  
Kari Modalsli Aaberg, Norway

**P332**  
Ketogenic versus modified Atkins diet for epilepsy: a single centre experience from Singapore  
Jeannie Chiam, Singapore

**P333**  
Idiopathic epilepsies child: study of a retrospective cohort of 186 children followed during 3 years at fann teaching hospital (Dakar – Senegal)  
Maouly Fall, Senegal

**P334**  
Post-stroke epilepsy in children: a retrospective cross-sectional study in Dakar  
Daniel Gams Massi, Senegal

**P335**  
Inertial sensor based epileptic seizure detector  
Martin Kudr, Czech Republic

**P336**  
Mutations in the CACNA1A gene as cause of epilepsy and of different (paroxysmal) movement disorders in 20 patients: common therapeutic approaches?  
Svetlana Moiseeva, Germany

**P337**  
Hot water epilepsy clinical profile and treatment. analysis of 13 cases from Kayseri  
Hüseyin Per, Turkey

**P338**  
Perampanel in therapy of drug-resistant epilepsies in children  
Svetlana Sivkova, Russian Federation
**TUESDAY 13TH SEPTEMBER**

13:00 – 14:30 **EPILEPSY IN CHILDHOOD 7**

P339  The neurological outcome of high-risk infants with neonatal seizures
Natasa M. Cerovac, Serbia

P340  The relationship of clinical factors to antiepileptic drug adherence
So-Hee Eun, Korea, Republic of

P341  Roles of globus pallidus externa in controlling absence seizures
Daqing Guo, China

P342  The correlation between febrile seizure and unprovoked seizure followed by febrile seizure
Seunghyo Kim, Korea, Republic of

P343  The burden of frequent seizures on patients, parents and society in a European study of non-institutionalized children with epilepsy
Lieven Legue, Belgium

P344  Treatment of pediatric intractable epilepsy with vaporized cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) - preliminary findings of the Israeli pediatric medical cannabis (MC) cohort
Ilan Linder, Israel

P345  Role of lead in provoking seizure in children: a case control study in Tehran, Iran
Samileh Noorbakhsh, Iran, Islamic Republic of

P346  The experience of using Zonegran to treat resistant epilepsy in children of early preschool age
Nataliya Perunova, Russian Federation

P347  Seizure duration with and without rescue medication in a European study of children who experience prolonged acute convulsive seizures
Federico Vigevano, Italy

---

**TUESDAY 13TH SEPTEMBER**

13:00 – 14:30 **EPILEPSY IN CHILDHOOD 8**

P348  Schooling of children with epilepsy
Kegnide Christelle Cadnelle Affognon, Senegal

P349  Typical absence epilepsy with onset before the age of four years-report of eleven patients
Matilda Kovac Sizgoric, Croatia

P350  7p22.3 microdeletion and 6q26 microduplication found in Bulgarian patients with generalized epilepsy, autistic features and intellectual disability
Valentina Peycheva, Bulgaria

P351  Learning problems in children with early-onset epilepsy
Kati Rantanen, Finland

P352  Is there a relationship between constipation and an increase in seizures in people with learning disabilities and refractory epilepsy within a care setting?
Sally-Ann Remnant, United Kingdom

P353  Why medications don’t work: considerations for pseudo-refractory epilepsy in children
Furkat Samadov, Uzbekistan

P354  Relationship of simple reaction time and spike frequency in benign childhood epilepsy with centrotemporal spikes
Ruta Samaitiene, Lithuania

P355  Clinical symptoms, EEG, MRI and psychological analysis of 16 patients with CSWS or ESES
Anna Winczewska-Wiktor, Poland

P356  Decision making process and somatic markers in patients with occipital lobe epilepsy
Naz Yeni, Turkey
TUESDAY 13TH SEPTEMBER

13:00 – 14:30 GENETICS 2

P374 Gender-related pharmacogenomics of transport- and target-proteins in drug resistant epilepsy patients
Dimitrios Chatzistefanidis, Greece

P375 Expanding the phenotype of TSC1 deletion – it’s not always what you expect
Tal Gilboa, Israel

P376 Duplications of the SLC9A6 gene cause syndromic intellectual disability with status epilepticus during slow-wave sleep – a new type of gene mutations involving the NHE6 dysfunction in ESES
Dorota Hoffman-Zacharska Dorota, Poland

P377 Epilepsy in patients with Down syndrome
Alexey Kholin, Russian Federation

P378 Experiences of receiving a genetic diagnosis and the impact on everyday life
Ditte B. Kjelgaard, Denmark

P379 Expanding the clinical spectrum associated with SLC6A1 mutations
Rikke Møller, Denmark

P380 Exome sequencing of families with autosomal dominant lateral temporal epilepsy (ADLTE) reveals a GRIN2A mutation in one family
Carlo Nobile, Italy

P381 Exome-based copy number variation analysis in patients with epileptic encephalopathies
Ramakrishnan Rajagopalan, USA

P382 Diagnostic whole exome sequencing in 100 individuals with both epilepsy and intellectual disability
Francesca Snoeijen-Schouwenaars, Netherlands

TUESDAY 13TH SEPTEMBER

13:00 – 14:30 GENETICS 3

P383 Linkage analysis in medium sized families as a tool to prioritize variants from exome sequencing
Zaid Afawi, Israel

P384 NTRK2 gene variants display association with temporal lobe epilepsy
Marino Muxfeldt Bianchin, Brazil

P385 Mutations in the PCDH19 gene in Polish patients with Dravet – like syndrome phenotype
Paulina Górka-Skoczylas, Poland

P386 Lack of pathogenic variants in SCN1A gene in familial febrile seizures with mesial temporal lobe epilepsy
Ioanna Kousiappa, Cyprus

P387 Novel phenotypic- and functional aspects of heterozygous de novo mutations in GRIN2B
Johannes Lemke, Germany

P388 Loss-of-function of the retinoid-related nuclear receptor (RORB) gene and epilepsy
Gaetan Lesca, France

P389 Next generation sequencing in rare childhood epilepsy of suspected genetic etiology
Francesca Ragona, Italy

P390 Gene IL-1B polymorphism and recurrent febrile seizures at children
Anna Diuzhakova, Russian Federation
TUESDAY 13TH SEPTEMBER

13:00 – 14:30

NEUROIMAGING 2

P411 MRI abnormalities and EEG patterns of symptomatic epilepsy in children with cerebral palsy
Khabibulla Aminov, Uzbekistan

P412 Non-invasive data-driven connectivity analysis correspond with areas of initial seizure propagation found by prior modalities from the hypothalamus
Varina Boerwinkle-Wolf, USA

P413 Mapping language in temporal lobe epilepsy – results of a functional connectivity and network-based analysis
Silvia Bonelli, Austria

P414 Objective background of the refractory epilepsy development founded on structural-metabolic alterations of the brain
Volha Kistsen, Belarus

P415 Morphological changes of cerebellum in epilepsy: Hypertrophy of selected vermian segments in patients with temporal lobe epilepsy
Václav Marcián, Czech Republic

P416 MRI volumetry of temporal lobes and its substructures in pharmaco-resistant temporal lobe epilepsy patients
Lukeas Martinovic, Czech Republic

P417 Nodular heterotopia: integration of multimodal neuroimaging and neurophysiological methods
Irene Pappalardo, Italy

P418 Does automated morphometric screening support MRI diagnostics in temporal lobe epilepsy patients?
Christian Rummel, Switzerland

P419 Investigation of global network synchrony in resting-state functional magnetic resonance imaging of patients with mesial temporal lobe epilepsy: a pilot study
Siti Nurbaya Yaakub, United Kingdom

P420 Paediatric clinical fMRI for epilepsy surgery
Arshad Zaman, United Kingdom

TUESDAY 13TH SEPTEMBER

13:00 – 14:30

NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 2

P453 Seizure counting of clinical drug trial participants
Barbara Blachut, Germany

P454 Epilepsy in elderly people and affective disorders
Andrey K. Druzhinin, Russian Federation

P455 Autoimmune (limbic and extralimbic) encephalitis – our recent experience with the new etiology of epilepsy
Veronika Jakubčiaková, Czech Republic

P456 Preliminary first Czech validation of EpiTrack®
Alena Javůrková, Czech Republic

P457 Clinical course of personality disorder associated with epilepsy
Seo-Young Lee, Korea, Republic of

P458 Risk for verbal memory deficits caused by depth hippocampal electrodes: an explorative study
Hanna Ljung, Sweden

P459 Ethical, clinical, and social aspects of treatment of epilepsy in patients with comorbid depression
Ekaterina P. Mikhalkovskaya-Karlova, Russian Federation

P460 Social cognition and prefrontal functions in patients with epilepsy treated with eslicarbazepine
Angela Sanabria, Spain

P461 Social cognition and emotion perception in patients with juvenile myoclonic epilepsy
Elisabeth Schmid, Austria

P462 A systematic review of neuropsychiatric comorbidities in patients with both epilepsy and intellectual disability
J.S. van Ool, Netherlands
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  OTHERS 4

P502  Sleep disordered breathing in patients with epilepsy – a polysomnographic study
Katarína Klobučníková, Slovakia

P503  The role of anxiety in the onset of epileptic seizures in Greek patients
Anna Maria Mouzak, Greece

P504  Stress and seizures: exploring the patterns of implicit attentional biases in patients with epilepsy and dissociative seizures
Markus Reuber, United Kingdom

P505  Management of patients with psychogenic nonepileptic seizures in South Africa: a survey of healthcare professionals
Chrisma Pretorius, South Africa

P506  A collaborative framework for the development and evaluation of an epilepsy first aid training intervention
Darlene Snape, United Kingdom

P507  Relapsing seizures after resective epilepsy surgery – are they always epileptic?
Anke Staack, Germany

P508  Stroke like migraine after radiation therapy syndrome induced by implantation of intracerebral deep electrodes
Alexander Timofeev, France

P509  The Minnesota multiphasic personality inventory-2 profile in patients with psychogenic non-epileptic seizures
Zdenek Vojtech, Czech Republic

P510  A critical evaluation of the role and effectiveness of the UK epilepsy specialist nurse
Elizabeth Wright, United Kingdom

P511  Stereotypy of psychogenic non epileptic seizures
Moshe Herskovitz, Israel

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  OTHERS 5

P512  Cross-cultural adaptation and validation of the Portuguese version of the quality of life questionnaire in epilepsy (QOLIE-89)
Anabela Almeida, Portugal

P513  Diagnostic accuracy of audio based seizure detection in patients with severe epilepsy and a mental impairment
Johan Arends, Netherlands

P514  Establishment of epilepsy group education – a local experience 2 years on
Claire Behan, Ireland

P515  Automated assessment of electrode reduction on detection of EEG patterns in intensive care patients
Johannes Herta, Austria

P516  Demographic and clinical findings of epilepsy patients who underwent follow-up at the newly established clinic of Mugla University Faculty of Medicine
Gulnihal Kutlu, Turkey

P517  Epilepsy patient’s referral pattern to the epilepsy center in Korea
Jun Hong Lee, Korea, Republic of

P518  Cochrane review of psychological treatments for people with epilepsy
Rosa Michaelis, Germany

P519  Carer perception of focal seizures in canine epilepsy
Rowena M.A. Packer, United Kingdom

P520  Frequency and the severity of complications during the Wada test
Andrzej Rysz, Poland

P521  An unusual feature of adult-onset fulminant SSPE
Sanja Vodopic, Montenegro

P522  Epilepsy and seizures in patients with low-grade gliomas: Is the current adult service delivering best practice?
Freya Waite-Taylor, United Kingdom

P523  Evaluation of left ventricular diastolic function by tissue Doppler imaging in patients with newly diagnosed and untreated focal epilepsy
Deniz Yerdelen, Turkey
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  PHARMACOLOGY/AEDS 4

P582  effectiveness of perampanel in refractory epilepsies: data from an apulian (Italy) open label study
Giovanni Boero, Italy

P583  Effectiveness of perampanel as adjunctive therapy in patients with refractory seizures
Paolo Bonanni, Italy

P584  Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures
Giuseppe Borzì, Italy

P585  Effectiveness of rufinamide in adults with Lennox-Gastaut syndrome – a monocentric retrospective audit
Anna-Lena Friedo, Germany

P586  Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in patients with focal seizures
Laura Mumoli, Italy

P587  Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: a questionnaire-based study
Andrea Romigi, Italy

P589  Efficacy and tolerability of monotherapy with lacosamide versus controlled-release carbamazepine in elderly patients with newly diagnosed epilepsy: a subgroup analysis of a prospective randomized double-blind trial
Felix Rosenow, Germany

P588  Efficacy of lacosamide monotherapy in patients with newly diagnosed epilepsy stratified by baseline disease severity: sub-analysis of data from a prospective non-inferiority trial versus controlled-release carbamazepine
Manuel Toledo, Spain

TUESDAY 13TH SEPTEMBER

13:00 – 14:30  PHARMACOLOGY/AEDS 5

P590  European non-interventional registry study of antiepileptic drug use in patients with Lennox-Gastaut syndrome
Stéphane Auvin, France

P591  Evaluation of preventive and neuroprotective effects of chronic daily topiramate, lacosamide and levetiracetam administration on pentylenetetrazol-induced status epilepticus in newborn rats
Özgür Duman, Turkey

P592  Focal inter-ictal epileptiform activity in the EEG suppressed by levetiracetam, a diagnostic problem in pre-treated patients
Koenig Kristina, Switzerland

P593  Fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
An-Sofie Schoonjans, Belgium

P594  Efficacy of perampanel by baseline seizure frequency in patients with partial seizures
Michael Sperling, USA

P595  Experience in the treatment of nocturnal seizures with lacosamide
Mónica Villas, Spain

P596  Innovative drug perampanel in the treatment of focal epilepsies
Irina Zhidkova, Russian Federation

P597  Eslicarbazepine vs brivaracetam for adults with refractory partial seizures: a meta-analysis
Xiaoyi Zou, China
PHARMACOLOGY/AEDS 6

P598 Mental retardation, refractory epilepsy and treatment with eslicarbazepine
Pedro Emilio Bermejo, Spain

P599 Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: a long-term study on 136 patients
Stefan Boettcher, Germany

P600 Long term effectiveness of perampanel: the Leeds experience
Jo Geldard, United Kingdom

P601 Long-term impact of antiepileptic drug treatment on cognitive development
Dominique Ijff, Netherlands

P602 Long-term efficacy, tolerability and retention rate of add-on lacosamide treatment in 105 children and adolescents with refractory epilepsy: a single centre retrospective observational study from Italy
Lucrezia Ilvento, Italy

P603 Management of adverse events due to perampanel and levetiracetam interactions
Galina Odintsova, Russian Federation

P604 No association between skin reactions from lamotrigine and UGT 1a4 variants *2 and *3
Maryam Shirzadi, Norway

P605 Optimising the control of the triggered epileptic attacks
Radwan Zaidan, Saudi Arabia

PHARMACOLOGY/AEDS 7

P606 Perampanel as adjunctive drug in children and young adults with refractory epilepsy
Giangennaro Coppola, Italy

P607 Pharmacovigilance of lamotrigine and valproate in Norway, 2004-2013
Maren Lima, Norway

P608 Own experience with perampanel, eslicarbazepine and zonisamide in the treatment of patients with epilepsy
Svetlana Nurmukhametova, Russian Federation

P609 Real world data of perampanel as adjunctive therapy in a German epilepsy center
Max Christian Pensel, Germany

P610 PROMETEO: a prospective observational study to assess the treatment effect after introduction of a different AED in patients with partial epilepsy fulfilling the 2010 ILAE criteria of drug-resistant epilepsy
Emilio Perucca, Italy

P611 Perampanel in children and adolescents with refractory epilepsy: PMK Hospital, Thailand experience
Piradee Suwanpakdee, Thailand

P612 Quality of life and psychiatric symptoms in patients undertaking perampanel treatment: preliminary results of a prospective study
Flavio Villani, Italy

P613 Perampanel in routine clinical practice
Pavel Vlasov, Russian Federation
TUESDAY 13TH SEPTEMBER

13:00 – 14:30 PROGNOSIS/EPIDEMIOLOGY 2

P638  Experience with first episode of consciousness loss assessment in a regional center of Romania  Adina Cuciureanu, Romania

P639  Evaluation of clinical features of patients with occipital lobe epilepsy, retrospectively  Sakir Delil, Turkey

P640  Secular trends in the incidence of epilepsy in the province of Saskatchewan, Canada (2001-2010)  Lizbeth Hernandez Ronquillo, Canada

P641  First epileptic seizure: Incidence and management of paroxysmal episodes in Ljubljana Emergency Unit for Neurology  Viktorija Kostadinova, Slovenia

P642  Injuries and accidents in epilepsy: a prospective, population-based cohort study on incident cases  Benno Mahler, Sweden

P643  Epilepsy in Qatar: causes, treatment and outcome  Gayane Melikyan, Qatar

P644  Prevalence of hospitalized in patients with epilepsy: a national data report from Thailand  Sineenard Pranboon, Thailand

P645  Prevalence and etiology of epilepsy in a Norwegian county – a population based study  Marte Syvertsen, Norway

TUESDAY 13TH SEPTEMBER

13:00 – 14:30 STATUS EPILEPTICUS 2

P664  Neurobrucellosis presenting with status epilepticus as an initial symptom  Ali Akyol, Turkey

P665  Etiology, clinical profile and immediate outcome of convulsive status epilepticus in children: resource poor country perspective  Adhi Arya, India

P666  Lateralized periodic discharges associated with status epilepticus in the first year after stroke  Nerses Bebek, Turkey

P667  Interleukin 17A is associated with the severity of epilepsy and BBB interruption in pilocarpine induced status epilepticus model  Jing Ding, China

P668  Predicting the outcome of status epilepticus: comparison of STESS and EMSE score in a prospective, monocentric, adult population  Giada Giovannini, Italy

P669  Prognosis of status epilepticus in elderly patients  Estevo Santamarina, Spain

P670  Prognosis of status epilepticus (SE) patients requiring intravenous anesthetic drugs (IVAD)  Estevo Santamarina, Spain

P671  Fatal cerebral edema with status epilepticus in children with Dravet syndrome  Ingrid Scheffer, Australia

P672  Intravenous levitiracetam as second line option for status epilepticus and seizure clusters  Aurelian Ungureanu, Romania
TUESDAY 13TH SEPTEMBER

13:00 – 14:30 **SURGICAL TREATMENT AND NEUROMODULATION 2**

**P692**
Vagus nerve stimulation and corpus callosotomy in refractory epilepsy – experience from a tertiary center in Rio de Janeiro
Isabella D Andrea-Meira, Brazil

**P693**
A prospective long-term study of health-related quality of life and mood after epilepsy surgery or pre-surgical work-up
Anna Edelvik, Sweden

**P694**
The effectiveness of vagal nerve stimulation therapy in patients with refractory epilepsy and mental retardation – a 12-month follow up
Jedrzej Flicinski, Poland

**P695**
A novel functional MRI paradigm for the pre-operative assessment of auditory perception in a musician undergoing temporal lobe surgery
Matthew Hale, United Kingdom

**P696**
TMS combined with EEG in genetic generalized epilepsy: A phase II diagnostic accuracy study
Vasili K. Kimiskidis, Greece

**P697**
Vagus nerve stimulation in epilepsy: a long-term analysis for outcome
Elisabeth Landré, France

**P698**
A clinical, neuroradiological, and neurophysiological study with surgical outcome on 45 patients with drug-resistant partial epilepsy related to periventricular nodular heterotopia
Laura Mirandola, Italy

**P699**
Vagus nerve stimulation in Lafora body disease
Zeljka Petelin Gadze, Croatia

**P700**
Vagus nerve stimulation devices can be completely removed or replaced safely
Baris Turak, France

---

TUESDAY 13TH SEPTEMBER

13:00 – 14:30 **SURGICAL TREATMENT AND NEUROMODULATION 3**

**P701**
Epilepsy surgery outcome – our center final results
Michal Bajaček, Czech Republic

**P702**
Endoscopic robot-guided disconnection of hypothalamic hamartomas: results in 18 cases
Alessandro De Benedictis, Italy

**P703**
Epilepsy surgery in children: clinical and follow-up data of the first 100 operated cases at the Bambino Gesù Children Hospital, IRCCS, Rome, Italy
Luca De Palma, Italy

**P704**
Correlation of surgical outcome with ictal and interictal EEG patterns in temporal lobe epilepsy
Swapan Gupta, India

**P705**
Frontal lobe epilepsy surgery in children: epilepsy syndromes, neuropathologies and seizure outcomes
Henna Jonsson, Finland

**P706**
Anterior callosotomy in children with Lennox-Gastaut syndrome (clinical cases)
Mikhail Nikolaenko, Russian Federation

**P707**
Dose callosotomy improve seizure and developmental prognosis in children with epileptic spasms in infancy and early childhood? Analysis of the FACE study
Taisuke Otsuki, Japan

**P708**
Health-related quality of life and emotional wellbeing in parents of children with epilepsy before and after epilepsy surgery
Colin Reilly, United Kingdom

**P709**
A simple and accurate frameless stereotactic implantation technique for stereo EEG depth electrodes in refractory epilepsy evaluated by intraoperative MRI imaging
Karl Roessler, Germany
TUESDAY 13TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 4

P710  Mesial temporal lobe epilepsy: long-term outcome of a tailored approach
Christian Dorfer, Austria

P711  Long-term outcome and neuroradiological changes after multiple hippocampal transection
Kensuke Kawai, Japan

P712  Morbidity related to surgery of mesial temporal lobe epilepsy associated with hippocampal sclerosis
Bertrand Mathon, France

P713  Parental reports of family life situation at long-term after hemispherotomy
Anneli Ozanne, Sweden

P714  Outcome analysis of the surgical treatment for refractory frontal lobe epilepsy
Ana Paula Pinheiro-Martins, Brazil

P715  Integration of multimodal imaging and intraoperative MR in resective surgery for medically refractory epilepsy: The Erlangen experience of 415 patients
Karl Roessler, Germany

P716  Quantitative analysis of intracranial EEG – relation to post-surgical seizure control in three patients with unfavorable outcome
Christian Rummel, Switzerland

P717  Prognostic predictors in non-selective amygdalohippocampectomy for refractory mesial temporal epilepsy
Alexandra Santos, Portugal

P718  Prediction of post-operative seizure-control using MRI, electric source imaging (ESI), ictal SPECT and PET
Margitta Seeck, Switzerland

P719  Recurrent seizures after anterior temporal lobectomy in patients with mesial temporal lobe epilepsy
Jong-Hwa Shin, Korea, Republic of

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  BASIC SCIENCE 5

P151  Using automated algorithms to analyze circadian changes of EEG biomarkers properties in patients with epilepsy
Jiri Balach, Czech Republic

P152  Identification of miRNA expression profiles in human mesial temporal lobe epilepsy with hippocampal sclerosis
Petra Bencurowa, Czech Republic

P153  Blood-brain barrier markers after tonic-clonic seizures
Agnieszka Cudna, Poland

P154  High-frequency oscillation ability to localize epileptogenic tissue in animal epilepsy model
Tomas Havel, Czech Republic

P155  Microseizures reliably localize primary epileptogenic areas in tetanus toxin model of temporal lobe epilepsy
Jan Kudlacek, Czech Republic

P156  Genome-wide microRNA expression profile and regulatory signaling pathways in Ganglioglioma
Atreye Majumdar, India

P157  Cognitive deficits and brain myo-inositol are early biomarkers of epileptogenesis in a rat model of epilepsy
Rosaria Pascente, Italy

P158  Retrospective analysis of seizure-related heart rate change
Maryam Ravan, USA
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  BASIC SCIENCE 6

P159  N-palmitoylethanolamine enhances anticonvulsant effects of some antiepileptic drugs against audiogenic seizures in DBA/2 mice
Rita Citraro, Italy

P160  Absence crisis are susceptible to lamotrigine and ethosuximide in male taiep rats
Carmen Cortes, Mexico

P161  Effects of ketogenic diet on hippocampal calbindin-D28k expression in mice with kainic acid-induced seizures
Dong Wook Kim, Korea, Republic of

P162  Isobolographic analysis of interactions of lacosamide with selected antiepileptic drugs in three-drug combinations against maximal electroshock-induced seizures in mice
Jarogniew Luszczki, Poland

P163  ACR-Oil from natural source affects the kindling process in mice: analysis of molecular markers during epileptogenesis
Saima Malhi, Pakistan

P164  Dynamic S1Pr subunit expression patterns and in vivo EEG analysis suggest fingolimod as promising therapy option in focal epilepsies
Julika Pitsch, Germany

P165  Synergistic anticonvulsant effect between thalidomide and morphine on pentylentetrazole-induced clonic seizures in mice
Nastaran Pourshadi, Iran, Islamic Republic of

P166  How different subchronic supplementation regiments with folate and L-arginine affect EEG characteristics of homocysteine epilepsy?
Aleksandra Rasic Markovic, Serbia

P167  Acute post-status administration of endocannabinoid receptor agonist WIN-55,212-2 has a neuroprotective effect but does not prevent epileptogenesis
Elena Suleymanova, Russian Federation

P168  Inhibition of monoacylglycerol lipase (MAGL) by PF-4645 protects mice against refractory SE
Gaetano Terrone, Italy

P169  Optogenetic control of human neurons in hippocampal tissue cultures
Jenny Wickham, Sweden

---

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  CLINICAL EPILEPSY 5

P204  Differences in quality of life of women and men with drug resistant epilepsy in Poland
Aleksandra Bala, Poland

P205  Educational video and story as effective interventions reducing epilepsy-related stigma among children measured by the verified Czech version of stigma scale of epilepsy
Dana Brabcová, Czech Republic

P206  Assessment of patients’ and caregiver’s perceived need to start actively participated outcome measures in epilepsy research
Maria Grazia Celani, Italy

P207  High rates of nicotine use and unemployment among pregnant women with epilepsy
Anette Huuse Farmen, Norway

P208  The added value of epilepsy experts in the emergency room after a first unprovoked seizure
Loraine Fisch, Switzerland

P209  Do we avoid talking about sex?
Oliver Henning, Norway

P210  Validation of a German version of the Glasgow epilepsy outcome scale (GEOS) for people with epilepsy and intellectual disability
Theodor May, Germany

P211  Utilization of an anti-epileptic drug response database (ARD) in a multi-disciplinary clinic
Viet-Huong Nguyen, USA

P212  The DICES project (Driving Integrated Care in the Emergency room for Seizures)
Jennifer Williams, Ireland
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  CLINICAL EPILEPSY 6

P213  Modern portrait of a woman with epilepsy of childbearing age  
Diana Dmitrenko, Russian Federation

P214  What areas of lives of caregivers of children with severe, refractory epilepsy are affected by caregiving? An expert panel report  
Mark Jensen, USA

P215  Perceptions and preferences concerning the use of wearable sensors in epilepsy and Parkinson’s disease: a focus group study  
Dongni Johansson, Sweden

P216  Juvenile myoclonic epilepsy and driving licence: restrictions and medicolegal issues  
Nebojsa Jovic, Serbia

P217  Premarriage counselling by neurologist, improves marriage sustainability  
Vijaya Mishra, India

P218  The knowledge and stigma for epilepsy in Japan  
Chizuko Nagamori, Japan

P219  A study of symptomatic epilepsy related to ischemic stroke  
Kei-Ichiro Takase, Japan

P220  Relation of perceived stigma to adverse events of medications in patients with epilepsy  
Ekaterina Viteva, Bulgaria

P221  Public awareness, understanding and attitudes toward epilepsy in Montenegro  
Slavica Vujisic, Montenegro

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  CLINICAL NEUROPHYSIOLOGY 4

P252  Predictors of postictal generalized EEG suppression  
Betül Baykan, Turkey

P253  The effects of fixation-off sensitivity on eye closure and eye closed status-related epileptiform discharges  
Hava Ozlem Dede, Turkey

P254  Semiological features of secondary generalized tonic-clonic seizures with postictal generalized EEG suppression  
Kazutaka Jin, Japan

P255  The safety of augmented visual stimulation: Does repeated, extensive visual stimulation within a time-frame of one hour increase sensitivity in photosensitive patients?  
Dorothee Kastelein-Nolst Trenite, Italy

P256  The diagnostic accuracy of initial routine electroencephalography after a first transient loss of consciousness  
Milena Kovic, Serbia

P257  Statistical learning methods for detection of generalized tonic-clonic seizures in accelerometer data  
Fredrik Ohlsson, Sweden

P258  Very high frequency oscillations in temporal lobe epilepsy  
Martin Pail, Czech Republic

P259  Time domain versus time-frequency domain as methods of analysis of single pulse electrical stimulation in patients with focal epilepsy  
Imogene K.G. Pieters, Netherlands

P260  TMS-EEG to measure anti-epileptic drug effect in the human brain  
Isabella Premoli, United Kingdom

P261  Zero-crossing interval analysis of EEG background rhythms – a new biomarker for epilepsy?  
Jan Pyrzowski, Poland
**WEDNESDAY 14TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 10**

**P271** Photosensitive epilepsy and hot water epilepsy: an unusual combination  
Zeynep Aydin-Özemir, Turkey

**P272** Seizures as presenting and prominent symptom in chorea-acanthocytosis with c.2343del VPS13A gene mutation  
Felix Benninger, Israel

**P273** Plasma catecholamine levels in epileptic seizures  
Scott Bowman, USA

**P274** Transient Epileptic Amnesia – the acute anterograde amnesia chameleon  
Carlota Cunha, Portugal

**P275** Evaluation of sensitivity and properties of clinical variables in differentiation of seizure versus pseudoseizure  
Mehran Homam, Iran, Islamic Republic of

**P276** Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement  
Rajesh Iyer, India

**P277** MELAS in a young adult patient presenting with status epilepticus  
Demet Kinay, Turkey

**P278** Focal epilepsy leads to the emergence of a large-scale epileptic network that sustains the pathological state  
Laurent Sheybani, Switzerland

**P279** Phenotypes of juvenile myoclonic epilepsy amound patients in Siberia, Russia  
Olga Shilkina, Russian Federation

**WEDNESDAY 14TH SEPTEMBER**

**13:00 – 14:30**  
**EPILEPSY IN CHILDHOOD 11**

**P280** Living with Landau Kleffner syndrome  
Marte Årva, Norway

**P281** early epileptic encephalopathies with suppression burst  
Prisca-Rolande Bassolé, Senegal

**P282** Typographic legibility and its phonological involvement in reading epilepsy  
Maria Graciela Cano Celestino, Mexico

**P283** Describing the humanistic burden of illness in Dravet syndrome – critical methodological questions remain  
John Irwin, United Kingdom

**P284** Drug resistant occipital epilepsy: Sturge-Weber variant or coeliac disease? A diagnostic dilemma  
Andreas Kiryttopoulos, Greece

**P285** Evolution of West syndrome in Georgia, predictors of outcome  
Ana Kvernadze, Georgia

**P286** EEF1A2 (eukaryotic elongation factor 1, alfa-2) related early infantile epileptic encephalopathy & myoclonic astatic epilepsy  
Ilan Linder, Israel

**P287** A novel description of a homozygous partial deletion of RBFOX1 gene causing epileptic encephalopathy, severe intellectual disability and progressive post-natal microcephaly  
Tally Lerman-Sagie, Israel

**P288** De novo KCNB1 mutations cause infantile epileptic encephalopathy with generalized epileptiform discharges  
Jun Tohyama, Japan
### WEDNESDAY 14TH SEPTEMBER

**EPILEPSY IN CHILDHOOD 12**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P289</td>
<td>The use of NGS for the diagnosis of early onset epileptic encephalopathies: The clinical experience of an Italian centre</td>
<td>Ilaria Contaldo</td>
<td>Italy</td>
</tr>
<tr>
<td>P290</td>
<td>Clinical cases of successfully treated phenobarbital refractory seizures by use of combination of two antiepileptic drugs in preterm infants</td>
<td>Valentina Ivanovna Guzeva</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>P291</td>
<td>Change of cytokine levels in neonatal seizures induced by hypoxic ischemic encephalopathy</td>
<td>In Goo Lee</td>
<td>Korea, Republic of</td>
</tr>
<tr>
<td>P292</td>
<td>Evaluation of etiology and prognostic factors of the developmental outcome in neonatal seizures</td>
<td>Bolyun Lee</td>
<td>Korea, Republic of</td>
</tr>
<tr>
<td>P293</td>
<td>Towards a composite clinical endpoint: identifying a core set of patient and caregiver relevant outcome measures through qualitative research on the global impact of Dravet syndrome</td>
<td>Rima Nabbout</td>
<td>France</td>
</tr>
<tr>
<td>P294</td>
<td>Optimization of treatment of pharmacological resistant forms of epilepsy in the case of epileptic encephalopathy</td>
<td>Komila Porsokhonova</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>P295</td>
<td>Management of seizures specifically in newborn hypoxic ischaemic encephalopathy (HIE) – review of the literature and results of a questionnaire on international practices- time for a fresh view?</td>
<td>Thorsten Villiers Stanley</td>
<td>New Zealand</td>
</tr>
</tbody>
</table>

**EPILEPSY IN CHILDHOOD 9**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P357</td>
<td>Clinical characteristics and ictal EEG findings of childhood and juvenile absence epilepsy in Algiers</td>
<td>Walid Abdellaoui</td>
<td>Algeria</td>
</tr>
<tr>
<td>P359</td>
<td>Benign familial and non-familial infantile seizures Fukuyama- Watanabe-Vigevano syndrome (F-W-V Syndrome) – two cases report</td>
<td>Sanja Delin</td>
<td>Croatia</td>
</tr>
<tr>
<td>P360</td>
<td>Clinical characteristics of Dravet syndrome and gene mutation analysis</td>
<td>Feng Gao</td>
<td>China</td>
</tr>
<tr>
<td>P361</td>
<td>A reaching/grasping movement by a patient with posttraumatic epilepsy</td>
<td>Toru Horinouchi</td>
<td>Japan</td>
</tr>
<tr>
<td>P362</td>
<td>The safety and efficacy of Perampanel among different groups of people with ID using the UK Anti-Epileptic Drug Intellectual Disability (Ep-ID) Register</td>
<td>Rohit Shankar</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>P363</td>
<td>Clinical findings of tuberous sclerosis patients in Menderes region</td>
<td>Ayse Tosun</td>
<td>Turkey</td>
</tr>
<tr>
<td>P364</td>
<td>Diagnostic and management pitfalls in JME: hospital based study</td>
<td>Aleksandre Tsereteli</td>
<td>Georgia</td>
</tr>
</tbody>
</table>
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 GENETICS 4

P391 Systematic recruitment and analysis of epilepsy families in Palestine
Amal Abu-Rayyn, Palestine

P392 NTRK2, the TrkB gene, is associated with mood disorders in temporal lobe epilepsy
Marino Muxfeldt Bianchin, Brazil

P393 Single nucleotide polymorphisms of antioxidant enzymes in progressive myoclonus epilepsy
Marko Ercegovac, Serbia

P394 The phenotypic spectrum of the recurrent SCN2A R1319Q mutation
Ingo Helbig, Germany

P395 PURA mutations: Intellectual disability with seizures or epileptic encephalopathy?
Helle Hjalgrim, Denmark

P396 Targeted next generation sequencing as a diagnostic tool in 230 patients with epileptic encephalopathies
Line H. G. Larsen, Denmark

P397 The phenotypic spectrum of a familial GRIN2A truncation mutation
Hiltrud Mühle, Germany

P398 Systematic large scale genome-wide analysis of CNVs in patients with ‘epilepsy plus’
Hannah Stamberger, Belgium

P399 Variable phenotypes in individuals with GRIN2A sequence variants or deletions
Danique R.M. Vlaskamp, Netherlands

P400 SLC6A8 and BEWD3 genes mutations: intellectural disability vs normal IQ, macrocephaly and seizures
Hector Waisburg, Argentina

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 NEUROIMAGING 3

P421 Reversible MRI findings in a nonconvulsive status epilepticus patient with hyperammonemic encephalopathy
Asli G. Akyol, Turkey

P422 Predictors of cortical representation in patients with lesional epilepsy: an fMRI study
Carmen Barba, Italy

P423 Reliability and reproducibility of single-voxel spectroscopy of the hippocampus in 1,342 consecutive studies of 670 patients with epilepsy
Tohru Hoshida, Japan

P424 Reversible MRI abnormalities in patients presenting with epileptic seizures
Dimitrios Kazis, Greece

P425 Resection extent of the uncinate fasciculus and postoperative seizure outcome in temporal lobe epilepsy
Simon Keller, United Kingdom

P426 Role of positron emission tomography (PET) of the brain in the diagnosis of epilepsy
Liudmila Lipatova, Russian Federation

P427 Resting-state fMRI showed abnormal local spatiotemporal consistency in frontal lobe epilepsy
Cheng Luo, China

P428 Peri-ictal changes on MRI neuroimaging
Joel Oster, USA

P429 Prevalence and importance of the intracranial cysts in focal epilepsy patients: a tertiary referral center study
Aleksandar Ristic, Serbia

P430 Postictal arterial spin labelling (ASL) MRI for the localization of seizure onset zone (SOZ): comparison with intracranial EEG-localization and postsurgical outcome
Shaily Singh, Canada

P431 Postsurgical effects on functional connectivity within the limbic system in mesial temporal lobe epilepsy
Christian Weisstanner, Switzerland
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  NEUROIMAGING 4

P432  Volume and shape analysis of thalamus in patients with newly diagnosed epilepsy
Batil Alonazi, United Kingdom

P433  The relationship between white matter abnormalities and cognitive functions in new-onset juvenile myoclonic epilepsies
Burcu Ekmekci, Turkey

P434  Source localization of ictal epileptic activity in patients with focal epilepsy validated with invasive EEG
Nino Epitashvili, Germany

P435  Thalamocortical microstructural abnormality in juvenile myoclonic epilepsy
Eman Esmail, Egypt

P436  The corticospinal tract in unilateral polymicrogyria – a multiparametric MRI study
Olivia Fösleitner, Austria

P437  Statistical cerebral blood flow mapping in patients with temporal lobe epilepsy
Barbara A. K. Kreilkamp, United Kingdom

P438  Social cognition in patients with juvenile myoclonic epilepsy: an fMRI study
Giorgi Kuchukhidze, Austria

P439  Visualisation of blood brain barrier impairment as early marker of post stroke epileptogenesis
Jakub Otáhal, Czech Republic

P440  Variable threshold in SPM analysis of ictal SPECT in epilepsy surgery patients
Vlastimil Sulc, Czech Republic

P441  Widefield imaging of seizure propagation through the visual cortex in an awake mouse
Robert Wykes, United Kingdom

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  NEUROPSYCHOLOGY AND PSYCHIATRY IN EPILEPSY 3

P463  The rate of psychiatric comorbidity in psychogenic nonepileptic seizures compared with epilepsy in whom have demand for working disability for epilepsy
Kezban Aslan, Turkey

P464  Predicting the diagnosis of psychogenic non epileptic seizures and epileptic seizures by videorecording
Ettore Beghi, Italy

P465  Let’s do the induction of psychogenic seizures nonepileptic?
Ibrahim Bora, Turkey

P466  Importance of long term EEG/video monitoring in distinguishing psychogenic non-epileptic seizures from epileptic seizures
Susanne Davelaar, Netherlands

P467  Quality of life (QoL) and depression in patients during VEEG (2005-2014) – who suffers the most?
Anke M. Hermsen, Germany

P468  Interictal dysphoric disorder in patients with epilepsy
Maja Milovanovic, Serbia

P469  Suicidal risk factors in people with epilepsy
Nikolay G. Neznanov, Russian Federation

P470  Personality traits in patients with temporal lobe epilepsy
Annalisa Parente, Italy

P471  Should every child with epilepsy undergo screening for psychiatric comorbidities?
Shpresa Pula, UK, United Kingdom

P472  Should children with attention deficit/hyperactivity disorder (ADHD) and interictal epileptiform discharges (IEDs) on awake EEG be treated with antiepileptic drugs (AEDs) for their ADHD symptoms?
Dobrinko Socanski, Norway
P524 Limbic encephalitis: the intriguing link between autoimmune processes, epileptogenesis and neurodegeneration
Sara Casciato, Italy

P525 Improvement of interictal epileptiform discharges detection during EEG-fMRI: Pulse artefacts correction based on non-local means filtering
Gianna R. Iannotti, Switzerland

P526 Limbic Encephalitis: Early description in 1908
Günter Krämer, Switzerland

P527 Frequent rhabdomyolysis in anti-NMDA receptor encephalitis
Jung-Ah Lim, Korea, Republic of

P528 Interictal and postictal headache in our epilepsy patients
Tomáš Nežádal, Czech Republic

P529 Hippocampal involvement in physiological déjà vu: subfield vulnerability rather than temporal lobe epilepsy
Eva Pešlová, Czech Republic

P530 Iron, Vitamin B12, folic acid and vitamin D levels in febrile convulsions
F. Mujgan Sonmez, Turkey

P531 HLA-A, -B, -DRB1 haplotypic association with antiepileptic drugs induced cutaneous adverse drug reactions among patients from mainland of China
Xintong Wu, China

P532 Effect of seizures on sleep quality in patients with chronic epilepsy
Sung Sang Yoon, Korea, Republic of

P533 Object and action naming in Russian individuals with epilepsy
Anna Yurchenko, Russian Federation

P534 Retinal nerve fibre layer asymmetry associated with diagnosis of focal epilepsy in a drug-resistant population
Ana Paula Bartmann, United Kingdom

P535 Periictal changes of the innate immune system
Müjgan Dogan Önügören, Germany

P536 Seizures in comatose CPR survivors treated with hypothermia
Anda Eilam, Israel

P537 Seizure prevention in angioplasty for symptomatic extracranial carotid and vertebral artery stenosis
Mohamed Elmahdy, Egypt

P538 Paraneoplastic anti-LGI1 limbic encephalitis in a patient with rectal cancer – a case report
Fatme Seval Ismail, Germany

P539 Prague and epilepsy
Günter Krämer, Switzerland

P540 What are the opinions of patients with epilepsy and the families on counseling about SUDEP and other risks of epilepsy? The experience of the French sentinel network on epilepsy-related mortality
Marie-Christine Picot, France

P541 What does a neurologist add to the management of brain tumour related epilepsy (BTRE)? – Experiences of setting up a BTRE clinic at the Queen Elizabeth Hospital, Birmingham UK
Rosalind Brewster, United Kingdom

P542 The relationship between rotavirus gastroenteritis and febrile convulsions
F. Mujgan Sonmez, Turkey
**WEDNESDAY 14TH SEPTEMBER**

13:00 – 14:30 **PHARMACOLOGY/AEDS 10**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>P551</td>
<td>Behavioral disinhibition and GABAergic treatment in childhood epilepsy</td>
<td>Hilgo Bruining, Netherlands</td>
</tr>
<tr>
<td>P552</td>
<td>A prospective analysis of the effectiveness and tolerance of lacosamide in patients with refractory partial epilepsy</td>
<td>Ewa Czapinska-Ciepiela, Poland</td>
</tr>
<tr>
<td>P553</td>
<td>Adverse psychological effects of levetiracetam compared to seven other common anti-epileptic drugs in adults with epilepsy in general practice</td>
<td>Colin B. Josephson, Canada</td>
</tr>
<tr>
<td>P554</td>
<td>Adverse effects of dual anticonvulsant drug therapy in epilepsy patients – experience of a tertiary epilepsy outpatient clinic</td>
<td>Alexander Kowski, Germany</td>
</tr>
<tr>
<td>P555</td>
<td>Long-term safety and efficacy of adjunctive perampanel in patients with drug-resistant primary generalised tonic-clonic seizures in idiopathic generalised epilepsy: results of an open-label extension</td>
<td>Terence O’Brien, Australia</td>
</tr>
<tr>
<td>P556</td>
<td>Esli-Atlántico: an observational study on the use of Eslicarbazepine in North-West Spain</td>
<td>Gema Pérez-Lorenzo, Spain</td>
</tr>
<tr>
<td>P557</td>
<td>CBD-enriched medical cannabis for intractable pediatric epilepsy</td>
<td>Michal Tzadok, Israel</td>
</tr>
<tr>
<td>P558</td>
<td>Dried blood spots- a novel method for therapeutic drug monitoring in children with epilepsy in a homebased setting</td>
<td>Katarina Wide, Sweden</td>
</tr>
</tbody>
</table>

**WEDNESDAY 14TH SEPTEMBER**

13:00 – 14:30 **PHARMACOLOGY/AEDS 11**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>P559</td>
<td>Flavonoids as potential reversing agents of the pharmacoresistance to antiepileptic drugs mediated by the P-glycoprotein</td>
<td>Ana Ferreira, Portugal</td>
</tr>
<tr>
<td>P560</td>
<td>Unraveling the role of blood-brain partitioning in the anticonvulsant and antiepileptogenic actions of lacosamide by in vitro pharmacokinetic studies</td>
<td>Zsolt Gáll, Romania</td>
</tr>
<tr>
<td>P561</td>
<td>A Phase 1 open-label crossover study to evaluate bioequivalence of oral suspension and tablet formulations of perampanel in healthy subjects</td>
<td>Antonio Laurenza, USA</td>
</tr>
<tr>
<td>P562</td>
<td>Eslicarbazepine acetate (ESL) and carotid intima-media thickness (cIMT) in males: The ESL-LIPID study</td>
<td>Pedro J. Serrano-Castro, Spain</td>
</tr>
<tr>
<td>P563</td>
<td>The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice</td>
<td>Torleiv Svendsen, Norway</td>
</tr>
<tr>
<td>P564</td>
<td>Two-dimensional metal nanoparticle arrays towards quantifying carbamazepine in human plasma</td>
<td>Matteo Tommasini, Italy</td>
</tr>
<tr>
<td>P565</td>
<td>Ketogenic diet in refractory childhood epilepsy: introduction of an all liquid formulation in an outpatient setting</td>
<td>Amerins Weijenberg, Netherlands</td>
</tr>
</tbody>
</table>
**WEDNESDAY 14TH SEPTEMBER**

**PHARMACOLOGY/AEDS 8**

**P614** The ROME study (Retrospective Observational Multicenter study on ESL): 'efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy for adult patients with partial onset seizures and global effect on quality of life'
Giovanni Assenza, Italy

**P615** Safety and tolerability of eslicarbazepine acetate as monotherapy in patients with newly diagnosed partial-onset seizures
Elinor Ben-Menachem, Sweden

**P616** Reversible liver dysfunction associated with high dose ketamine in refractory status epilepticus
Hoe Chin Chua, Singapore

**P617** Surveillance of the orphan drug rufinamide in Norway: patient and population aspects
André Gottås, Norway

**P618** Retrospective study with perampanel in the Fjord District in Norway from 2013 up to February 2016. Patients diagnosed with POS and PGTC
Terje Kristensen, Norway

**P619** Seizure freedom with perampanel treatment in patients with refractory epilepsy
Jukka Peltola, Finland

**P620** The factors of pharmacoresistance of focal seizures, the efficacy of perampanel
Olga Rakhmanina, Russian Federation

**P621** Safety and efficacy of zonisamide in refractory epilepsy patients: a retrospective study based on an early data
Songul Senadim, Turkey

**WEDNESDAY 14TH SEPTEMBER**

**PHARMACOLOGY/AEDS 9**

**P622** Use of rufinamide and other antiepileptic drugs in the management of adult patients (≥18 years) with Lennox–Gastaut syndrome
Christian Brandt, Germany

**P623** Comparison of the serum cytokine levels before and after adrenocorticotropic hormone (ACTH) therapy in patients with infantile spasm
Ali Cansu, Turkey

**P624** Addressing the challenges in conducting international European multicenter trials in rare diseases: Time for action?
Floor Jansen, Netherlands

**P625** Transitioning patients from oxcarbazepine to eslicarbazepine acetate
Jussi Mäkinen, Finland

**P626** Valproate induced severe hyperammonemic encephalopathy successfully treated by carglumic acid in a child
Beata Rosdy, Hungary

**P627** Time-to-seizure modeling of lacosamide monotherapy – impact of disease severity and other covariates on dropouts and seizure probability
Armel Stockis, Belgium

**P628** Therapeutic drug monitoring of antiepileptic drugs and the correlation with seizure control
Supinya Tuntapakul, Thailand

**P629** Efficacy and tolerability of perampanel in adolescent patients with generalized seizure types: a pooled analysis of six randomized studies
J Eric Piña-Garza, USA
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 PROGNOSIS/EPIDEMIOLOGY 3

P646 The clinical outcome of Lennox-Gastaut syndrome in adults
Güneş Altıokka Uzun, Turkey

P647 Long term prognostic role of EEG in juvenile myoclonic epilepsy
Vibeke Arntsen, Norway

P648 Clinical experiences in psychogenetic nonepileptic seizures between 2003 and 2016 explaining the diagnosis is the first and most important step of the treatment in clinical practice, and careful patient-doctor communication has a certain positive impact on patients’ seizure prognosis
Aylin Bican Demir, Turkey

P649 The surgery for drug-resistant epilepsy and quality of life
Irena Dolezalova, Czech Republic

P650 The results of the comparison of statistical data on epilepsy in Ukraine, obtained in different ways
Andriy Dubenko, Ukraine

P651 Clinical and etiological profiles of of adult patients with post stroke seizures in Bishkek
Asel Jusupova, Kyrgyzstan

P652 Differences in long-term outcomes in patients with focal cortical dysplasia type Ib with and without somatic MTOR mutations
Takao Komatsubara, Japan

P653 Mortality in a cohort of 831 patients after noninvasive video-EEG telemetry
Dragoslav Sokic, Serbia

P654 The role of epilepsy surgery treatment in quality of life of the patient with refractory epilepsy- experience from local outpatient care
Ariunjargal Togtokhjargal, Czech Republic

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30 STATUS EPILEPTICUS 3

P673 SESA syndrome with a novel EEG pattern
Asli G. Akyol, Turkey

P674 Status epilepticus in pediatric age: etiology, semiology and outcome in 173 children
Marcello Bellusci, Spain

P675 Sporadic case of Creutzfeldt-Jacobs’s disease with EEG features of non-convulsive status epilepticus
Georgios Karafyles, Greece

P676 Topiramate for refractory nonconvulsive status epilepticus in elderly
Jooyong Kim, Korea, Republic of

P677 Seven cases of new onset refractory status epilepticus (NORSE) in Qatar: improved outcome with early immunotherapy
Gayane Melikyan, Qatar

P678 Reversible posterior leukoencephalopathy syndrome associated with nonconvulsive status epilepticus
Davorka Milat, Croatia

P679 Status epilepticus – can data from the past change our strategy today?
Iva Nachmilnerová, Czech Republic

P680 Refractory status epilepticus, are we refining treatment pathways?
Shanika Samarasekera, United Kingdom

P681 Short-term outcomes and major barriers in the management of convulsive status epilepticus in children
Teona Shatirishvili, Georgia

P682 StatNet EEG: an effective tool to diagnose non-convulsive status epilepticus after hours
Alexandra Voll, Canada
WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 5

P720  The contemporaneous issues of the epilepsy surgery
Konstantin Abramov, Russian Federation

P721  SEEG and subdural electrodes: analyzing the trend of their use in a large
Canadian Epilepsy Program
Jorge Burneo, Canada

P722  Stereo tubes technique: a novel substitute for intraoperative MRI in
epilepsy surgeries
Nilesh Kurwale, India

P723  Surgical treatment of medically intractable temporal lobe epilepsy in
prescol children
Magomed Mamntekhanov, Russian Federation

P724  Temporal lobe epilepsy with not lateralizing scalp-EEG ictal onset
underwent intracranial investigation: electroclinical findings and surgical
outcome
Addolorata Mascia, Italy

P725  Temporal lobectomy for epilepsy: outcomes and surgical complications
Catherine Pringle, United Kingdom

P726  Seizure outcome two years after posterior quadrant resections 1990-2011
– prospective and population based data from the Swedish National
Epilepsy Surgery Register
Bertil Rydenhag, Sweden

P727  Surgical treatment of drug-resistant forms of epilepsy
Igor Trifonov, Russian Federation

WEDNESDAY 14TH SEPTEMBER

13:00 – 14:30  SURGICAL TREATMENT AND NEUROMODULATION 6

P728  Vagus nerve stimulation in children with focal epilepsy – 5 year follow up
study
Eva Brichtova, Czech Republic

P729  Verbal learning and memory outcome in selective
amygdalohippocampectomy versus temporal lobe resection in 108 patients
with hippocampal sclerosis
Mette Thrane Foged, Denmark

P730  The Danish epilepsy surgery programme aligns with best international
standards
Emil Holm, Denmark

P731  The implication of reduction of antiepileptic medication on postoperative
outcome after epilepsy surgery
Ekaterina Pataraia, Austria

P732  Two-year and long-term seizure outcome after resective epilepsy surgery
in patients with low IQ
Jesper Reinholdson, Sweden

P733  Three-dimensional visualization of morphometric brain anomalies in
patients with temporal lobe epilepsy
Jakob Rosén, Sweden

P734  The role of regional epileptologist – can the estimated time of epilepsy
onset to epilepsy surgery be effectively shortened?
Jana Slonkova, Czech Republic

P735  Visual field defects in epilepsy patients treated with temporal lobe
resection
Alvilda T. Steensberg, Denmark

P736  Trans-sylvian disconnection surgeries for medically intractable epilepsy
including temporal lobe
Hidenori Sugano, Japan

P737  Utility of depth electrodes for epilepsy surgery and surgical outcome
Jae Hong Yi, Korea, Republic of
JOIN MORE THAN 6000 COLLEAGUES AT THE THIRD CONGRESS OF THE EUROPEAN ACADEMY OF NEUROLOGY!

www.ean.org/amsterdam2017
TRAVEL BURSARIES

42 abstracts were selected for Travel Bursaries by the International Scientific and Organising Committee. The Travel Bursaries cover flights, accommodation and registration and are provided by the ILAE Commission on European Affairs. The 12th ECE Travel Bursary recipients are:

<table>
<thead>
<tr>
<th>SURNAME</th>
<th>FIRST NAME</th>
<th>COUNTRY</th>
<th>SESSION TYPE</th>
<th>DATE</th>
<th>TIME</th>
<th>HALL</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abi Warde</td>
<td>Marie</td>
<td>France</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ahl</td>
<td>Matilda</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Almaka Uzun</td>
<td>Gunes</td>
<td>Turkey</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Altenova</td>
<td>Jana</td>
<td>Czech Republic</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Apps</td>
<td>Richard</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Aranica</td>
<td>Eleonora</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Aranica</td>
<td>Eleonora</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Arzimanoglu</td>
<td>Alexis</td>
<td>France</td>
<td>Special Symposium</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Arzimanoglu</td>
<td>Alexis</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Audnat</td>
<td>Etienne</td>
<td>France</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Auvin</td>
<td>Stephane</td>
<td>France</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Auvin</td>
<td>Stephane</td>
<td>France</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Auvin</td>
<td>Stephane</td>
<td>France</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Auvin</td>
<td>Stephane</td>
<td>France</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Avoli</td>
<td>Massimo</td>
<td>Canada</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Parallel Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Avoli</td>
<td>Massimo</td>
<td>Canada</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Avoli</td>
<td>Massimo</td>
<td>Canada</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baftiu</td>
<td>Arton</td>
<td>Norway</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bagajda</td>
<td>Emilia</td>
<td>USA</td>
<td>Special Symposium</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bar Klein</td>
<td>Guy</td>
<td>Israel</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bartolomei</td>
<td>Fabrice</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Basic</td>
<td>Silvio</td>
<td>Croatia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Basic</td>
<td>Silvio</td>
<td>Croatia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baulac</td>
<td>Michel</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baumgartner</td>
<td>Christoph</td>
<td>Austria</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baykan</td>
<td>Betul</td>
<td>Turkey</td>
<td>Special Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Baykan</td>
<td>Betul</td>
<td>Turkey</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Beck</td>
<td>Heinz</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Beck</td>
<td>Heinz</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Becker</td>
<td>Albert</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Becker</td>
<td>Albert</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>-----------------</td>
<td>----------------------</td>
<td>----------</td>
<td>------------------</td>
<td>-----------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Biedner</td>
<td>Peter</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Biedini</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Chair Symposium</td>
<td>15-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Biedini</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>15-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Biedini</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Biedini</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Biedini</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bencúrníva</td>
<td>Petra</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>07:30-16:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Beniczky</td>
<td>Sándor</td>
<td>Denmark</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>07:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Beniczky</td>
<td>Sándor</td>
<td>Denmark</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Beniczky</td>
<td>Sándor</td>
<td>Denmark</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Beniczky</td>
<td>Sándor</td>
<td>Denmark</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bergin</td>
<td>Peter</td>
<td>New Zealand</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bergin</td>
<td>Peter</td>
<td>New Zealand</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blaier</td>
<td>Meir</td>
<td>Israel</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bibi</td>
<td>David</td>
<td>Israel</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blessen</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Blessen</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brasilli</td>
<td>Francesca</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bjelkhåll</td>
<td>Johan</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blumcke</td>
<td>Ingmar</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Blumenfeld</td>
<td>Hal</td>
<td>USA</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Böning</td>
<td>Vanka</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bion</td>
<td>Paul</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Bion</td>
<td>Paul</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Bion</td>
<td>Paul</td>
<td>Belgium</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Bion</td>
<td>Paul</td>
<td>Belgium</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Boran</td>
<td>Ivo</td>
<td>Switzerland</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brandt</td>
<td>Christian</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall IV</td>
<td>Chair</td>
</tr>
<tr>
<td>Brandt</td>
<td>Christian</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brandt</td>
<td>Claudia</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brouns</td>
<td>Kees</td>
<td>Netherlands</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Brouns</td>
<td>Kees</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Brázdil</td>
<td>Milan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>--------------------</td>
<td>----------</td>
<td>------------</td>
<td>---------------</td>
<td>------------</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>de Curtis</td>
<td>Marco</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>De Jonghe</td>
<td>Pierre</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Weerd</td>
<td>Al</td>
<td>Netherlands</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>de Weerd</td>
<td>Al</td>
<td>Netherlands</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dedouweneere</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Dedouweneere</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Dedouweneere</td>
<td>Stefanie</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Delanty</td>
<td>Norman</td>
<td>Ireland</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Detofol</td>
<td>Bertrand</td>
<td>France</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Devinsky</td>
<td>Orin</td>
<td>USA</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dolebalow</td>
<td>Irina</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Donath</td>
<td>Vladimir</td>
<td>Slovakia</td>
<td>Special Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Doms</td>
<td>Larm</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Doms</td>
<td>Larm</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Dudek</td>
<td>FE</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elkele Nicole</td>
<td>Ekane</td>
<td>Finland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elkhaven</td>
<td>Sonia</td>
<td>Egypt</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Eliau</td>
<td>Martin</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ellinger</td>
<td>Lars</td>
<td>Denmark</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Finnell</td>
<td>Richard</td>
<td>USA</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>SURNAME</th>
<th>FIRST NAME</th>
<th>COUNTRY</th>
<th>SESSION TYPE</th>
<th>DATE</th>
<th>TIME</th>
<th>HALL</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devinsky</td>
<td>Orin</td>
<td>USA</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Dimova</td>
<td>Petta</td>
<td>Bulgaria</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Dolebalow</td>
<td>Irina</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Donath</td>
<td>Vladimir</td>
<td>Slovakia</td>
<td>Special Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Doms</td>
<td>Larm</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Doms</td>
<td>Larm</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall V</td>
<td>Chair</td>
</tr>
<tr>
<td>Dudek</td>
<td>FE</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Eisermann</td>
<td>Monika</td>
<td>France</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elkele Nicole</td>
<td>Ekane</td>
<td>Finland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elkhaven</td>
<td>Sonia</td>
<td>Egypt</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elger</td>
<td>Christian</td>
<td>Germany</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Elias</td>
<td>Martin</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ellinger</td>
<td>Lars</td>
<td>Denmark</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Finnell</td>
<td>Richard</td>
<td>USA</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------</td>
<td>-----------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Hellwig</td>
<td>Katharina</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hellwig</td>
<td>Inga</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Helmstaedter</td>
<td>Christoph</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Helmstaedter</td>
<td>Christoph</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hersh Phillips</td>
<td>David</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Hersh Phillips</td>
<td>David</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Heuser</td>
<td>Kaill</td>
<td>Norway</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hinch</td>
<td>Edouard</td>
<td>France</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holhausen</td>
<td>Hans</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holhausen</td>
<td>Hans</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Holthaussen</td>
<td>Hans</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hollkamp</td>
<td>Martin</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Hollkamp</td>
<td>Martin</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hong</td>
<td>Robert</td>
<td>United Kingdom</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huberfield</td>
<td>Gilles</td>
<td>France</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huberfield</td>
<td>Gilles</td>
<td>France</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Huishof</td>
<td>Hanna</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Irani</td>
<td>Sarosh</td>
<td>United Kingdom</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jędrzejczak</td>
<td>Joanna</td>
<td>Poland</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jacobs</td>
<td>Julia</td>
<td>Germany</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jansen</td>
<td>Floor</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jansen</td>
<td>Floor</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jefferys</td>
<td>John</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jenum</td>
<td>Poul</td>
<td>Denmark</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jesberger</td>
<td>Sebastian</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jira</td>
<td>Viktor</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jira</td>
<td>Viktor</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jiruška</td>
<td>Prejmyš</td>
<td>Czech Republic</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Jiruška</td>
<td>Prejmyš</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Jobst</td>
<td>Barbara</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Johannessen</td>
<td>Svein</td>
<td>Norway</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannessen</td>
<td>Svein</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannessen</td>
<td>Svein</td>
<td>Norway</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Johannessen</td>
<td>Landmark</td>
<td>Cecile</td>
<td>Norway</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>------------</td>
<td>--------------</td>
<td>------------</td>
<td>------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Kikoč</td>
<td>Ivona</td>
<td>Slovenia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Knik</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallIV</td>
<td>Chair</td>
</tr>
<tr>
<td>Kisek</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting HallIV</td>
<td>Chair</td>
</tr>
<tr>
<td>Krystl</td>
<td>David</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallIV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Krystl</td>
<td>David</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting HallIV</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>10:30-12:30</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kubova</td>
<td>Hana</td>
<td>Czech Republic</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kullmann</td>
<td>Dimitri</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>13:40-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kumilen</td>
<td>Eva</td>
<td>Sweden</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Kumilen</td>
<td>Eva</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Labate</td>
<td>Angelo</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagae</td>
<td>Leen</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallI</td>
<td>Chair</td>
</tr>
<tr>
<td>Lagae</td>
<td>Leen</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Lagae</td>
<td>Leen</td>
<td>Belgium</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Lagae</td>
<td>Leen</td>
<td>Belgium</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Lagae</td>
<td>Leen</td>
<td>Belgium</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lagarde</td>
<td>Stanislas</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Lee</td>
<td>Jo-Young</td>
<td>Korea, Republic of</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting HallV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lee</td>
<td>Wên Gu</td>
<td>Korea, Republic of</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lemke</td>
<td>Johannes</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Licchetta</td>
<td>Laura</td>
<td>Italy</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Linehan</td>
<td>Christine</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Linehan</td>
<td>Christine</td>
<td>Ireland</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting HallI</td>
<td>Speaker</td>
</tr>
<tr>
<td>Maguire</td>
<td>Melissa</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting HallV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Maillard</td>
<td>Louis</td>
<td>France</td>
<td>ECE Forum</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Melngren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Melngren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Melngren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallIV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Melngren</td>
<td>Kristina</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Mentreghia</td>
<td>Massimo</td>
<td>France</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting HallI</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mentreghia</td>
<td>Massimo</td>
<td>France</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting HallIV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallI</td>
<td>Chair</td>
</tr>
<tr>
<td>Marchi</td>
<td>Nicola</td>
<td>USA</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting HallI</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting HallI</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mareš</td>
<td>Pavel</td>
<td>Czech Republic</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting HallIV</td>
<td>Speaker</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>----------</td>
<td>----------------------</td>
<td>--------</td>
<td>----------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>O'Brien</td>
<td>Terence</td>
<td>Australia</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Østby</td>
<td>Yva</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Østby</td>
<td>Yva</td>
<td>Norway</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ous</td>
<td>Lea</td>
<td>France</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Page</td>
<td>Rupert</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Paragonakis</td>
<td>Eleni</td>
<td>France</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Penrucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Penrucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Penrucca</td>
<td>Emilio</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Pittau</td>
<td>Francesca</td>
<td>Switzerland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pittau</td>
<td>Francesca</td>
<td>Switzerland</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Polster</td>
<td>Tilman</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Presler</td>
<td>Kent</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Puk</td>
<td>Oliver</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ramanani</td>
<td>Georgia</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ravizza</td>
<td>Teresa</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Redfors</td>
<td>Petra</td>
<td>Sweden</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rektor</td>
<td>Ivan</td>
<td>Czech Republic</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Reiner-Princic</td>
<td>Zvonika</td>
<td>Slovenia</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rihams</td>
<td>Sykian</td>
<td>France</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rihams</td>
<td>Sykian</td>
<td>France</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Richardson</td>
<td>Mark</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Richardson</td>
<td>Mark</td>
<td>United Kingdom</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Riddlell</td>
<td>Leone</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Meeting Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Riley</td>
<td>Kate</td>
<td>Australia</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Platform Session</td>
<td>15-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>15-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>16-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Parallel Session</td>
<td>16-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogawski</td>
<td>Michael</td>
<td>USA</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-12:30</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rossetti</td>
<td>Andrea</td>
<td>Switzerland</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-12:30</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Rossetti</td>
<td>Andrea</td>
<td>Switzerland</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Roulet</td>
<td>Perez</td>
<td>Switzerland</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rubboli</td>
<td>Guido</td>
<td>Denmark</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>RueggelIESRCHKE</td>
<td>Cristina</td>
<td>Ireland</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Russo</td>
<td>Emilio</td>
<td>Italy</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Ryvlin</td>
<td>Philippe</td>
<td>Switzerland</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Ryvlin</td>
<td>Philippe</td>
<td>Switzerland</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Ryvlin</td>
<td>Philippe</td>
<td>Switzerland</td>
<td>Satellite Symposium</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Sairanen</td>
<td>Jari</td>
<td>Finland</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sakelloukas</td>
<td>Demnis</td>
<td>Greece</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sakuma</td>
<td>Satoru</td>
<td>Canada</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sargysas</td>
<td>Armen</td>
<td>Australia</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schaller</td>
<td>Karl</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Scharfman</td>
<td>Helen</td>
<td>USA</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Scharfman</td>
<td>Helen</td>
<td>USA</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Scheffer</td>
<td>Ingrid</td>
<td>Australia</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Scheffer</td>
<td>Ingrid</td>
<td>Australia</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Scheffer</td>
<td>Ingrid</td>
<td>Australia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Schevron</td>
<td>Catherine</td>
<td>USA</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schindler</td>
<td>Keapar</td>
<td>Switzerland</td>
<td>Neurobiology Symp.</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schahitz</td>
<td>Sophie</td>
<td>Germany</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Schmidt</td>
<td>Dieter</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Schmidt</td>
<td>Dieter</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Schmidt</td>
<td>Dieter</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Schmidt</td>
<td>Dieter</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Scholky</td>
<td>Julia</td>
<td>France</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schulze-Bonhage</td>
<td>Andreas</td>
<td>Germany</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST_NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
<td>---------</td>
<td>--------------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>Schulze-Bonhage</td>
<td>Andreas</td>
<td>Germany</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Schulze-Bonhage</td>
<td>Andreas</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Main Session</td>
<td>13-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Seck</td>
<td>Margitta</td>
<td>Switzerland</td>
<td>Highlights Session</td>
<td>15-Sep</td>
<td>12:30-13:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Sen</td>
<td>Stefano</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sen</td>
<td>Stefano</td>
<td>United Kingdom</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Senatosa</td>
<td>José</td>
<td>Spain</td>
<td>Satellite Symposium</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shirazu</td>
<td>Hoshihi</td>
<td>Japan</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shmuely</td>
<td>Sharon</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shvoorn</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shvoorn</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Shvoorn</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Shvoorn</td>
<td>Simon</td>
<td>United Kingdom</td>
<td>United Kingdom</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Singee</td>
<td>Shabana</td>
<td>Pakistan</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Simonato</td>
<td>Michele</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Skauup</td>
<td>Christian</td>
<td>Denmark</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Skauup</td>
<td>Christian</td>
<td>Denmark</td>
<td>Teaching Course</td>
<td>15-Sep</td>
<td>08:00-10:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Silverme</td>
<td>Sharon</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sommer</td>
<td>Björn</td>
<td>Germany</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Congress Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Specchio</td>
<td>Nicola</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Spinke</td>
<td>Gunther</td>
<td>Austria</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Spering</td>
<td>Michael</td>
<td>USA</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sproasfo</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Sproasfo</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sproasfo</td>
<td>Roberto</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Staley</td>
<td>Kevin J.</td>
<td>USA</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall IV</td>
<td>Speaker</td>
</tr>
<tr>
<td>Stefan</td>
<td>Hermann</td>
<td>Germany</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>16:30-18:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steiger</td>
<td>Bettina</td>
<td>Switzerland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>11:00-12:30</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steiner</td>
<td>Emilia</td>
<td>Sweden</td>
<td>Main Session</td>
<td>14-Sep</td>
<td>09:00-11:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Steinhauser</td>
<td>Christian</td>
<td>Germany</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>South Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>SURNAME</td>
<td>FIRST NAME</td>
<td>COUNTRY</td>
<td>SESSION TYPE</td>
<td>DATE</td>
<td>TIME</td>
<td>HALL</td>
<td>ROLE</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------</td>
<td>---------------</td>
<td>----------------</td>
<td>------------------</td>
</tr>
<tr>
<td>van Vliet</td>
<td>Erwin</td>
<td>Netherlands</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>van Vliet</td>
<td>Erwin</td>
<td>Netherlands</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vangoo</td>
<td>Vanshiladh</td>
<td>Netherlands</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vareli-Yonuz</td>
<td>Enbe Nur</td>
<td>Turkey</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Veensema</td>
<td>Tim</td>
<td>Netherlands</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Annamaria</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Annamaria</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>11-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Annamaria</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Annamaria</td>
<td>Italy</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Federico</td>
<td>Italy</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Federico</td>
<td>Italy</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:30</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Federico</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Vezzani</td>
<td>Federico</td>
<td>Italy</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Platform Session</td>
<td>13-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Villanueva</td>
<td>Vicente</td>
<td>Spain</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>van Padewis</td>
<td>Felix</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vonck</td>
<td>Kristl</td>
<td>Belgium</td>
<td>Chair Symposium</td>
<td>12-Sep</td>
<td>09:00-11:00</td>
<td>Congress Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vonck</td>
<td>Kristl</td>
<td>Belgium</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Chair</td>
</tr>
<tr>
<td>Vorderwülbeck</td>
<td>Remd</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vrba</td>
<td>Lubica</td>
<td>Slovenia</td>
<td>ECE Forum</td>
<td>14-Sep</td>
<td>18:15-19:45</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vuillemoz</td>
<td>Serge</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall V</td>
<td>Speaker</td>
</tr>
<tr>
<td>Vuillemoz</td>
<td>Serge</td>
<td>Switzerland</td>
<td>ECE Forum</td>
<td>15-Sep</td>
<td>09:00-10:30</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Wadman</td>
<td>Wytse</td>
<td>Netherlands</td>
<td>Special Symposium</td>
<td>14-Sep</td>
<td>14:30-16:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Walla Saadi</td>
<td>Nebal</td>
<td>Iraq</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Waldman</td>
<td>Jack</td>
<td>United Kingdom</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Waller</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Parallel Session</td>
<td>12-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Waller</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Chair</td>
</tr>
<tr>
<td>Waller</td>
<td>Lauren</td>
<td>United Kingdom</td>
<td>ECE Forum</td>
<td>13-Sep</td>
<td>18:00-19:30</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Waller</td>
<td>Matthew</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>13-Sep</td>
<td>07:30-09:00</td>
<td>Panorama Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wang</td>
<td>Xiaohan</td>
<td>China</td>
<td>Platform Session</td>
<td>12-Sep</td>
<td>11:30-13:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wedehuyzen</td>
<td>Sarah</td>
<td>Belgium</td>
<td>Parallel Session</td>
<td>14-Sep</td>
<td>16:30-18:00</td>
<td>South Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Werhahn</td>
<td>Konrad</td>
<td>Germany</td>
<td>Parallel Session</td>
<td>13-Sep</td>
<td>14:30-16:00</td>
<td>Forum Hall</td>
<td>Speaker</td>
</tr>
<tr>
<td>Whalley</td>
<td>Ben</td>
<td>United Kingdom</td>
<td>Satellite Symposium</td>
<td>12-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wellander</td>
<td>Franziska</td>
<td>Germany</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>West</td>
<td>Roland</td>
<td>Switzerland</td>
<td>Teaching Session</td>
<td>14-Sep</td>
<td>07:30-09:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
<tr>
<td>Wrenell</td>
<td>Elaine</td>
<td>USA</td>
<td>Platform Session</td>
<td>14-Sep</td>
<td>11:30-13:00</td>
<td>Meeting Hall I</td>
<td>Speaker</td>
</tr>
</tbody>
</table>
EXHIBITION INFORMATION

EXHIBITION OPENING HOURS

Monday, September 12, 2016 09.00 – 16.30
Tuesday, September 13, 2016 09.00 – 16.30
Wednesday, September 14, 2016 09.00 – 16.30

EXHIBITION FLOOR PLAN

---

12th European Congress on Epileptology

---

EXHIBITION STANDS

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Stand No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad-Tech Medical Instrument Corporation</td>
<td>1</td>
</tr>
<tr>
<td>AIT Austrian Institute of Technology</td>
<td>17</td>
</tr>
<tr>
<td>ALCIS NEURO</td>
<td>34</td>
</tr>
<tr>
<td>Amplexa Genetics</td>
<td>18</td>
</tr>
<tr>
<td>BIAL</td>
<td>10</td>
</tr>
<tr>
<td>BIOCODEX</td>
<td>31 &amp; 32</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>28</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>16</td>
</tr>
<tr>
<td>Compumedics Neuroscan</td>
<td>29</td>
</tr>
<tr>
<td>DEYMED Diagnostic</td>
<td>14 &amp; 15</td>
</tr>
<tr>
<td>EB NEURO SpA</td>
<td>2</td>
</tr>
<tr>
<td>Eisai</td>
<td>A</td>
</tr>
<tr>
<td>Electrical Geodesics, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>ELEKTA</td>
<td>12 &amp; 13</td>
</tr>
<tr>
<td>Epilog</td>
<td>3</td>
</tr>
<tr>
<td>EpiNet</td>
<td>39</td>
</tr>
<tr>
<td>HOLBERG EEG</td>
<td>35</td>
</tr>
<tr>
<td>International Bureau for Epilepsy</td>
<td>23</td>
</tr>
<tr>
<td>International League Against Epilepsy</td>
<td>23</td>
</tr>
<tr>
<td>JOHN LIBBEY EUROTEXT</td>
<td>8</td>
</tr>
<tr>
<td>Lifelines iEEG</td>
<td>B</td>
</tr>
<tr>
<td>LivaNova</td>
<td>24 &amp; 25</td>
</tr>
<tr>
<td>Medtronic International Sàrl</td>
<td>33</td>
</tr>
<tr>
<td>Micromed</td>
<td>36</td>
</tr>
<tr>
<td>Natus Neurology Inc.</td>
<td>5</td>
</tr>
<tr>
<td>NIHON KOHDEN EUROPE GmbH</td>
<td>26 &amp; 27</td>
</tr>
<tr>
<td>Persyst Development Corporation</td>
<td>30</td>
</tr>
<tr>
<td>Shire</td>
<td>9</td>
</tr>
<tr>
<td>The Anita Kaufmann Foundation</td>
<td>39</td>
</tr>
<tr>
<td>UCB BIOPHARMA SPRL</td>
<td>11</td>
</tr>
<tr>
<td>WILEY</td>
<td>38</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>4</td>
</tr>
</tbody>
</table>

---

12th European Congress on Epileptology

Other Information
SPONSORS

The International League Against Epilepsy (ILAE) would like to acknowledge the support of the following companies for the 12th European Congress on Epileptology:

Eisai

Bial

LivaNova

ELEKTA

Shire

Zogenix

GW Pharmaceuticals

These companies have provided funding towards the costs of the Congress, but have had no input into or influence over the programme schedule or content.

Sponsoring companies’ staff will be present at the Congress and sponsoring companies may have exhibition stands promoting their products.
Treat them like family!
Improve patient wellbeing with VNS Therapy®

- Fewer Seizures
- Shorter Seizures
- Faster Recovery
- Decreased Seizure Severity
- Fewer Medications
- Improved Alertness, Mood and Memory
- Improved Quality of Life

VNS THERAPY EUROPEAN INDICATION FOR USE
VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications. The Model 106 AspireSR® (Seizure Response) features the Automatic Stimulation Mode, which is intended for patients who experience seizures that are associated with cardiac rhythm increases known as ictal tachycardia.

CONTRAINDICATIONS:
The VNS Therapy system cannot be used in patients after a bilateral or left cervical vagotomy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy on patients implanted with the VNS Therapy system. Diagnostic ultrasound is not included in this contraindication. Cardiac arrhythmia (Model 106 only)—The AutoStim Mode feature should not be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere with normal intrinsic heart rate responses.

WARNINGS:
Physicians should inform patients about all potential risks and adverse events discussed in the VNS Therapy Physician Manuals, including information that VNS Therapy may not be a cure for epilepsy. Since seizures may occur unexpectedly, patients should consult with their physician before engaging in unsupervised activities, such as driving, swimming, and bathing, or in strenuous sports that could harm them or others. A malfunction of the VNS Therapy system could cause painful or direct current stimulation, which could result in nerve damage. Removal or replacement of the VNS Therapy system requires an additional surgical procedure. Patients who have pre-existing swallowing, cardiac, or respiratory difficulties (including, but not limited to obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them since there is the possibility that stimulation might worsen their condition. Postoperative bradycardia can occur among patients with certain underlying cardiac arrhythmias. MRI can be safely performed; however, special equipment and procedures must be used.

ADVERSE EVENTS:
The most commonly reported side effects from stimulation include hoarseness (voice alteration), paresthesia (prickling feeling in the skin), dyspnea (shortness of breath), sore throat and increased coughing. The most commonly reported side effect from the implant procedure is infection.

*The information contained here represents partial excerpts of important prescribing information from the product labeling. Patients should discuss the risks and benefits of VNS Therapy with their healthcare provider. Visit www.VNSTherapy.com for more information.

For more information or to refer a patient, visit www.statustrial.com

The STATUS Trial is a Phase III study to evaluate the efficacy and safety of SAGE-547 Injection in the treatment of patients with Super-Refractory Status Epilepticus (SRSE).

Evaluating an investigational drug for Super-Refractory Status Epilepticus

For more information or to refer a patient, visit www.statustrial.com
Your Complete Neurology Solution from Compumedics

LONG TERM MONITORING LTM  BRAIN RESEARCH
AMBULATORY  SLEEP TESTING
ROUTINE CLINICAL EEG  LABORATORY BASED
CEEG FOR ICU  CLOUD SOLUTIONS
FACILITY MANAGEMENT  WIRELESS

INNOVATION. VALUE. VERSATILITY.

Explore Compumedics’ comprehensive range of amplifiers and recorders for all your applications.

GRAEL HD RANGE  SIESTA WIRELESS  SYNAMPS RESEARCH  NEUVO LTM

Seamless and integrated software suite for diagnosis, data and facility management.

www.compumedics.com
Australia • USA • Germany • France

‘Defining Life’s Signals’
13th European Congress on Epileptology

26th - 30th August 2018

Vienna